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1. Abstract
Background
Globally, 422 million adults have type 2 diabetes mellitus (T2DM), causing 1.5 million deaths per year.
Kuwait has one of the highest T2DM prevalence in the world and determining the proportion of
patients and relatives who have pre-diabetes (PDM), insulin resistance (IR) and T2DM is crucial to
inform preventive activities and curative services.
Study objectives:
The study describes the prevalence and risk factors of PDM, IR and T2DM, in adult patients attending
a primary health care facility in Kuwait and the prevalence and risk factors of the same conditions
among the patients’ first-degree relatives. The study also describes the degree of glycaemic control
achieved by patients with T2DM and risk factors for poor glycaemic control. Finally, we assessed the
agreement of a point of care (POC) device to measure glycated haemoglobin (HbA1c) to monitor
T2DM control.
Methods
We conducted cross-sectional surveys of patients and first-degree relatives attending Nuzha health
care facility in Kuwait and case-control studies of participants attending Nuzha’s diabetic clinic.
Diabetic participants were consecutively tested by the Quo-test (POC) device to compare its
agreement with a reference test.
Results
The prevalence of T2DM, IR and PDM among patients attending the clinics were 29.6% (95% CI:
25.1%-34.1%), 34.6% (95% CI: 29.1%-40.2%) and 26.0% (95% CI: 21.6%-30.4%), respectively. The
proportion of patients with T2DM increased with age (AOR=5.4), with the highest prevalence
occurring at 60-69 years of age. T2DM was associated with hypertension (AOR=1.95) and being a
widow (AOR=6.11). IR was associated with low HDL (AOR=1.96), overweight (OR=8.25), obesity
(OR=18.33) and increased waist circumference (OR= 5.5). Sugar-sweetened beverages were
associated with IR.
The prevalence of T2DM, IR and PDM among first-degree relatives of T2DM patients were 29.1%
(95%CI: 23.7%-34.5%), 32.8% (95%CI: 26.2%-39.4%), 20.4% (95%CI: 15.6%-25.2%). The risk factors for
T2DM were similar among patients and first-degree relatives, but IR was associated with manual
labour occupations (AOR=3.6).
Only 30% of T2DM patients achieved good glycaemic. Poor control was associated with high
triglycerides (AOR=2.2), smoking (AOR=4.1) and the number of years since diagnosis (AOR=4).
The Quo-Test had comparable performance to the reference test, with a Coefficient of Variation of
2.1% (r2 = 935, Kappa 90% and 87% at HbA1c cut-offs of 7.0 and 9.0% respectively).  The POC and the
reference tests performed poorly in patients with haemoglobinopathies.
Conclusion
This study demonstrates that a high proportion of patients and first-degree relatives attending one of
the main primary health care centres in Kuwait have T2DM. Many patients and relatives were
unaware of their condition. There was also a very high prevalence of IR and PDM suggesting the
burden of T2DM will increase further in the future. Major efforts are needed to upscale detection,
and preventive programmes for IR, PDM and T2DM and the quality of T2DM management needs to
improve. The POC device tested could provide timely information for the management of T2DM.
vList of abbreviations
ACCORD Action to Control Cardiovascular Risk in Diabetes
ACE angiotensin converting enzyme
ADA American Diabetes Association
AGEs advanced glycation end products
AMI acute myocardial infarction
AMPK adenosine monophosphate protein kinase
ARBs angiotensin receptor blocker
HbA1c glycated haemoglobin
BMI body mass index
BP blood pressure
BW body weight
CHD coronary heart disease
CVD cerebrovascular disease
DALY disability-adjusted life years
DCCT Diabetes Control and Complication Trial
DKA diabetic ketoacidosis
DKD diabetic kidney disease
DM diabetes mellitus
DME diabetic macular oedema
DN diabetic nephropathy
DPN diabetic polyneuropathy
DR diabetic retinopathy
EMR Eastern Mediterranean Region
ESRD end-stage renal disease
ETDRS Early Treatment Diabetic Retinopathy Study
FFA free fatty acid
FPG fasting plasma glucose
vi
GCC Gulf Cooperation Council
Hb Haemoglobin
HCF healthcare facility
HDL High-density lipoprotein
HHS hyperosmolar hyperglycaemic state
HOMA homeostatic model assessment
HPLC High-performance liquid chromatography
IDF International Diabetes Federation
IFG impaired fasting glucose
IGT impaired glucose tolerance
IR Insulin resistance
IRAS Insulin Resistance Atherosclerosis Study
IRS Insulin receptor substrate
K Potassium
KATP adenosine triphosphates sensitive potassium
LDL Low-density lipoprotein
LPL lipoprotein lipase
MENA Middle East and North Africa
MI myocardial infarction
MS metabolic syndrome
NCDs Non-communicable diseases
NGSP National Glycohemoglobin standardization program
NGT normal glucose tolerance
NHIS National Health Interview Survey
NIDDK National Institute of Diabetes and Digestive and Kidney Diseases
NPH neutral protamine Hagedorn
OGTT oral glucose tolerance test
OR Odds Ratio
PCOs polycystic ovaries
PDM Prediabetes
PKC protein kinase C
vii
POC point of care
ROS reactive oxygen species
RR Relative Risk
SMBG self-monitoring blood glucose
TG Triglyceride
UKPDS United Kingdome Prospective Diagnostic Study
VEGF vascular endothelial growth factor
WHO World Health Organization
WHR waist/hip ratio
YLDs years lived with disability
YLLs years of life lost due to premature death
viii
Table of Contents
Thesis submitted in accordance with the requirements of the University of
Liverpool, Liverpool School of Tropical Medicine for the degree of Doctor in
Philosophy................................................................................................................. i
Acknowledgement ...................................................................................................iii
1. Abstract .............................................................................................................iv
Background ......................................................................................................... iv
Study objectives: ................................................................................................. iv
Methods .............................................................................................................. iv
Results ................................................................................................................. iv
Conclusion ........................................................................................................... iv
List of abbreviations..................................................................................................v
Table of Contents ...................................................................................................viii
List of Tables.......................................................................................................... xvii
List of Figures .........................................................................................................xxi
2. Literature review.................................................................................................. 1
ix
Introduction ............................................................................................................. 1
2.1 Importance of studying Diabetes....................................................................... 3
2.2 Definition of diabetes......................................................................................... 5
2.3 Types of diabetes ............................................................................................... 6
2.4 Pathogenesis of diabetes mellitus ..................................................................... 8
2.5 Glucose homeostasis.......................................................................................... 9
2.6 Key hormones influencing glucose level .......................................................... 10
2.6.1 Insulin ........................................................................................................ 10
2.7 Clinical and subclinical features of hyperglycaemia ........................................ 16
2.7.1 Prediabetes ............................................................................................... 16
2.7.2 Clinical presentation of T2DM .................................................................. 19
2.8 Complication of T2DM ..................................................................................... 21
2.8.1 Acute metabolic complications................................................................. 22
2.8.2 Long-term complications of T2DM ........................................................... 23
2.8.3 Mechanism of DM chronic complications ................................................ 24
2.8.4 Macrovascular complications ................................................................... 25
x2.8.5 Microvascular complications .................................................................... 28
2.9 Monitoring of Diabetes Mellitus ...................................................................... 33
2.9.1 Short-term monitoring system ................................................................. 33
2.9.2 Long-term monitoring system .................................................................. 36
2.9.3 Point of care devices ................................................................................. 43
2.10 Risk factors for diabetes mellitus................................................................... 46
2.10.1 Urbanization............................................................................................ 46
2.10.2 Racial Predisposition ............................................................................... 47
2.10.3 Genetic Risk............................................................................................. 48
2.10.4 Ageing...................................................................................................... 48
2.10.5 Anthropometric Characteristics.............................................................. 49
2.11 Burden of diabetes......................................................................................... 50
2.11.1 Global Burden of T2DM .......................................................................... 50
2.11.2 Diabetes burden in developing countries............................................... 52
2.11.3 Diabetes burden in the Eastern Mediterranean Region......................... 54
2.11.4 Prevalence of diabetes in the countries of the GCC ............................... 56
xi
2.11.5 The state of Kuwait and its Health system ............................................. 57
2.12 Management of T2DM................................................................................... 61
2.12.1 Dietary control ........................................................................................ 62
2.12.2 Pharmacological control ......................................................................... 65
3: Methodology...................................................................................................... 74
3.1 Research design (by objectives)....................................................................... 74
3.1.1 Objective 1: To determine the prevalence of T2DM and IR among a
Kuwaiti adult population attending Nuzha health facility. ................................ 74
3.1.2 Objective 2: To determine the risk factors for (a) T2DM and (b) IR in the
same adult population. ...................................................................................... 77
3.1.3 Objective 3: To describe the prevalence of IR among first-degree relatives
of patients with T2DM. ...................................................................................... 80
3.1.4 Objective 4: To establish the proportion of patients with T2DM who
achieve adequate glycaemic control and risk factors for poor glycaemic control.
............................................................................................................................ 82
3.1.5 Objective 5: To assess the agreement of a POC device to measure HbA1c
with a reference HbA1c assay kit to monitor DM control among patients with
DM and/or patients with known haemoglobinopathies. .................................. 84
xii
4: Results ................................................................................................................ 87
4.1 Objective 1: To determine the prevalence of T2DM and IR among adult
population attending a primary health care facility in Kuwait. ............................. 87
Demographic characteristics of participants. .................................................... 87
Biochemical profile of participants. ................................................................... 89
Participants unaware of having T2DM............................................................... 90
Prevalence of prediabetes ................................................................................. 90
Prevalence of T2DM and IR among participants ............................................... 91
4.2 Objective 2: Risk factors for T2DM and IR in a clinic study population. .......... 95
Comparison of participants with and without T2DM or IR................................ 95
Biochemical characteristics of normoglycaemic, IR and T2DM participants..... 97
Anthropometric measurements, nutritional habits, and physical activity in a
sub-sample of participants............................................................................... 105
Anthropometric measurements of participants with normoglycaemia, IR and
T2DM................................................................................................................ 106
Recall diet of participants and its association with IR and T2DM.................... 109
Prevalence of metabolic syndrome ................................................................. 111
xiii
4.3 Objective 3: Prevalence of IR among first-degree relatives of patients with
T2DM.................................................................................................................... 111
Demographic description................................................................................. 111
Prevalence of IR................................................................................................ 114
Prevalence of T2DM among first-degree relatives .......................................... 116
Prevalence of prediabetes ............................................................................... 117
Characteristics of normoglycaemic, IR and T2DM participants....................... 118
4.4 Objective 4: To establish the proportion of patients with T2DM who achieve
adequate glycaemic control and the risk factors for poor glycaemic control. .... 121
Demographic characteristics of participants ................................................... 121
Biochemical characteristics of study participants ........................................... 123
Demographic characteristics of participants by glycaemic status................... 125
Biochemical characteristics by glycaemic control status................................. 131
Anthropometric measurement of study participants by glycaemic control
status................................................................................................................ 133
Risk factors for poor glycaemic control – Univariate and multivariate analyses.
.......................................................................................................................... 135
xiv
Nutritional behaviour of participants by glycaemic control status ................. 139
4.5 Objective 5: Accuracy of a point-of-care device to measure HbA1c for the
monitoring of HbA1c among patients with T2DM and patients with known
haemoglobinopathies. ......................................................................................... 140
Demographic characteristic of participants..................................................... 140
The accuracy of the Quo-test in the diagnosis of the HbA1c status in individuals
with T2DM........................................................................................................ 141
5: Discussion......................................................................................................... 147
Objectives 1 and 2................................................................................................ 147
Prevalence of T2DM......................................................................................... 147
Risk factors for T2DM....................................................................................... 148
Prevalence of IR................................................................................................ 152
Prevalence of metabolic syndrome ................................................................. 154
IR and PDM risk factors .................................................................................... 154
Objective 3 ........................................................................................................... 159
Prevalence of IR in first-degree relatives of T2DM patients............................ 159
Risk factors for IR and T2DM in first-degree relatives of T2DM...................... 160
xv
Objective 4 ........................................................................................................... 162
Prevalence of good glycaemic control ............................................................. 162
Risk factors for poor glycaemic control ........................................................... 163
Objective 5 ........................................................................................................... 166
Performance of the Quo-Test against the gold standard test ......................... 167
6: Recommendations ........................................................................................... 168
Future research questions ............................................................................... 169
References............................................................................................................ 171
Appendices........................................................................................................... 202
Prevalence of Type 2 DM and IR questionnaire (objective 1) ............................. 202
DM and IR risk factors questionnaire (for objective 2)........................................ 203
IR in first degree relative’s questionnaire (objective 3)....................................... 206
Diabetic clinic questionnaire (for objective 4) ..................................................... 207
Accuracy of POC test questionnaire (objective 5) ............................................... 210
Consent Form (English) ........................................................................................ 211
Consent form (Arabic) .......................................................................................... 212
xvi
Ethical approval (LSTM) ....................................................................................... 214
Ethical approval (Kuwait) ..................................................................................... 215
Ethical committee proposal ................................................................................. 216
Aim of the study............................................................................................... 222
Objectives of the study .................................................................................... 223
Capacity building and training ......................................................................... 223
Study plan......................................................................................................... 225
Study design ..................................................................................................... 225
Methodology.................................................................................................... 225
Sample size calculation .................................................................................... 234
Study outcome ................................................................................................. 236
Study management .......................................................................................... 237
Statistical analysis ............................................................................................ 241
xvii
List of Tables
Table 1: Aetiological classification of diabetes mellitus .............................................. 6
Table 2: Presenting symptoms of T2DM (overlapped symptoms) ............................ 20
Table 3: Acute and chronic complications of DM ...................................................... 21
Table 4: Ideal values for blood glucose control in T2DM patients ............................ 35
Table 5: Suggested targets of HbA1c based on ADA/EASD recommendations......... 42
Table 6: Top 10 causes of DALYs globally 2015 ( ....................................................... 51
Table 7: Indications for Insulin ................................................................................... 70
Table 8: Demographic characteristics (and blood pressure status) of participants .. 87
Table 9: Biochemical characteristics of participants.................................................. 89
Table 10:  Agreement of FPG and HbA1c among participants not known to have
T2DM.......................................................................................................................... 90
Table 11: Agreement of FPG and HbA1c in participants with no diabetes ............... 91
Table 12: Proportion of participants with T2DM and IR............................................ 91
Table 13: Demographic characteristics and blood pressure status of participants
with normoglycaemia, IR and T2DM.......................................................................... 96
Table 14: Biochemical characteristics of participants with/without IR and T2DM. .. 98
xviii
Table 15:  Descriptive analysis and odds ratios for the study groups. .................... 101
Table 16: Adjusted odds ratios (normal vs IR) ......................................................... 104
Table 17: Adjusted odds ratio (normal vs T2DM) .................................................... 105
Table 18: Anthropometric measurements of participants ...................................... 108
Table 19: Median and IQR for patients with normal glucose and T2DM ................ 109
Table 20: Median and IQR rank for participants with normal glucose and IR. ........ 110
Table 21:  Demographic characteristics of first-degree relatives of patients with
T2DM........................................................................................................................ 112
Table 22: Biochemical characteristics of first-degree relatives of patients with T2DM
.................................................................................................................................. 113
Table 23: HOMA-IR, HbA1c and FPG of first-degree relatives of T2DM participants.
.................................................................................................................................. 114
Table 24: Agreement of FPG and HbA1c among relatives of patients with T2DM. 116
Table 25: Agreement of FPG and HbA1c in participants with no diabetes ............. 117
Table 26: Demographic characteristics of first-degree relatives with and without IR
.................................................................................................................................. 119
Table 27: Demographic characteristics of participants ........................................... 122
xix
Table 28: Biochemical characteristics of participants.............................................. 124
Table 29: Demographic characteristics of participants by glycaemic control status
.................................................................................................................................. 128
Table 30: Biochemical characteristics of participants by glycaemic control status 132
Table 31: Anthropometric measurements for participants according to their
glycaemic status ....................................................................................................... 133
Table 32: Descriptive analysis and odds ratios comparing patients with good and
poor glycaemic control............................................................................................. 135
Table 33: Adjusted odds ratios (good vs poor glycaemic control)........................... 137
Table 34: Anthropometric characteristics and odds ratios for participants with good
and poor glycaemic control ..................................................................................... 138
Table 35: Median and IQR for participants with good and poor glycaemic control 139
Table 36: Demographic characteristics of participants with T2DM and no
haemoglobinopathies .............................................................................................. 140
Table 37: Demographic characteristics of participants with abnormal haemoglobin
.................................................................................................................................. 141
Table 38: Agreement between Quo-test POC HbA1c and Tosoh Laboratory HbA1c
(reference) when using an HbA1c cut-off of 9%...................................................... 144
xx
Table 39: The agreement of POC HbA1c and Lab HbA1c (Kappa) when HbA1c cut-off
point is 7%................................................................................................................ 144
xxi
List of Figures
Figure 1: Map of WHO's Eastern Mediterranean Region (http://www.iapb.org/) ... 55
Figure 2: Map showing the Gulf Cooperation Council countries
(http://www.erutledge.com/) ................................................................................... 56
Figure 3: Map of Kuwait (http://www.worldatlas.com) ............................................ 57
Figure 4: Nuzha health care centre............................................................................ 74
Figure 5: Anthropometric and blood pressure measurement room......................... 80
Figure 6: Nuzha laboratory ........................................................................................ 82
Figure 7: The main researcher filling a questionnaire ............................................... 83
Figure 8: A participant giving finger-prick sample for HbA1c .................................... 86
Figure 9: Illustration of collecting blood and running the test .................................. 86
Figure 10: Age distribution by sex.............................................................................. 93
Figure 11: Glycaemic status in males, normal, prediabetes, and T2DM (HbA1c) ..... 94
Figure 12: Glycaemic status in females, normal, prediabetes, and T2DM (HbA1c) .. 94
Figure 13: Mean and 95% CI (a) LDL, (b) HDL and (c) triglyceride levels in participants
with normal glucose, IR and T2DM. ........................................................................... 99
xxii
Figure 14: Mean and 95% CI of LDL, HDL, and TG in normoglycaemic, newly
diagnosed T2DM, and known T2DM........................................................................ 100
Figure 15: Mean and 95% CI BMI and waist (a. female and b. male) of participants
with normal glucose, IR and T2DM. ......................................................................... 107
Figure 16: Age distribution of participants by gender ............................................. 112
Figure 17: Homa2 IR distribution among first-degree relatives of patients with T2DM
.................................................................................................................................. 115
Figure 18: HbA1c distribution among first-degree relatives of patients with T2DM
.................................................................................................................................. 115
Figure 19: FPG distribution among first-degree relatives of patients with T2DM .. 116
Figure 20: Correlation between FPG and HbA1c (lines are the 95% CI) among first-
degree relatives of patients with T2DM. ................................................................. 118
Figure 21: Dispersion of HbA1c level among participants ....................................... 124
Figure 22: A scattered diagram showing the dispersion of HbA1c according to age
.................................................................................................................................. 125
Figure 23: A stacked histogram showing the prevalence of good, moderate and poor
glycaemic control in different age group................................................................. 126
Figure 24: Mean and 95% CI TG level among the three glycaemic control groups. 131
xxiii
Figure 25: Mean and 95% CI of HbA1c in non-smoker, ex-smoker, and smoker
groups....................................................................................................................... 132
Figure 26: Mean and 95%CI of BMI in the three glycaemic control groups ............ 134
Figure 27: Quo-test POC/Tosoh Laboratory HbA1c results ..................................... 142
Figure 28: Bland-Altman plot ................................................................................... 143
Figure 29: POC/LAB agreement plot in people with abnormal haemoglobin ......... 145
Figure 30: HbA1c difference (Lab-POC) plot according to HbF level ....................... 146
12. Literature review
Introduction
Diabetes Mellitus (DM) is a syndrome that includes a group of metabolic
disorders characterised by insufficient insulin secretion, resistance to the action
of insulin or both (American Diabetes, 2009).
DM is a seriously growing public health problem which has reached epidemic
proportions, and its prevalence is increasing globally. In 2003, it was estimated
that there were 194 million individuals with DM, with a worldwide prevalence of
5.1% (Federation, 2003). By 2015, the International Diabetes Federation (IDF)
world atlas indicated that the prevalence had increased to 9.1%, with more than
415 million people living with DM around the world.  Even worse, 46.5% of the
individuals with DM are unware of their condition and remain undiagnosed.
These individuals are likely to age prematurely and to suffer the major health
consequences of poor DM management.  It is estimated that one person dies
every six minutes due to DM and that governments will need to spend one-ninth
of their health care expenditure on DM (IDF, 2015).
Type 2 DM (T2DM) is the most common presentation of DM; Gestational DM is
frequent but short-lived, followed by Type 1 DM (William T. Cefalu, 2015). T2DM
is characterized by hyperglycemia resulting from a defect in the pancreas insulin
secretory function and/or Insulin resistance (IR) (Gareth Williams, 2002).
IR is a condition in which the insulin target cells fail to respond to the normal
actions of insulin. The pancreas produces insulin, but the cells in the body tissues
become resistant to insulin and are unable to use it as efficiently, leading to high
blood glucose concentration. Subsequently, β cells increase their production of
insulin trying to reach proper glycemic control, causing a high blood insulin level
(Chiu et al., 2007)
2With the purpose of developing a programme to control the progression of DM in
Kuwait, it is important to do a situation analysis of the disease in the country and
to describe the leading risk factors associated with T2DM in the community.
Chapter 2 (literature review) principally sets the scene for the whole thesis as it
provides an overview of the literature relating to the global and regional
prevalence and risk factors of T2DM, emphasising the importance of studying
T2DM in Kuwait.
Furthermore, this chapter will debate the pathogenesis of T2DM, discussing IR
and β cell dysfunction. Then, it will confer the mechanism of glucose homeostasis
and the key hormones regulating blood glucose concentration. This review will
discuss the clinical presentation of T2DM, including acute and chronic
complication.
Short and long-term monitoring methods will be included in this chapter,
followed by a brief section on the management of T2DM.
Chapter 3 will discuss the methodology used in this study; the methodology is
separated into five sections, describing the method of each objective including
the analysis plan.
Chapter 4 presents the results of the study. The results will include the
prevalence and risk factors of T2DM, prediabetes, IR in the selected population. It
also contains the prevalence of IR in first degree relatives of individuals with
T2DM. Furthermore, it shows the prevalence and the risk factors of poor
glycaemic control in patients with T2DM attending a diabetic clinic. This is
followed by a section showing the performance of a POC device against a
reference test in determining the glycaemic status of people with T2DM.
Chapter 5 discusses the results of our study and compare it to other local,
general, and global studies.
3Finally, chapter 6 provides a brief discussion of the findings and outlines
implications for health care professionals, health promotion and future research.
2.1 Importance of studying Diabetes.
Diabetes Mellitus (DM) is one of the main public health challenges, the extent of
the disease demands regular population-based studies to determine the
prevalence and risk factors for T2DM. Studies should also assess the trends and
impact of interventions, especially in countries with a significant diabetes burden
such as Kuwait. According to the NCD risk factor collaboration, the crude
estimate of T2DM prevalence in Kuwait in 2004 was 14.8% in men and 14.6 in
women (NCDs, 2014) It is now well recognised that countries of the Gulf
Cooperation Council (GCC) are among the countries facing the greatest burden of
T2DM. This has been linked mainly to the increasing and rapid urbanization and
socioeconomic development in these countries, the sudden extraordinary
increase in income and prosperity which resulted in substantial lifestyle changes
of their populations toward sedentary life and consumption of “Western-style”
fast foods (Klautzer et al., 2014).
The International Diabetes Federation (IDF) recognises that the Eastern
Mediterranean Region (EMR) as a major hot-spot for T2DM (Majeed et al., 2014).
With a projected 96% increase in T2DM prevalence among 20- 79 years old adults
(2013 vs 2035), which is only second to the Sub-Saharan region, where the
increase is expected to be as high as 110% of the 2013 baseline (World Economic
Forum, 2014). However, the healthcare systems in these countries are
unprepared to deal with this increasingly pressing health problem. Public health
sector planners and decision makers need to be more aware of the current
burden posed by T2DM and its complications. They must plan for effective
primary health care strategies to prevent ` diabetes onset, early disease detection
and improved management of patients with diabetes, including self-disease
management and management in primary care and community settings.
4In 2014, 9% of human adults had diabetes (World Health Organization, 2014), and
in 2012, diabetes was the direct cause of 1.5 million deaths (Al-Mawali, 2015).
Furthermore, T2DM is expected to be the 7th leading cause of death in 2030
(Mathers and Loncar, 2006).
In England, more than one in ten (11.6%) deaths of adults are diabetes-related
(National Health Service, 2010), and in 2013/2014 NHS prescriptions for diabetes-
related items cost was £803.1 million, consuming 9.5% of the total health care
expenditure of the primary care (National Health Service, 2015). Life expectancy
in people with T2DM is estimated to be reduced, and for example, people with
diabetes in the UK are 34.4% more likely to die younger than other individuals
without diabetes (Diabetes UK, 2016).
Data on 161,161 participants from 31 cohort studies in the Asia-Pacific region
showed that patients with diabetes were 1.8 times more likely to have
cardiovascular disease than patients with no diabetes (Murakami et al., 2012).
Diabetic retinopathy is also a major microvascular complication of T2DM, the
prevalence of diabetic retinopathy is increasing worldwide, with a higher
prevalence in developing countries. A relatively recent study in China showed
that 43% of patients with diabetes have retinopathy (Zheng et al., 2012). This is
why T2DM is the one of the leading cause of blindness (Nentwich and Ulbig,
2015). A foot ulcer is another common microvascular complication.  Data from a
systemic review have shown that diabetes is second only to smoking as a cause of
peripheral artery diseases which is the most important cause of limb amputation
worldwide (Thiruvoipati et al., 2015).
T2DM is strongly associated with modifiable risk factors. These include obesity,
sedentary lifestyle, dyslipidaemia, hypertension, smoking, and low intake of high
fibres food (Wu et al., 2014). It is important to implement more comprehensive
diagnostic and preventive strategies to decrease mortality and morbidity caused
by T2DM (Zahra et al., 2015) especially that T2DM is now recognised as a
preventable disease (Tuso, 2014).
52.2 Definition of diabetes
Diabetes mellitus is a chronic disease that occurs when the body cannot produce
enough insulin or when the body cannot use insulin effectively, or both
(American Diabetes, 2010). Insulin is a hormone produced by the β cells of the
islets of Langerhans in the pancreas; it allows the glucose obtained from food to
enter the body’s cells where it is transformed into energy needed by muscles and
tissues to maintain its function. A person with diabetes cannot utilize glucose
properly, and glucose remains circulating in abnormally high concentrations in
the blood. This condition is called hyperglycaemia and it  causes severe damages
to body tissues over time (Beale, 2013). This damage can lead to disabling and
life-threatening health complications (Hage Hassan et al., 2014).
According to the American Association of Diabetes, the current criteria for the
diagnosis of diabetes are:
 A glycated haemoglobin (HbA1c) ≥ 6.5%. The test should be performed in a
laboratory using a method that is certified by the National Glycohemoglobin
Standardization Program (NGSP) and standardised to the Diabetes Control
and Complications Trial (DCCT) assay.
Or
 Fasting plasma glucose ≥ 7 mmol/l (≥ 126 mg/dl). Fasting is defined as no
caloric intake for at least 8 hours.
Or
 Two-hour plasma glucose ≥ 11.1 mmol/l (≥ 200 mg/dl) during an oral
glucose tolerance test (OGTT). The test should be performed as described
by the World Health Organization (WHO), using a glucose load containing
the equivalent of 75 g anhydrous glucose dissolved in water.
Or
 In a patient with classic symptoms of hyperglycaemia or hyperglycaemic
crisis, random plasma glucose ≥ 11.1 mmol/l (≥ 200 mg/dl).
6In the absence of unequivocal hyperglycaemia, the result should be confirmed by
repeating the test.
2.3 Types of diabetes
Hyperglycaemia may occur in a variety of situations, with different clinical
presentations. In 1951 Lawrence classified diabetes into two classes (Lawrence,
1951), type 1 or juvenile diabetes with absolute insulin deficiency or type 2 with
relative insulin deficiency (Table 1).
Table 1: Aetiological classification of diabetes mellitus
1) Type 1 diabetes (β cell destruction, usually leading to absolute insulin
deficiency)
a. Immune-mediated
b. Idiopathic
2) Type 2 Diabetes (may range from predominantly insulin resistance with relative
insulin deficiency to a predominantly secretory defect with insulin resistance)
3) Other specific types
a. Genetic defects of β cell function
1. Maturity-onset diabetes in young (MODY)
2. Transient neonatal diabetes
3. Permanent neonatal diabetes
4. Mitochondrial deoxyribonucleic acid
b. Genetic defect in insulin action
1. Type A insulin resistance
2. Leprechaunism
3. Rabson-Mendenhall syndrome
4. Lipoatrophic diabetes
c. Disease of the exocrine pancreas
1. Pancreatitis
72. Trauma/pancreatectomy
3. Neoplasia
4. Cystic fibrosis
5. Hemochromatosis
6. Fibrocalculous pancreatopathy
d. Endocrinopathy
1. Acromegaly
2. Cushing’s syndrome
3. Glucagonoma
4. Pheochromocytoma
5. Hyperthyroidism
6. Somatostatinoma
7. Aldosteronoma
e. Drug or chemically induced
1. Vacor
2. Pentamidine
3. Nicotinic acid
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide
7. - adrenergic agonists
8. Thiazides
9. Dilantin
10. -interferon
f. Infections
1. Congenital rubella
2. Cytomegalovirus
g. Uncommon forms of immune-mediated diabetes
1. “Stiff-man” syndrome
2. Anti-insulin receptor antibodies
h. Genetic syndrome
81. Klinefelter syndrome
2. Turner syndrome
3. Wolfram syndrome
4. Friedrich ataxia
5. Huntington chorea
6. Laurence-Moon Biedl syndrome
7. Myotonic dystrophy
8. Porphyria
9. Prader-Willi syndrome
4) Gestational diabetes mellitus
Source: (American Diabetes, 2013)
2.4 Pathogenesis of diabetes mellitus
The secretion of insulin is mainly modulated by the existing levels of glucose in
the blood and interstitial fluid (Cerf, 2013). During the fasting period, the basal
rate of insulin secretion maintains the plasma glucose levels between 4.0 and
5.5 mmol/l (70 to 100 mg/dl) (Horton, 2009). After ingestion of food, there is a
sharp increase in insulin secretion in response to incretin hormones. These
insulinotropic hormones are secreted by the gastrointestinal system (Kim and
Egan, 2008). Failure of β cells to maintain an adequate level of insulin secretion is
believed to be the primary pathway for the development of T2DM.
T2DM is a heterogeneous disorder with highly complex pathogenicity. Two
factors operate in parallel with the evolution of T2DM:
1. Impaired insulin sensitivity, a condition known as insulin resistance (IR).
2. β cell defect: Insulin secretory dysfunction.
Furthermore, both insulin sensitivity and β cell action are modulated by genetic
and environmental factors (Fradin and Bougnères, 2011).
92.5 Glucose homeostasis
Blood glucose values average (throughout the day) approximately 5.0 mmol/l (90
mg/dl), the maximal level after meal ingestion should not exceed 9.3 mmol/l (168
mg/dl), and glucose levels remain above 3.6 mmol/l (65 mg/dl) even after
moderate starvation. This narrow glycaemic range defines normoglycaemia;
which is maintained by the neurohormonal regulatory system. A decrease in
blood glucose from 5.0 to 3.9 mmol/l (90 to 70 mg/dl) will suppress insulin
production from the pancreas and reduce glucose uptake by the hypothalamus,
where glucose sensors are located. This will trigger the sympathetic system to
release counter-regulatory hormones including; glucagon, cortisol,
catecholamines and growth hormones (Freckmann et al., 2007, Sprague and
Arbeláez, 2011).
Plasma glucose comes from diet or as a result of the breakdown of glycogen in
the liver in a process called glycogenolysis. Alternatively, it originates
“gluconeogenesis” from the formation of glucose in the kidney, liver, intestine,
and muscles from other glucose precursors such as alanine, lactate, and pyruvate.
Some recent studies have shown that gluconeogenesis can even occur in the
brain (Yip et al., 2016). Glucose under different conditions may have other fates
in various tissues, but the pathways for its clearance are relatively restricted. It
may be directly stored as glycogen or may undergo glycolysis in the cytoplasm
producing pyruvate (Rui, 2014). Non-oxidative glycolysis carbons undergo
gluconeogenesis creating glucose, and according to the different metabolic
conditions, the newly formed glucose is either stored as glycogen or released
back into the blood (Guo et al., 2012). Although free fatty acids are the primary
fuel for the majority of organs, glucose remains the only metabolic fuel for the
brain under normal physiologic conditions, that is because of the limitations of
free fatty acids (FFA) transportation across the blood-brain barriers (Schönfeld
and Reiser, 2013).
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2.6 Key hormones influencing glucose level
Insulin, together with glucagon, is the crucial factor regulating the plasma levels
of glucose, metabolism, energy production and formation of fat in the body
(lipogenesis). Insulin coordinates processes related to glucose uptake, lipolysis,
and gluconeogenesis, its level in plasma increase promptly after a meal, in direct
response to the rise of glucose in the bloodstream (Wilcox, 2005). Skeletal muscle
is the primary organ responsible for blood glucose consumption after a meal,
followed by liver and adipose tissue. Moreover, Insulin facilitates vasodilatation,
causing increase in blood flow to the peripheral tissues allowing for more
nutrients delivery, especially to the skeletal tissues (Lambadiari et al., 2015).
2.6.1 Insulin
History of Insulin
In 1889 two German scientists, von Miring and Oskar Minkowski noted, from
their studies on animals, which after total pancreatectomy animals developed
severe diabetes. They theorised that there was a substance secreted by the
pancreatic cells responsible for the glycaemic control. The hypothesis was later
refined by others, recognising diabetes to be associated with the destruction of
the islets of Langerhans. Minkowski and Zuelzer in Germany, as well as Scott in
the USA and the Romanian Paulesco, attempted to isolate and administer the
missing pancreatic islet substance (Karamitsos, 2011). Belgian scientist de Meyer
in 1909 suggested the name “insulin”; this name has also been proposed by the
British researcher Schaefer later in 1916 (De Meyts Pierre, 2014).
In 1921, insulin was isolated, purified and became available in a form for
therapeutic administration. In May 1921, a young orthopaedic surgeon called
Banting, assisted by his medical student Best, and under the supervision of
McLeod, head of the physiology department at Toronto University began
experiments in dogs. They infused saline extracts of pancreas intravenously to
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deliberately diabetic dogs (by pancreatectomy) and observed the lowering effect
of the insulin on the blood glucose (Rosenfeld, 2002). Collip, who was a
biochemist, joined McLeod’s experimental team in Toronto and demonstrated
that this extract lowered sugar excretion in urine and established that the
deficiency in insulin secretion was the cause of diabetes (Lakhtakia, 2013).
In January 1922, the first human experiments began on a 14-year-old boy with
diabetes. He was clinically symptomatic; his biochemical deviations were
reversed by the administration of the pancreatic isolate (Rosenfeld, 2002). In May
1922, the pancreatic extract had been named insulin, and the results of these
experiments were presented to the Association of American Physicians. Eli Lilly
began production of porcine insulin, enhancing purification and the production of
commercial quantities in early 1923. Subsequently, Banting and McLeod were
awarded the 1923 Nobel prize (Quianzon and Cheikh, 2012).
Insulin receptors signalling cascade
T2DM is increasing worldwide; a primary focus of research is understanding the
signalling pathways influencing this disease. Insulin signalling regulates glucose
homeostasis, lipid, and energy production, mostly via their action on the adipose
tissue, liver, and skeletal muscle. Accurate control of this pathway is crucial for
adaptation as the situation moves from feeding to a fasting state. Positive and
negative receptor signals work at different stages of the signalling pathway, as
well as the variety of protein isoform interfacing to ensure an appropriate and
synchronised Insulin biological action in various tissues. Insulin controls a wide
range of biological processes by acting on two closely related tyrosine kinase
receptors. Activation of insulin receptors by their binding molecules starts a
sequence of phosphorylation events that lead to the activation of proteins that
controls metabolism and growth (Bononi et al., 2011). Insulin receptor signalling
consists of several points of regulatory steps. These steps are controlled both
negatively and positively, to ensure proper signal intensity and duration.
Dysfunctions in these signalling pathways can lead to IR (Boucher et al., 2014).
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(Pearson Education, https://goo.gl/images/Bb97nG)
Insulin action
Dysfunction of any glucose homeostasis pathway would disturb metabolic
regulation and promote the development of pre-diabetes and eventually, if not
corrected, to T2DM.
Defect in Insulin signalling
As mentioned before, skeletal muscle is the primary site of insulin-mediated
glucose clearance and play a significant role in decreasing glucose uptake, as in
states of IR. Dysfunction in the early insulin-signalling pathway leading to the
reduction of glucose uptake plays a primary role in the development of IR.
13
A substantial body evidence supports that insulin-signalling pathway dysfunction
contributes to IR in tissues like the skeletal muscle and human as general. For
example, in patients with T2DM or obesity, several investigators have shown
decreased phosphorylation of the insulin receptors, decreased PI3K activation
and decrease IRS-1 tyrosine phosphorylation (Bandyopadhyay et al., 2005).
Scientific evidence that a reduction in the insulin receptor kinase itself can add to
the development of IR is increasing (Chiu and Cline, 2010). However, it is
indefinite whether these changes in insulin receptor role represent a primary
defect that causes IR or whether they occur secondary to hyperglycaemia or
hyperinsulinemia. Even if the defect at the level of the insulin receptor can cause
these physiological behaviours, whether decreased insulin receptor function can
account for the insulin-resistant pathophysiology present in the general patient
population is doubtful (American Diabetes, 2009).
Impaired β cell function
Some studies were conducted during the late 80s and early 90s on
normoglycaemic participants with a genetic predisposition for T2DM from
vulnerable ethnic groups such as African American, Mexican American, and
Pacific Islands populations, demonstrating IR as the predictor and precursor for
T2DM. Other studies suggested that β cell dysfunction is the primary defect in
type2 diabetes (Doria et al., 2008). In 1979, DeFronzo introduced the euglycemic
and hyperglycaemic clamp technique and later, this technique was used by
Pimenta, to conclude that an insulin secretion defect is the major factor for T2DM
(Pimenta et al., 1995, Tam et al., 2012). Furthermore, Van Haeften et.al.
compared the importance of β cell dysfunction to IR, concluding that impaired β
cell function has a predisposed genetic predisposition in T2DM patients (Van
Haeften et al., 2000).
More recently, diabetes experts have suggested that a continuous decline in the
secretion of insulin starts many years before the diagnosis of T2DM, with the
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progressive dysfunction of β cells as the leading factor in the development of
hyperglycaemia (Halban et al., 2014).
Mechanism of β cell dysfunction
Failure of the β cells to maintain an adequate amount of insulin secretion in
response to blood glucose level is the main and final pathway in the pathogenesis
of T2DM. The integrity of β cells is crucial.  The islets of Langerhans are affected
by several elements including obesity, consumption of saturated fat and FFA and
cytokine-induced inflammation (Cerf, 2013).
Hypothetically, the β cells decompensation process can develop in five stages.
These stages are based on experimental evidence and clinical observation. Stage
1 is indicated by adequate adaptation to the increase in blood glucose level, to
overcome IR which is usually present in individuals with a predisposition to
T2DM. At this stage, there will be an increase in β cells mass and normal or
sometimes higher insulin level. Stage 2 is characterized by early signs of
decompensation, β cells secretory action will start to regress, and this stage
shows increase blood glucose up to 6.6 mmol/l (120 mg/dl). By the time fasting
blood glucose reaches up to 6.1 mmol/l (110 mg/dl), the condition will be called
prediabetes.
In Stage 3, progressive β cell dysfunction and apparent decompensation is
eminent. This phase demonstrates the rise of blood glucose to a diabetes
threshold. Glucose-induced Insulin secretion is entirely impaired. Other non-
glucose insulin responses may still be in action but significantly compromised.
Stage 4 is characterized by chronic functional decompensation with structural
changes characteristics of T2DM. These consist of Amyloid deposition in the
pancreas and the presence of lipid droplets; fibrosis; apoptosis; degeneration and
glycogen deposits. Stage 5 is the last stage of diabetes, there will be severe loss of
β cell function. Patients at this stage will depend on external insulin to survive,
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otherwise, will develop fatal diabetic ketosis. This stage is typically present in
type 1 diabetes (Weir and Bonner-Weir, 2004, Curran et al., 2016).
It is accepted that T2DM is a genetically predetermined failure of the β cell
(DeFronzo and Abdul-Ghani, 2011). However, according to recent diabetes
studies, decreased insulin receptor function, particularly in skeletal muscles, can
account for the insulin-resistant pathophysiology present in the general patient
population, and the hypothesis of pooled defects in insulin secretion and insulin
sensitivity appear to be more accepted (Taylor, 2012). Polonsky and co-workers
suggested that T2DM is a genetically programmed failure of the β cell to
compensate for IR (Polonsky et al., 1996). Further, Miyazaki and co-workers and
Rendell et. al. share a similar interpretation where it has been proposed that
abdominal obesity, which is believed to be genetically inherited, is associated
with fat deposits in pancreatic cells, muscles, and liver, can suggest the common
explanation for defects in insulin secretion and insulin sensitivity (Miyazaki et al.,
2002, Rendell et al., 2001).
The genes predisposing to T2DM and the metabolic syndrome are energy-saving
thrifty genes that helped our ancestors to survive by storing energy in the form of
fat (Genné-Bacon, 2014). This perhaps clarifies the fact of the high prevalence of
T2DM among Pima Indians, Pacific Islanders, and Native Australian. Similarly, it
may explain the recent massive epidemic in several developing countries like
Arabian Peninsula (Acton et al., 2002, Sherif and Sumpio, 2015).
The challenging hypothesis of relative superiorities in the defective insulin
secretion or IR is still a debatable issue (Cernea and Dobreanu, 2013). Highlighting
the importance of IR is the fact of the frequent initial finding of hyperinsulinemia
in the early stages of T2DM (Roberts et al., 2013).
Higher insulin response to glucose may be prominent during progression from
normal glucose tolerance (NGT) to impaired glucose tolerance (IGT).  The second
phase of increased insulin secretion is noticeable in patients with prediabetes for
some years before the onset of T2DM (Haffner et al., 2000, Fonseca, 2009).
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Hence, it is possible to assume that both factors are equally liable for the
pathogenesis of T2DM. So far, it is accepted to say that whichever comes first the
other follows (Cerf, 2013). Recently, the roles of incretin, leptin, renal tubular
glucose resorption and hypothalamic nuclei in homeostasis have been
emphasised (DeFronzo et al., 2014).
An innovative study with the hypothesis that high caloric intake will increase the
deposition of fatty liver and high content of TG in the liver, leading to decrease in
hepatic insulin sensitivity, furthermore, the fat content in the pancreatic cell will
increase, leading to the increase of ATP production and insensitivity to glucose.
This condition will lead to the prognosis of T2DM. The study showed that low
caloric intake with significant weight loss was able to cause a substantial fall in
fasting plasma glucose. This was the first study to show that β cells are inhibited
rather than permanently damaged in T2DM (Taylor, 2013).
2.7 Clinical and subclinical features of hyperglycaemia
In T2DM, the onset and the progress of hyperglycaemia are so slow as to remain
unnoticeable.  These asymptomatic patients come to attention usually by
accident, as a part of the preoperative evaluation, screening campaigns and
individuals having a regular annual check-up (Kasznicki, 2014). Apart from this,
some patients are detected when they are under stress such as acute myocardial
infarction (AMI) or stroke. These patients could become normoglycaemic once
the stressful condition is over, but remain quite prone to develop diabetes in the
future and should be closely monitored (Arnold et al., 2015).
2.7.1 Prediabetes
Prediabetes is defined by blood glucose concentrations higher than normal, but
lower than established threshold for the diagnosis of diabetes. Prediabetes is also
known as intermediate hyperglycaemia, a state in which the risk of developing
diabetes is increased. The expert committee on diagnosis and classification of DM
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in 1997 and 2003 recognised these intermediate group of individuals whose
glucose levels, although not meeting criteria for diabetes, are however too high
to be considered normal.
These persons were defined as having impaired fasting glucose (IFG) [FPG levels
5.6 mmol/l (100 mg/dl) to 6.9 mmol/l (125mg/dl)] or IGT (2-h) values in the oral
glucose tolerance test (OGTT) of 7.8 mmol/l (140 mg/dl) to 11 mmol/l
(199mg/dl). However, the WHO and some other diabetes organisations define
the cutoff for IFG at 6.1 mmol/l (110 mg/dl) (Bansal, 2015).
Prediabetes is a high-risk state not only for developing diabetes, but also the
associated cardiovascular complications. These categories of IFG and IGT should
not be viewed as clinical terms, but rather as risk factors or a predictor of
diabetes as well as cardiovascular disease.
Likewise, an HbA1c in the range of 5.7-6.4% also defines individuals with
prediabetes and recognise a significantly higher risk for the future development
of diabetes and cardiovascular disease (Matfin and Pratley, 2010).
The relationship of HbA1c to the potential for subsequent development of
diabetes has also been studied in several large prospective studies which have
analysed the HbA1c values in the intermediate range. These studies have
demonstrated a strong, continuous association between HbA1c values and
subsequent diabetes. In a systematic review of 44,203 individuals from 16 cohort
studies with an average follow-up of 5.6 years, those with an HbA1c between
5.5% and 6% had a substantially increased risk of diabetes with five years’
incidence ranging from 9% to 25%, while an HbA1c range of 6-6.5% had a five
years’ risk of developing diabetes between 25% and 50% and relative risk (RR) 20
times higher compared with an HbA1c of 5% (Zhang et al., 2010b).
In another community-based study of non-diabetes individuals of a mixed racial
descent, the baseline HbA1c was a stronger predictor of subsequent diabetes and
cardiovascular events than fasting glucose (Selvin et al., 2010).
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Therefore, based on these data, it is reasonable to consider an HbA1c range of
5.7-6.4% as identifying individuals with prediabetes. As is the case for individuals
found to have IFG and IGT, persons with an HbA1c of 5.7-6.4% should be
informed of their increased risk for diabetes as when as cardiovascular disease
and counselled about effective strategies to lower their risks. Accordingly,
interventions should be intensive and follow-up particularly cautious for those
with HbA1c above 6% who should be considered to be at very high risk for
developing diabetes.
Impaired glucose tolerance (IGT)
Although IGT has become established as a category of abnormality in glucose
metabolism, there remain some problems with the categorisation of individuals
as IGT. Firstly, there is up to 40% variation in 2-h plasma glucose concentrations,
most of which is biological. Secondly, to apply cut-off values to a continuously
distributed variable with such large variability creates further difficulties. This is a
problem in defining IGT as there is a narrow 2-h plasma glucose range of 3.3
mmol/l (from 7.8 to 11.1) which separates normal glucose tolerance (NGT) from
T2DM (WHO and IDF, 2006). Subjects who have IGT on one occasion may not
have it when tested on another day. Those who test normal, on the second test
have been classified by some as having “transient IGT”, compared to those who
have IGT on repeat testing “persistent IGT”. Data from Pima Indians have shown
that subjects transient IGT also have increased the risk of future diabetes
although it would appear to be less than that seen in those with persistent IGT.
These data suggest that transient IGT at least in some populations represent an
earlier stage in the progression from NGT to the more serious category of glucose
intolerance (Kanat et al., 2015, Saad et al., 1988).
Aetiology and pathogenesis of IGT
Prediabetes represents an intermediate stage of glucose intolerance with the
likelihood that most people who develop T2DM pass through a stage of abnormal
glucose tolerance. Although there remains a debate about the underlying primary
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nature of the defect, data support the view that subjects with IGT have impaired
insulin action, i.e. their insulin-stimulated glucose uptake is less than those with
NGT. However, these subjects, maintain plasma glucose concentrations at levels
lower than those seen in manifest diabetes by compensatory hyperinsulinemia. It
is only when the exhausted pancreas can no longer adequately compensate for
the degree of IR that insulin deficiency arises and evident diabetes develops
(Aoyama-Sasabe et al., 2016).
In a study comparing Caucasians and South Asians showed that IR was more
prevalent in South Asian individuals (Bakker et al., 2013). Longitudinal data from
Pima Indians confirmed that the transition from NGT to IGT is characterised by
initial hyperinsulinemia and a further decrease in insulin secretion leads to the
development of the full picture of T2DM (Weyer et al., 1999).
Conversion to diabetes
IGT is neither a disease nor a syndrome. It has a certain predictive ability.
Subjects with IGT are at an increased risk of diabetes, the risk of conversion
depends upon some other risk factors as well. The conversion rate of diabetes in
individuals with glucose intolerance varies among populations. In a 10-year study,
the conversion rate from IGT to diabetes was 6.8% and 6.1% from IFG, and if both
were present, then the conversion to diabetes was 13.4% (Anjana et al., 2015).
2.7.2 Clinical presentation of T2DM
Clinically, patients with T2DM present with the overt disease when they are 50
years or above, but recently, studies have shown that it often occurs earlier.
Recently, T2DM is becoming increasingly common in children and young adults all
over the world including the Middle East (Al-Rubeaan, 2015, Wilmot and Idris,
2014). Individuals in this region have high suitability for developing vascular
complications earlier and more frequently.
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Markers for the diagnosis of T2DM include positive family history, obesity
especially central obesity, acanthosis nigricans and polycystic ovarian syndrome
(Wu et al., 2014).
The classic osmotic symptoms of polyuria, polydipsia, as well as low polyphagia,
when present, are very suggestive of diabetes. However, their symptoms are
more applicable to type 1 diabetes. On the other hand, fatigue, tingling of hands
and feet, generalised muscle ache and pain are more often seen in T2DM. Even
these symptoms usually occur after an extended and variable asymptomatic
period. Other presentations could include a non-healing wound or ulcer,
recurrent boils, unexplained vaginal itching, fungal infection and recurrent
bacterial infection. Male patients may complain of impotence as the first
symptoms. A collection of ants of places of urination is a common indicator in the
rural setting. Whitish spots from dried up urine on hard surfaces or
undergarments may offer another indication for glycosuria (Ramachandran,
2014, Karamanou et al., 2016).
As an example, a descriptive study of 132 T2DM patients attending a diabetes
clinic in India, reported that their average age was 55.2 ± ten years, 56% were
male, and 44% female. About 35% had a sedentary life, 42% were obese, 58%
with central obesity, presenting complaints in these patients (Table 2) were
osmotic symptoms polyuria, polydipsia, and nocturia in 39%, 37%, 37%
respectively, and lethargy in 61%. Weight loss in 11%, polyphagia in 40%,
progressive loss of vision in 3% delay in wound healing in 3%, paraesthesia in
17%, dyslipidaemia in 37%, hypertension in 50%, and obesity in 42%. However,
8% of the patients were asymptomatic (Borah and Goswami, 2017).
Table 2: Presenting symptoms of T2DM (overlapped symptoms)
Characteristics presenting symptoms n (%)
polyuria
nocturia
51 (39)
49 (37)
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2.8 Complication of T2DM
The disease burden of T2DM is mainly due to its wide range of complications.
Diabetes consequences result from the duration and degree of hyperglycaemia
and mainly affect the heart, kidney, and eye. Several prospective studies have
also shown that strict control of the glucose levels prevents or postponed the
complications (King et al., 1999). The broad spectrum of complications includes
acute and late complications, as shown in table 3. The late “chronic”
complications are mostly due to microvascular or macrovascular changes.
Table 3: Acute and chronic complications of DM
Acute metabolic complications
 diabetic ketoacidosis
 hyperosmolar hyperglycaemic state (HHS)
 lactic acidosis
Chronic complications
 microvascular
- retinopathy
- neuropathy
- nephropathy
polydipsia
polyphagia
lethargy
delay in wound healing
visual impairment
paraesthesia
weight loss
no symptoms
49 (37)
53 (40)
81 (61)
4 (3)
4 (3)
22 (17)
14 (11)
11 (8)
Co-morbidities
obesity
dyslipidaemia
hypertension
56 (42)
49 (37)
66 (50)
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 macrovascular
- hypertension
- coronary heart disease (CHD)
- cerebrovascular disease (CVD)
- peripheral vascular disease (PVD)
Other
 cardiac
- diabetic cardiomyopathy
 infection
- fungal, bacterial, mycobacterial
 ocular
- infections
- cataract
- glaucoma
 dermatological
- necrobiosis lipoidca diabeticorum
- granuloma annulare
- diabetic scleroderma
- diabetic bullae
 connective tissue
- carpal tunnel syndrome
- limited joint mobility
- osteopenia, osteoarthritis
- adhesive capsulitis of shoulder joint
 oral
- periodontal disease
- caries
- candidiasis
2.8.1 Acute metabolic complications
Acute metabolic complications are more common with T1DM. The main acute
metabolic complications are often grouped as Hyperosmolar hyperglycaemic
state (HHS) and Diabetic ketoacidosis (DKA) (Gosmanov AR et al., 2015).
A better understanding of the pathogenesis of DKA, standardisation of fluid and
insulin therapy and patient education has rapidly decreased the incidence of DKA
and consequent mortality (Misra et al., 2013). The management of DKA depends
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on some very basic principles of fluid/electrolyte balance accompanied by insulin
therapy. The treatment requires replacement of fluids, potassium and sometimes
sodium bicarbonate, Insulin is usually administered through intravenous infusion.
Major metabolic complications of DKA include hypokalaemia, cerebral oedema,
and hypoglycaemia (Gosmanov et al., 2014).
HHS is usually found in T2DM, often among older patient who has insufficient
water intake due to mental limitations. In this case, the water deficit is massive,
but there is minimal or no acidosis, and insulin infusion is required in quantities
smaller than that administered in DKA (Pasquel and Umpierrez, 2014).
Lactic acidosis is a life-threatening condition, which can occur in any
hypoperfusion state, or altered glucose metabolism. Acidosis is usually severe,
and its management requires an introduction of large doses of sodium
bicarbonate intravenously (Cox et al., 2012). The administration of thiamine with
insulin has shown a beneficial effect in the treatment of lactic acidosis (Amrein et
al., 2011).
2.8.2 Long-term complications of T2DM
The long-term complications of T2DM are responsible for serious chronic health
problems. The atherosclerotic macrovascular complication such as CHD, CVD, and
peripheral vascular disease are all common complications (Chait and Bornfeldt,
2009). Diabetes tissue damage occurs mainly in tissues were glucose uptake is
insulin independent, and therefore, the influx of glucose in the cells is
unregulated and greatly increased in the presence of hyperglycaemia. Target
organ damage in diabetes occurs mainly in the retina, kidneys, peripheral nerves,
cardiac arteries and blood vessels, although no organ is spared.
Overall, the vascular wall appears to be the principal site of injury regardless of
the organ. Since little can be done after the development of overt complications,
the emphasis has always been on preventing or delaying complications (Mather,
2013, Asif, 2014).
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2.8.3 Mechanism of DM chronic complications
The role of hyperglycaemia in the development of diabetes complication and the
beneficial effect of strict glycaemic control have now been well established by
well-designed controlled clinical trials (Mannucci et al., 2013). Four major
pathways are believed to mediate the development of complications:
1. Polyol pathway flux
2. The advanced glycation end-products (AGEs)
3. The protein kinase C (PKC) isoforms
4. The over-activation of the hexosamine pathway.
Hyperglycaemia is the preliminary catalytic agent for most steps of these
pathways, which through a cascade of events exclusive to each pathway result in
tissue damage. The role of oxidative stress is critical in this process, elevated
extracellular glucose significantly increases the production of reactive oxygen
species (ROS), and several studies support the essential role of ROS in oxidative
stress (Giacco and Brownlee, 2010). In patients with diabetes, hyperglycaemia
primarily, and subsequent production of ROS decrease insulin gene expression
and secretion, eventually leading to the destruction and death of the tissue cells
(Asmat et al., Wright et al., 2006). Major links in the oxidative stress pathway
especially the stress sensitive gene expression mechanisms and other events
leading to nuclear factor-kappa B (NF- B) activation have now been fully
explained, thereby, our understanding of the basis of diabetes complications has
been greatly increased (Patel and Santani, 2009). Recently, a unifying innovative
theory for the development of diabetes complications has been proposed that
the oxidative stress is the catalyst in all the major pathways. Studying the cellular
and molecular mechanisms that mediate diabetes complications has identified
areas of potential therapeutic benefit (Roberts and Porter, 2013).
In general, the long-standing damaging effects of diabetes are divided into
microvascular (diabetic neuropathy, retinopathy, and nephropathy) and
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macrovascular complications (peripheral arterial disease, CVD, and CHD)
(Collinson et al., 2004).
2.8.4 Macrovascular complications
There is an agreement that the main pathological mechanism in macrovascular
disease is atherosclerosis, which contributes to the increase in the thickness of
the vessels wall and narrowing of arterial lumens throughout the body.
Atherosclerosis is believed to develop from the damage of the arterial wall and
the chronic inflammation in the peripheral vascular system, most prominent in
the coronary arteries (Rajendran et al., 2013). As a result of endothelial
inflammation and damage, oxidised lipids from low-density lipoprotein (LDL)
particles aggregate in the endothelial wall of arteries (Badimon et al., 2012). A
peptide hormone that causes vasoconstriction called Angiotensin II may stimulate
the oxidation of the LDL particles into VLDL. Monocytes then penetrate the
intima of the arteries and differentiate into macrophages, which builds up
oxidised lipids to form foam cells. Once formed, foam cells excite macrophage
production and attract T-lymphocytes. T-lymphocytes causes smooth muscle
proliferation in the arterial walls causing collagen build-up. The final result of this
process is the development of a fatty atherosclerotic lesion indicating a plaque
formation (Singh et al., 2002). Rupture of this atheroma will lead to acute
vascular infarction. Along with atheroma build-up, there is solid evidence that in
T2DM, the ability of blood coagulation and platelet aggregation is significantly
increased (Nicholaos Kakouros et al., 2011, Suslova et al., 2014).
Diminished nitric oxide production in platelets and increased formation of free
radical formation, as well as abnormal calcium regulation, may endorse platelet
aggregation (Vélez and García, 2015). The combination of impaired fibrinolysis
and increased coagulability anticipated to further increase the risk of
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cardiovascular events and vascular obstructions in patients with T2DM (Lorber,
2014).
Furthermore, hyperglycaemia appears to contribute directly to the development
of cardiomyopathy, rather than solely via coronary atherosclerosis and
hypertension. While the exact mechanisms by which diabetes increases the
chance of atherosclerotic plaque formation are not yet completely established,
the association between the two is well established (Laakso, 2010, Leon and
Maddox, 2015). CHD is the most common cause of death in people with T2DM,
and it is responsible for the uppermost part of health care expenditure (Zhuo et
al., 2014).
Among macrovascular diabetes complications, CHD is the most common serious
complication in many studies. Beginning about 70 years ago with the Framingham
study (Kannel and McGee, 1979). More recent studies have revealed that the risk
of developing myocardial infarction (MI) in people with diabetes is comparable to
the risk in patients with no diabetes with a history of the previous cardiovascular
event (Juutilainen et al., 2005). These findings led to new recommendations by
the  American Heart Association and ADA that diabetes mellitus should be
considered as a risk equivalent to coronary artery disease as a risk factor for
developing MI (Boyko and Meigs, 2011).
T2DM usually occurs as a component of metabolic syndrome, which also includes
hypertension, increased ability to form blood clots, dyslipidaemia, and abdominal
obesity. These other factors can also facilitate the development of CHD. Even in
this situation of several co-existing risk factors, T2DM by itself acts as an
independent risk factor for the development of CHD, CVD, and death (Martín-
Timón et al., 2014). Among individuals with T2DM, females may be at greater risk
for CHD than males, increasing the risk by three folds in males and up to 6 folds in
females (Maas and Appelman, 2010, Ergul et al., 2012). Coronary heart events
can be similarly predicted by the presence of microvascular disease. Likewise,
diabetes is a strong independent predictor of risk of cerebrovascular disease and
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stroke, as in coronary artery disease (Arboix et al., 2005). The potential for
stroke-related dementia as well as mortality is notably elevated in patients with
diabetes (Kalaria et al., 2016).
People with diabetes have higher mortality from CHD at all ages, and their
cardiovascular mortality rate is higher for all ages matched to the general
population (Lee et al., 2015c). The recognition of these associations has led to the
strictest treatment of DM to attain an effective prevention of CHD. Studies in
type 1 diabetes have shown that IR and uncontrolled hyperglycaemia is
associated with a higher resting heart rate, which is associated with increased risk
of CHD (Perciaccante et al., 2006). An innovative study showed that during 17
years of strict prospective treatment of diabetes, including lowering HbA1c, the
outcome was associated with a 57% decrease in total risk of nonfatal stroke, or
death from CVD, and 42% risk reduction in all CHD events (Skyler et al., 2009).
Another aim of treatment is to reduce blood lipid levels. Various studies have
shown that patients with diabetes managed with anti-cholesterol agents have a
reduced risk of macrovascular disease. These agents are effective in preventing
CHD, and diabetes patients with a history of CHD may benefit most from this
treatment (Eldor and Raz, 2009).
Studies like the UK Prospective diabetes study (UKPDS) showed that introducing
metformin to the therapy reduces the risk of CHD events (Kishore et al., 2012).
Reducing blood pressure in patients with T2DM has also been associated with a
reduction in the cardiovascular events and mortality (Conget and Giménez,
2009). There is an added advantage to lowering blood pressure with angiotensin
receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors.
Obstructing the renin-angiotensin system using either an ARBs or an ACE inhibitor
decreases cardiovascular endpoints more than other antihypertensive drugs
(Dézsi, 2014).
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2.8.5 Microvascular complications
The microvascular complication of diabetes involves kidneys, eyes, and the
nervous system, the economic and logistic burden of the individuals with
diabetes, plus the societal, national and global burden of these complications.
There has been much interest in the pathophysiology to (or “intending to”)
develop suitable pharmacologic preventive and therapeutic strategies (Kahn et
al., 2014).
These complications are already present in the prediabetes stages (IFG and IGT)
and metabolic syndrome and continue to damage the patients even when the
hyperglycaemia has apparently subsided. Indeed, there is evidence of
physiological abnormalities such as pancreatic dysfunction, C-peptide secretion,
even when patients are normoglycaemic (Praveen et al., 2012).
Diabetic polyneuropathy
Neuropathy is the most frequent complication of diabetes. Diabetic neuropathy
has a distal symmetric form which progresses proximally with a severe effect on
quality of life which can extend to several physiological systems (Schreiber et al.,
2015). The early detection and proper management of neuropathy in the patients
with diabetes is crucial because effective treatment options are available which
not only provide symptomatic relief but also delay the progression of the disease
efficiently and around 50% of the cases may be asymptomatic and can be
recognized only by specific tests, which include autonomic and sensory function
testing and nerve conduction studies too. Autonomic neuropathy is also a
common presentation, which can lead serious and may be life-threatening
complications and their main complaints are neuropathic pain, burning sensation,
tingling, decreased sensation and loss of temperature sensation (Pasnoor et al.,
2013).
The definition of diabetic neuropathy is “the presence of symptoms and/or signs
of peripheral nerve dysfunction in people with diabetes after the exclusion of
other cases” (Raza, 2016).
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The exact nature of the damage to the peripheral nerves from hyperglycaemia
has not been identified, but it is likely linked to mechanisms such as oxidative
stress injury from advanced glycation end products and polyol accumulation
(Schreiber et al., 2015).
This definition indicates that most but not all patients with peripheral nerve
dysfunction and diabetes have diabetic polyneuropathy (DPN).  The prevalence of
DPN ranges between 5 and 66% in people with diabetes (Hasani et al., 2013).
Confirmation of the aetiology requires quantitative electrophysiology, autonomic
and sensory function testing (Misra et al., 2008).
One of the largest published series reported a prevalence of DPN of 7.5 % at the
time of a diagnosis of diabetes, with the prevalence increasing steadily after
diagnosis. Most patients with diabetic neuropathy are asymptomatic at diagnosis,
soon after, many patients manifest with a mixture of neuropathic manifestations
(Hasani et al., 2013).
The most important risk factors for the development of neuropathy are the long
duration and the severity of hyperglycaemia. Other factors for developing DPN
include; male gender, increased height, smoking, the presence of
microalbuminuria, and alcoholism (Misra et al., 2008, Rosenberg et al., 2001).
Neurological dysfunction may occur in a wide variety of organ systems and can by
manifest by bladder dysfunction, constipation, diarrhoea, impotence,
tachycardia, and even sudden cardiac death (Stone et al., 2005).
Diabetic retinopathy
Diabetic retinopathy is one of the leading causes of preventable blindness.
Annual retinal examinations are mandatory in all patients with diabetes as it can
be asymptomatic. The main motivation for screening for diabetic retinopathy is
the preventing visual loss. The risk of acquiring diabetic retinopathy is affected by
both severity and the duration of hyperglycaemia (Lee et al., 2015a).
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The early treatment of diabetic retinopathy study (ETDRS) demonstrated that
argon laser photocoagulation treatment is beneficial in reducing the risk of retinal
bleeding and visual loss from clinically significant diabetic macular oedema (DME)
and proliferative diabetic retinopathy (Royle P et al., 2015). Innovative
technology like optical coherence tomography and novel treatment options like
intravitreal steroid injections have presented new hope to the patients with
diabetes with severe vision impairment (Sarao et al., 2014). National level
programs should be formulated for early detection, prompt referral and
appropriate treatment and lifelong follow-up of patients with sight-threatening
retinal detachment as more than 90% of cases of blindness could be prevented
(Wu et al., 2013).
There are several pathological mechanisms by which diabetes may lead to the
development of retinopathy. Retinal complications are a result of a loss of the
cellular components of retinal capillaries: the perivascular cells “pericyte”, and
the blood vessel inner lining cells “endothelial cell”. In addition, there is a
formation of new vessels, microaneurysms and breakdown of the blood-retinal
barrier (Safi et al., 2014).
Histologically, vascular lesion in the early stages of diabetic retinopathy is
characterised by the presence of saccular capillary microaneurysms, pericyte-
deficient capillaries and obliterated and degenerated capillaries (Ezra et al.,
2013).
Hyperglycaemia increases the glucose molecules turnover through the activation
of the polyol pathway, which leads to sorbitol accumulation in cells. Sorbitol
causes osmotic stress, which is the chief factor involved in the pathogenesis of
the retinopathy (Brocker et al., 2012, Zhang et al., 2014). Another significant
factor is the oxidative processes which play an important role in cellular injury
from hyperglycaemia. Elevated glucose levels can stimulate the production of
free radicals (Kawahito et al., 2009). Genetic and biochemical factors, vascular
endothelial growth factor (VEGF), cytokines, chemokines, growth factors,
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neuronal factors, have been claimed to play roles in the development of diabetic
retinopathy. VEGF production is augmented in diabetic retinopathy, probably in
response to hypoxia (Gupta et al., 2013).
Diabetic nephropathy
Diabetic nephropathy is the leading cause of End Stage Renal Disease (ESRD) in
the developed world (Gross et al., 2005) and is a common microvascular
complication, contributing to chronic renal failure. If not treated, patients with
diabetes with microalbuminuria usually proceed to proteinuria and in a
significant proportion to diabetic nephropathy. There are strong associations
between glycaemic control and the risk of diabetic nephropathy (Fares et al.,
2010).,
Diabetic nephropathy is diagnosed by the presence of excess protein (albumin) in
the urine and is defined by the passage of more than 500 mg protein in a 24
hours urine in the presence of diabetes (Robles et al., 2015).  This condition is
preceded by a mild form of proteinuria or  “microalbuminuria”, which is defined
as urine albumin of 30-299 mg/24 hours (Toto, 2004, Van Buren and Toto, 2011).
A study of 2630  patient with diabetes who attended a specialised diabetes care
centre in Chennai, India over 12 years, reported that the incidence of
microalbuminuria was a 44% (Viswanathan et al., 2012). In the UKPDS, the
incidence was 2% per year, and after ten years of diagnosis, the prevalence
increased to 25% (King et al., 1999). This progression occurred in both type 1 and
T2DM. As many as 7% of patients with T2DM might already have
microalbuminuria at the time of diagnosis (Roshan and Stanton, 2013).
Recently, the term Diabetic nephropathy has been replaced by diabetic kidney
disease (DKD) and is now best suited only to describe the histopathological
condition. The term DKD covers the clinical state produced by, the various
pathologies that may combine to produce chronic kidney disease in a person with
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diabetes such as DN, nephrosclerosis, atherosclerosis and interstitial nephritis
(Hung et al., 2013).
Figures from the U.S. Renal Data System over the last two decades have shown a
continual increase in the incidence of renal failure among patients with diabetes
(Rivara and Mehrotra, 2014). Earlier it was thought that the risk of renal
complications was lower among patients with T2DM than among patients with
type 1 diabetes. However, the incidence of ESRD in patients with T2DM has
increased dramatically, which might be due to the availability of better
management options for hypertension and CHD in patients with diabetes. As a
result, more patients with T2DM live longer enough for DKD and ESRD to develop
ESRD (Ghaderian et al., 2015). The incidence of proteinuria and
glomerulosclerosis increases because of the increased duration of diabetes, DKD
increases in both T1DM and T2DM for up to 20-25 years of diabetes disease after
which there is a decline in the number of patients developing renal disease
(Gheith et al., 2016).
There is a greater relative risk of DKD in men than in women (RR = 1.17, 1.01–
1.36). Certain racial and ethnic groups such as Asians, West Indians, Pima Indians
and Hispanic Americans have a higher incidence. This may relate to their
predisposing to develop diabetes more frequently and at an earlier age than
other populations as well as to their lesser renal blood flow and increased
vascular resistance (Ozawa et al., 2015).
Familial clustering of DKD was reported. The cumulative incidence of overt
proteinuria in siblings of patients with advanced DKD is 38%, whereas out of the
siblings with diabetes without DKD, only 17% had DKD (Harjutsalo et al., 2004).
Hyperglycaemia is an important factor in the development and evolution of DKD,
Patients who adequately control their blood glucose develop less
glomerulosclerosis than patients whose diabetes is poorly controlled. Patients
with diabetes should be treated to the lowest safe glucose level that can be
achieved to prevent or control diabetic nephropathy.
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2.9 Monitoring of Diabetes Mellitus
The DCCT and the UKPDS have confirmed that intensive treatment (maintaining
HbA1c to approximately 7% or 1% above the upper limit of normal) is associated
with less long-term diabetes complications provided early intervention be
commenced to attain good glycaemic control and modify risk factors. However,
intensive control increases the risk of severe hypoglycaemia and weight gain
(Schwartz, 2013).
Diabetes complications claimed 13% of healthcare budget, and people with
diabetes incurred 23 % of the healthcare expenditures in developed nations
(ADA, 2013). To prevent diabetes complications, it is crucial that proper diagnosis
and monitoring is carried out; first to detect response to treatment (glycaemic
control) and second to detect any complications. Monitoring glycaemic control is
essential to guide therapeutic interventions to achieve the best possible Blood
glucose control (Parkin and Davidson, 2009).
2.9.1 Short-term monitoring system
Urine Glucose
An English physician called Matthew Dobson experimentally demonstrated in
Liverpool the presence of sugar in the urine of a patient with diabetes. He boiled
the urine to evaporate the fluids and examined the residues.  He observed there
was a crystalline substance that tasted like sugar (Karamanou et al., 2016).
Urine glucose testing has been the traditional method of monitoring glycaemic
status since the discovery of insulin in 1922 until it was replaced by the
introduction of home glucose monitoring.
Urine glucose reflects the mean blood glucose over the time the urine was
collected. The maximum renal threshold for glucose ranges between 10 and 11.1
mmol/l (180-200 mg/dl). The kidneys do not reabsorb glucose beyond a renal
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threshold of 11mmol/l (200mg/dl). The urine glucose depends on the blood
glucose concentrations and urine flow. The urine glucose is the average of the
blood glucose level over the time of urine accumulation (Shubrook et al., 2015).
However, the renal threshold differs within and across individuals at different
times. Therefore, urine glucose may not have a fixed relationship with blood
glucose. For example, the renal threshold is higher in long-standing T2DM
patients, who may mark hyperglycaemia without glycosuria (Osaki et al., 2016).
Ketones
Urine ketones indicate insulin deficiency and impending ketoacidosis or
established ketonemia.
There are three ketones bodies: (1) acetoacetic acid; (2) acetone; and (3)
hydroxyl -butyric acid. It is important to test for these bodies as a part of routine
evaluation of patients with diabetes. Ketone bodies are normally present in urine,
but their concentrations are below the limit of detectability with conventional
detection methods. The excretion of > 1 mmol/l of these substances indicates
ketonuria (Luethi et al., 2016).
Blood Glucose
Blood, plasma or serum glucose can be analysed using the same principle as
described for urine glucose. Most standard laboratories now use the enzymatic
determination for blood glucose testing (Nagaraja et al., 2012). Ideal values for
blood glucose control in T2DM patients are shown in table 4 (WHO and IDF,
2006).
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Table 4: Ideal values for blood glucose control in T2DM patients
Plasma glucose test Normal Prediabetes Diabetes
Random < 11.1 mmol/l
< 200 mg/dl
N/A ≥ 11.1 mmol/l
≥ 200 mg/dl
Fasting < 6.1 mmol/l
< 110 mg/dl
6.1 to 6.9 mmol/l
110 to 125 mg/dl
≥ 7.0 mmol/l
≥ 126 mg/dl
2 hours post-
prandial
< 7.8 mmol/l
< 140 mg/dl
7.8 to 11.0 mmol/l
140 to 200 mg/dl
≥ 11.1 mmol/l
≥ 200 mg/dl
Reagent Strips
Just as urine glucose can be estimated using test strips, blood glucose estimation
can also be performed using test strips. A drop of blood is obtained by a finger
prick. The skin can be punctured by a needle or by various finger-pricking devices
comprising a lancet. The procedure is quick and virtually painless. Washing the
hands in warm water, shaking the hands, and avoiding spirit which tends to
harden the skin could minimise pain. The finger is pricked on its lateral aspect,
which has relatively fewer nerve endings (Heinemann, 2008).
Other Methods of Non-invasive Blood Glucose Monitoring
Innovative methods to measure blood glucose include:
Near-infrared radiation spectroscopy: This method uses an external light source
whose wavelength is just above the visible spectrum. The light passes through or
is reflected by a body part and glucose and other blood constituents absorb a
small amount of light at each wavelength. The reflected light is analysed to
determine the Blood glucose level (Maruo and Yamada, 2015).
Mid/Far-infrared radiation spectroscopy: this device measures natural thermal
emissions or body heat. When radiation in the mid/far-infrared, well outside the
visual spectrum, passed out of the body, glucose in the blood absorbs part of it.
The absorption can be spectroscopically determined by comparing measured and
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predicted amounts of thermal energy at the skin surface, and the difference can
be converted to a blood glucose concentration (Yoshida et al., 2013).
Radio wave impedance:When a radio wave passes through a solution that
contains a non-ionic solute, such as glucose, the solute interacts with the beam to
attenuate the amplitude and shift its phase of the beam. Using a conversion
factor, the glucose concentration in blood can be calculated by measuring the
impedance of the radio wave as it passes through the fingertip (Murthy et al.,
2008).
Optical rotation of polarised light: If a beam of polarised light is passed through a
fluid containing glucose, the polarisation plane rotates in proportion to the
concentration of glucose in that fluid. A beam can be passed through a body
compartment such as ocular aqueous humour and the amount of rotation used
to calculate the glucose concentration (Purvinis et al., 2011).
2.9.2 Long-term monitoring system
Glycated haemoglobin (HbA1c) is considered the best laboratory parameter
available to assess long-term metabolic control. It is a highly valuable tool in
research studies and has been used widely.
Kunkel et al. found in 1955 that using electrophoresis, adult haemoglobin (Hb)
could be shown to consist of fast and slow migrating components, and in 1968,
Rahbar established that the fast haemoglobin component was increased in
persons with uncontrolled diabetes (Sacks, 2012). The clinical relevance of HbA1c
was established by Bunn, and Nathan and its kinetics were studied by Goldstein
(Kahn and Fonseca, 2008).
Process of Glycation of Haemoglobin
Glycation of haemoglobin takes place by the interaction of glucose with amino-
terminal valine of one or both chains of haemoglobin A (HbA). This glycation
site alters the mobility of haemoglobin in cation exchange chromatography.
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Glycation also occurs at other sites of the Hb molecule. For example, at the -
amino groups of lysine residues and even chains. Although the glycation
occurring at the latter site is extensive, it does not alter the ionic charge and
hence cannot be separated from the non-glycated haemoglobin (HbA0) by cation
exchange chromatography (Baeshen et al., 2014). The chemical method
measures total GHb, i.e. HbA1c plus the glycated non-N-terminal sites, including
an amino group of lysine residues. The initial process of glycation results in an
unstable compound produced by the interaction of amine group in haemoglobin
with the carbonyl group of glucose. This produces the unstable Schiff base, which
is proportional to the actual glycaemia and therefore can impair the quality of
GHb assessment in cation exchange chromatography where Schiff base pre-
glycohemoglobin (pre-GHb) co-elutes with HbA1c (Pandey et al., 2015). It is
possible to remove Schiff base by a simple process of saline incubation. This
process has been used in many methods to separate pre-GHb from GHb (Nathan,
1981).
Methodology to estimate Glycation
Methods of GHb assays have primarily evolved around four core principles:
 The difference in ionic charge.
 Structural characteristics (e.g. boronic affinity methods).
 Chemical reactivity.
 Enzyme method.
Methods Based on Differences in Ionic Charge
These methods are extensively used. Cation exchange chromatography can either
be undertaken on mini-columns or in a sophisticated, automated system. The pH
and temperature conditions affect the results significantly; hence, the need for a
sophisticated system where the conditions can be adequately controlled
(Chandrashekar, 2016).
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HbA1c possesses lesser charge positivity and can be washed faster from a cation
exchange column than HbA0. Pre-glycohemoglobin has similar mobility in this
system, and hence, it should be removed before column chromatography. Most
of these systems cannot differentiate between abnormal HbS, but many
advanced systems possess such ability. Foetal haemoglobin co-elutes with HbA1c,
and hence, produces falsely high values, while HbS and HbC co-elute with HbA0
and thus produce falsely low values (Ryan et al., 2010).
Methods Based on Structural
One method called boronate affinity method uses a column containing -
aminophenyl-boronic acid coupled to agarose. GHb possesses more cis-diol
groups, which has a stronger affinity to the -aminophenylboronic acid and
hence washed later than HbA0. This method is influenced to a lesser extent by
haemoglobinopathies (Little and Roberts, 2009, Chen et al., 2016).
Clinical relevance and application of HbA1c
a) Relationship to mean blood glucose
The clinical relevance of HbA1c was established and has been re-examined
extensively. A total of 507 participants from 10 international centers in the USA,
Europe, and Africa, were recruited in a study to determine the relationship
between HbA1c and the average glucose, after three months average glucose
results were compared to the HbA1c and a close correlation of the estimated
average glucose ( AG) with HbA1c was documented (Nathan et al., 2008).
In the Diabetes Control and Complications Trial (DCCT) in the USA, initial
feasibility data measured HbA1c and seven-point blood glucose profiles quarterly
for a 1-year period in 1439 patients with type 1 diabetes, bringing out a close
linear relationship between glycaemic control and HbA1c. In this study, each 1%
increase in HbA1c corresponded to an increase of average blood glucose by 2
mmol/l (35 mg/dl) (Rohlfing et al., 2002). More recently, this relationship has
been confirmed (Cha and Ko, 2016).
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Glycated haemoglobin cannot be used as a measure of hypoglycaemia, but in the
DCCT study, the patients in the intensive group had a two to three-fold increase
in hypoglycaemic episodes, and this group had a significantly lower HbA1c (DCCT,
1993).
It is clinically relevant to know that stress hyperglycaemia increases HbA1c levels.
In a group of 826 critically ill patients with stress hyperglycaemia, as determined
by an initial and follow-up OGTT, a significant elevation of HbA1c was observed in
45.5% of patients (Zhang et al., 2013). This may support the fact that such
transient hyperglycaemia is important and could justify treatment.
Discrepancies between HbA1c and blood glucose values reported by patients are
expected, as self-monitoring of blood glucose (SMBG) is not yet an accurate
procedure, and many studies have shown that SMBG has failed to correlate to
the glycaemic control (Karter, 2006). This brings out the importance of HbA1c as
a non-manipulable and reliable parameter in assessing metabolic control as
compared to SMBG or one-point blood glucose estimations.
b) Glycaemic level variations and Relationship to FBG and post-prandial blood
glucose
Although the relationship between the mean blood glucose and HbA1c is well
established, it is important to understand that HbA1c does not reflect the
glycaemic range. A patient having a markedly high mean of glucose level may
show the same HbA1c values as one with an acceptable mean of glucose level
during the day because the peaks and troughs of glycaemic level during the day
tend to cancel each other. Hence, blood glucose monitoring by itself, or
continuous glucose monitoring, continue to retain their role.
HbA1c and blood glucose values were measured in 12,527 patients and
interpreted in three FPG levels, < 5.6, 5.6-9 and > 9. A strong relationship
between FPG in the range of 5.6-9.0 mmol/l and the corresponding HbA1c was
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seen across different ethnic groups and geographic regions (Ramachandran et al.,
2012a)
The relative contributions of fasting versus prandial hyperglycaemia toward
HbA1c values have been documented. Postprandial glucose has a higher
correlation with HbA1c than FPG, and the major contributor to HbA1c is the
prandial glucose (Ceriello, 2010, Ketema and Kibret, 2015).
c) Anaemia and HbA1c
The commonest anaemia seen is due to iron deficiency, and there is a positive
correlation between iron deficiency anaemia and HbA1c level (L. Christy et al.,
2014). Any stable anaemic condition (normal retics count) does not affect the
estimation directly when HPLC, boronic affinity or immunoassay or enzyme
methods are used, as there is an adequate amount of haemoglobin is used to
carry out the estimation.
Haemolytic anaemias will alter the result HbA1c, because of the ongoing
destruction of erythrocytes or accelerated erythropoiesis during recovery
increases the retics count. A study of HbA1c in haemolytic anaemia showed that
HbA1c value could decide the reduced half-life of erythrocytes by correlating the
dropping in HbA1c level and degree of haemolysis (Cohen et al., 2008).
Haemoglobinopathies that alter the ionic change of the Hb molecule produce
unreliable results HbA1c by methods that use ionic charge to separate HbA1c
from HbA0 (Nasir et al., 2010).
d) Relationship HbA1cwith Complications of Diabetes
The relationship is stronger for microvascular disease than the macrovascular
disease. In the DCCT, the intensive method control group maintained an average
HbA1c at about 7% and conventional method control groups at about 9%. The
10% lowering of HbA1c level in the intensive group resulted in significant
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reduction (about 30-44 %) of microvascular and neurological complications like
retinopathy, nephropathy, and peripheral neuropathy.
The intensive control group continued to maintain benefits for 17 years of post-
study follow up, as the risk of any cardiovascular disease was reduced by 42% as
compared to the standard treatment group (Kitsios et al., 2011).
In the UKPDS, the mean HbA1c was about 1% lower in the intensive control group
as compared to the standard control group. This resulted in 16% reduction in
macrovascular disease and 25% reduction in microvascular disease. A 10-year
follow-up continued to reveal reduced diabetes-related endpoints (9%, p= 0.04),
microvascular disease (24%, p= 0.001) and myocardial infarction (15%, p= 0.01) in
intensively treated group as compared to standard treatment group (King et al.,
1999). This firmly establishes the importance of HbA1c as an important
parameter in long-term studies. However, rapid and marked lowering of HbA1c in
the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the Veterans
Affairs Diabetes Trial studies could have been responsible for an increase in the
cardiovascular diseases (Kishore et al., 2012).
e) HbA1c Targets and Current State of Target Achievement
Glycaemic control has a well-documented relationship with vascular
complications of diabetes.
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Table 5: Suggested targets of HbA1c based on ADA/EASD recommendations
Diabetes category Targets
T2DM
 Newly discovered T2DM 6.0-6.5%
 Most T2DM <7.0%
 Long-standing T2DM <8.0%
 Long-standing T2DM with complication <8.5%
Type 1 diabetes
 On multiple dose insulin <7.5%
 On insulin pump therapy <7.0%
(ADA: American Diabetes Association; EASD: European Association for the Study of Diabetes).
The HbA1c targets are derived from population studies showing a threshold of
6.3-6.7% for a sudden deterioration in the retina. Various associations have
recommended targets in general and in specific situations in diabetes. In general,
more recent onset T2DM calls for a stricter target and long-standing T2DM
requires more relaxed targets. Fortunately, achieving stricter targets is feasible in
the first 5-10 years of T2DM, this also leads to greater long-term benefits as
shown in the follow-up studies of DCCT and UKPDS.
In type 1 diabetes, the targets are somewhat relaxed, because, with the current
standard insulin therapy, the desired targets are usually not achievable without
producing unjustifiable hypoglycaemia (Martín-Timón and del Cañizo-Gómez,
2015).
The present state of metabolic control, as reflected by HbA1c values, is far from
satisfactory. It is probably due to imperfect treatment tools, the patient
behavioural problems and imperfect application of therapy. In most diabetes
clinics, only 37% of patients with diabetes achieve an HbA1c < 7.0%. To sustain
this degree of control over an extended period seems to be more difficult. Data
from the USA reveal that the percentage of patients that achieved the targeted
HbA1c of 7.0% in 1999-2002 was 37%, which was later improved to 57.1% in
2003-2006 (Pérez et al., 2012).
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f) Use of HbA1c in the Diagnosis of Diabetes
Most studies have highlighted that OGTT is a more sensitive diagnostic method
than HbA1c test.  An impaired OGTT may be associated with normal HbA1c
especially in anaemic patients or individuals with abnormal haemoglobin (Sacks,
2011).
The sensitivity and specificity of HbA1c in the diagnosis of diabetes have been
compared with the standard OGTT. Using different HbA1c cut-off points, the best
balance of sensitivity and specificity is achieved by using a threshold < 6.1% as
normal, 6.1- 6.5% as IGT and > 6.5% as diabetes (John et al., 2007). When these
thresholds were compared to the diagnostic accuracy of OGTT in 997
participants, the sensitivity was 57.2% and specificity 67.4% for HbA1c compared
to 69.1% and 61.6%, respectively for FPG (Gomyo et al., 2004).
The Insulin Resistance Atherosclerosis Study (IRAS) of over 850 participants,
compared the performance of OGTT, FPG, and HbA1c. HbA1c diagnosed 44
(5.2%), FPG 61 (7.1%), and OGTT 132 (15.4%) patients with DM (Lorenzo and
Haffner, 2010).
Using HbA1c instead of a blood glucose estimation offers several advantages.
Currently, the Coefficient of variation of HbA1c assays has been brought down to
2% while that of blood glucose continues to be at about 5% (NGSP, 2016).
Samples for HbA1c are stable for more than a week while pre-analytical glycolysis
in blood samples offers poor stability. HbA1c may also be useful for
epidemiological purposes, but the cost of the test remains high at present
(Bonora and Tuomilehto, 2011).
2.9.3 Point of care devices
POCs devices are increasingly used for a broad range of diagnostic tests and
treatment monitoring (Rajendran and Rayman, 2014). POC testing is on-site, and
the timeliness of results minimise the delay associated with traditional laboratory
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procedures condcuted at centralised laboratories and reduce the need for further
office visits (Bhurosy and Jeewon, 2014).
The availability of instant results by HbA1c POC devices has benefited patient
care services. Comparing the standard laboratory HbA1c testing with POC
devices, POC devices allow health care providers to swiftly evaluate the efficiency
of diabetes treatment and boost therapy outcomes (Hermayer et al., 2015).
Together, this will help the medical staff to improve patients’ future HbA1c
figures, specifically for T2DM patients with poor glycaemic control, by enabling
timely therapeutic adjustments (Joseph, 2013).
There are very few National Glycohemoglobin Standardization Program (NGSP)-
certified POC HbA1c devices. This thesis will compare the NGSP-certified Quo-test
HbA1c POC device to the traditional laboratory HbA1c testing, to help guide
healthcare facilities in deciding on the performance of the quo-test device in
testing HbA1c in outpatient clinics.
The capability of a POC device to duplicate the laboratory HbA1c results of any
given patient is the ultimate quest (Schwartz et al., 2009). Since its establishment
in 1996, the NGSP has been the reference in developing guidelines and protocols
for standardising HbA1c testing for both laboratory apparatuses and POC devices
since 1996. The Diabetes Control and Complications Trial (DCCT) was a medical
study conducted by the United States National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) (Penttilä et al., 2016). From the 1990s onwards, the
findings in this study were the key to the changes that shaped the principles of
management of DM (DCCT, 1993). To ensure continued precision, the NGSP
requires annual device certification, during which the HbA1c device must be
tested in a 40-samples compared to an NGSP secondary reference laboratory in a
controlled environment. The 40 HbA1c test samples are ranged from 4% to 10%.
Certificates are only issued when at least 37 of the 40 samples fall within 6%
(lowered from ±15% in 2007) of the NGSP secondary reference laboratory values
(NGSP, 2016). This strict evaluation test provides health care providers
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confidence in the precision and accuracy of the devices in a controlled
environment (John et al., 2007). The ADA endorsed the criterion set by the NGSP
and strongly recommends that laboratories use only methods that have been
approved by NGSP (Sacks, 2012).
Even though the NGSP has not set clear targets for precision and accuracy, it does
endorse a mean bias of < 0.2 and CV < 3% (preferably < 2%) and labelling those
with a mean bias of > 0.3 and a CV > 5% as less satisfactory assay methods.
Alternatively, the ADA recommends a CV <4%, and ideally <3% (Whitley et al.,
2015).
In this thesis, we will study the performance of a POC device called Quo-test, the
NGSP-certified Quo-test device is based on structural differences (boronate
affinity) rather than the ionic charge differences (e.g., cation-exchange
chromatography and agar gel electrophoresis) (NGSP, 2016).
According to the NGSP guidelines, abnormal haemoglobins such as haemoglobin
C (HbC), D (HbD), E (HbE), and S (HbS) causes assay interference in more than half
of laboratory and POC HbA1c instruments. The Que-test, reports that it has no
interference in the presence of the common Hb-variants HbS, HbC, HbD, HbE,
HbJ, elevated A2 ( thalassemia) and showed no significant bias in the presence
of < 8.6% Hbf in the blood sample (Lenters-Westra, 2016).
Normally, HbF levels drop to < 1% soon after birth. However, abnormal levels can
remain high or increase in neonates until the end of the first month, hereditary
persistence of fetal haemoglobin, thalassemia’s, and patients with abnormal Hb
variants. Normal haemoglobin A (HbA) is composed of two and two chains
compared to the two and two chains in HbF. This structural change decreases
the ability of antigenic sites on immunoassays to recognize glycated fetal
haemolobin. During HbA1c analysis, non-glycated HbF can be detected as a
glycated haemolobin. Therefore, immunoassays used in patients with significantly
high HbF (>10%) will have falsely low results , which may lead to inadequate
clinical interventions (Nasir et al., 2010).
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In addition to improving glycaemic control, introducing HbA1c POC devices is
anticipated to lower health care system expenditure. The economic impact of
strict glycaemic control on overall health care costs is manifested in the
subsequent prevention of complications and reduction in the need for further
care. For every one-percentage-point increase above HbA1c of 4.4 %, there is an
increase in overall medical costs, and about 30% of the pharmacy charges are
correlated to the glycaemic level (Fitch et al., 2013). Patients with strict glycaemic
control (HbA1c <7.0 %)  are hospitalised less frequently with pneumonia
compared to those with an HbA1c ≥ 9.0% (Kornum et al., 2008).
2.10 Risk factors for diabetes mellitus
Researchers do not fully understand why some people develop prediabetes and
T2DM and others do not. Specific factors increase the risk, these factors include:
2.10.1 Urbanization
The developing countries are undergoing rapid urbanisation and migration of
population to urban areas. A major redistribution of the population is already
occurring, and it is projected that by the year 2030, 60% of the world’s
population would be living in urban areas (Ferreira et al., 2010). According to the
WHO estimates, in the last five decades two-fold to five-fold increase in urban
population has occurred in Asia (Sherif and Sumpio, 2015).
The increase in urban population and ageing has been attributed as main
determinants of the global rise in the prevalence of diabetes. Internal rural to
urban migration adversely impacts lifestyle factors such as a reduction in physical
activity, unhealthy changes in dietary habits, and increasing adiposity and obesity
(Carrillo-Larco et al., 2016). As shown in recent studies in China, considerable
changes have occurred in the lifestyle of rural populations resulting in marked
increase in overweight and diabetes (Guo et al., 2014). The situation is similar in
most Asian countries.
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In Kuwait, the percentage of the population living in urban centres is 99% (CSB,
2005). The rise in prevalence of diabetes has been attributed to socioeconomic
and behavioural changes in recent decades (Ahmed et al., 2013).
Studies from different parts of India have shown that social and economic
changes occurring in rural India have produced significant changes in the
occupational, dietary and activity levels.Many villagers have sought jobs in urban
areas involving less manual labour. Physical activity levels have decreased with
better transport facilities, Increased calorie intake with consumption of fat and
carbohydrates (Hu, 2011).
The changing demography of diabetes is evident from studies in Singapore and
Malaysia. A phenomenal increase in diabetes occurred in Singapore; increasing
from 2% in 1975 to 4.7 in 1984, 8.6% in 1992 and 9% in 1998. Sedentary lifestyle
and growing rate of obesity were strongly associated with the increasing
prevalence of glucose intolerance (Lee, 2000). National initiatives taken to
improve the health status of the population resulted in a decrease in the
prevalence of diabetes (from 9% in 1998 to 8.2% in 2004), but the prevalence is
increasing again, reaching 12.3% in 2013 (Shuyu Ng et al., 2015).
2.10.2 Racial Predisposition
A racial predisposition to diabetes has been evident from migrant Indian studies
which showed that Asian populations living in different parts of the world had a
higher prevalence of diabetes compared with the co-inhabitants of other races.
In the UK, the prevalence of diabetes in Asian migrants is about five times higher
than the native inhabitants (Montesi et al., 2016). Even internal migration within
a country, resulting in prosperity and sedentary lifestyle, reveals the tendency for
diabetes in the Asian races (Ramachandran et al., 2010).
Asians have a high predisposition to diabetes, but there are wide variations in the
prevalence rates and age at development of diabetes in different Asian cohorts
(Ramachandran et al., 2012b).
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2.10.3 Genetic Risk
Both the thrifty phenotype and thrifty genotype hypotheses appear to play
etiological roles in the development of diabetes in Middle East populations
(Sherif and Sumpio, 2015). While the thrifty genotype hypothesis suggests a
discrepancy between the ancestral genes and modem environment, the
hypothesis assumes a divergence between intrauterine and adult life
environments. The combination of gestational diabetes, in utero-nutritional
imbalance, childhood obesity, and overnutrition in adulthood will continue to fuel
the epidemic in countries undergoing rapid nutritional transitions. The genetic
risk factors for T2DM are complex and still largely elusive. However, the genetic
predisposition is obvious from the heritable nature of the disease. A strong
familial aggregation of the disease has been noted in Asian populations. In India,
nearly 75% of T2DM patients, have a first-degree family history of diabetes
(Mehta et al., 2009).
2.10.4 Ageing
The increase in life expectancy and a decline in fertility are expected to result in
faster ageing of the global population in the 21st century. Diseases of the elderly,
such as diabetes, hypertension, CVD, CHD, and cancer will become more common
(Lunenfeld and Stratton, 2013). The prevalence of diabetes increases with
increasing age. In China and Japan, diabetes usually occurs in individuals between
70 and 89 years old. In India, the onset of diabetes occurs at a younger age (60-69
years). Studies have shown a much younger age at onset of diabetes compared to
the western population. The DECODA study made a comparative analysis of age
at diagnosis of diabetes in different races. The overall effect of age on prevalence
of diabetes differed considerably between ethnic, groups even after correcting
for other confounding factors such as body mass index (BMI). The association
between age and diabetes was higher in the Indian population compared to all
other populations studied (Qiao et al., 2003).
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The age and sex-specific prevalence and the peak prevalence of diabetes were
higher in the Indian and Singapore cohorts than in the Chinese and Japanese
cohorts (Nakagami et al., 2003).
An early occurrence of diabetes in the population has a severe economic impact;
as serious morbidity and early mortality occur in the most productive years of
life, and T2DM subjects live long enough to develop the debilitating vascular
complications of diabetes (Deshpande et al., 2008).
2.10.5 Anthropometric Characteristics
Although the prevalence of obesity and overweight are relatively lower in Asia
compared with Western populations, the recent socio-economic transition in Asia
is resulting in a parallel increase in its prevalence of obesity and diabetes. Among
younger Asians, diabetes occurs at lower levels of BMI than in Western
populations and small increments in weight trigger glucose intolerance in the
susceptible subjects (Hu, 2011).
Analysis of the National Health Interview Survey (NHIS) in the United States (USA)
from 1997 to 2008 showed that Asian Americans had significantly higher rates of
diabetes than white populations. There was a significant upward trend in both
groups for diabetes and BMI with age. However, Asian Americans had higher
odds of developing diabetes; they are 30-50% more likely to have diabetes,
despite having significantly lower BMI than the white populations (Lee et al.,
2011).
An excess of body fat especially concentrated within the abdomen has a range of
potentially harmful effects. It includes increased risk for diabetes, blood pressure,
dyslipidaemia, IR, CHD and some forms of cancer. It has also been observed that
Asian have a higher percentage of body fat, for a given BMI, when compared with
the white population (Davis et al., 2013). For diabetes, obesity and specifically,
abdominal obesity, is a major risk factor. In the white population, overweight is
defined as a BMI ≥25 kg/m2 and obesity as BMI ≥30 kg/m2 (Friedl, 2009).
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However, several studies have shown that overweight BMI levels in Asians range
between 23 kg/m2 and 27 kg/m2, while obesity should be a BMI ≥ 27 kg/m2.  The
risk of metabolic disease in Asian individuals increases progressively > 23 kg/m2
(Jih et al., 2014).
The ADA and WHO have considered a BMI ≤23 kg/m2 as the cut-off for normal in
Asian populations (Misra, 2015). China has adopted standards to define
overweight as a BMI > 24 kg/m2 and obesity as a BMI > 28 kg/m2 (Wang et al.,
2006).
Abdominal obesity is defined by a waist circumference > 94 cm in men and >80
cm in women. Similarly, the cut-off for waist circumference is lower in Asian
populations (World Health Organization, 2008) as several studies have
highlighted the "metabolically obese” phenotype among normal weight
individuals in Asian populations. Greater abdominal obesity characterises this
phenotype despite a normal BMI, less muscle mass, a higher proportion of body
fat and an increased tendency for IR compared with Western populations, leading
to a higher predisposition for diabetes and vascular diseases (Lee et al., 2015b,
Dulloo et al., 2010).
2.11 Burden of diabetes
2.11.1 Global Burden of T2DM
According to the WHO Global Burden of Disease (GBD) 2012, T2DM is one of the
15 leading disability-adjusted life years (DALYs) diseases (table 6).
In 2015, there were 5 million deaths caused by T2DM, accounting for a death
every 6 seconds (IDF, 2015). This is despite the fact that the diabetes-related
mortality is greatly underestimated, as diabetes is often under-reported on death
certificates (Cheng et al., 2008).
The direct health care costs of T2DM in 2010 was estimated to be $ 376 million,
accounting for 12% of the annual global healthcare budgets (Zhang et al., 2010a).
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It is hard to measure the indirect cost of diabetes since it is affecting not only
patients but also the families and the society, that is why we are expecting that
the indirect costs are more likely to be much higher.
Table 6: Top 10 causes of DALYs globally 2015 (
Rank Cause DALYs (000s) %
DALYs
DALYs per
100,000
All Causes 2,668,296 100.0 36331
1 Ischemic heart disease 192,056 7.2 2615
2 Lower respiratory infections 142,384 5.3 1939
3 Stroke 139.874 5.2 1905
4 Preterm birth complications 102,297 3.8 1393
5 Diarrheal diseases 84,928 3.2 1156
6 Road injuries 76,020 2.8 1035
7 COPD 72,815 2.7 991
8 Diabetes mellitus 70,667 2.6 962
9 Birth asphyxia and birth
trauma
67,266 2.5 916
10 Congenital anomalies 64,825 2.4 883
Wild et al. projected the global prevalence of diabetes for all age groups in 2000
and made estimates for 2030 (reference). They obtained age- and sex-specific
data on diabetes prevalence from population-based prevalence studies from a
restricted number of countries. Diabetes prevalence estimates from these
countries were extrapolated to the 191 WHO member states, using a
combination of criteria including ethnicity, socioeconomic state, and geographical
proximity. Prevalence estimates were then applied to the UN population
estimates for individual countries.  The estimated prevalence was 2.8% in 2000
and 4.4% in 2030 (Wild et al., 2004).
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The future projections in diabetes prevalence were informed by demographic
changes alone. It was assumed that other diabetes risk factor levels (e.g. obesity
and decreased physical activity) would remain constant in developed countries.
In comparison, in developing countries, urbanization was used as an indirect
measure of the levels of risk factors, as urbanization in these countries is
associated with increased prevalence of obesity, reduced physical activity, and
changes in dietary habits. It was estimated that in 2013, 382 million adults had
diabetes (20-79 years), and it was projected this number would increase to 592
million by 2035 with higher rates in developing countries (Guariguata et al.,
2014).
In an earlier study, King et al. (1998) used age-specific diabetes prevalence
estimates from the WHO’s diabetes database (collected from 32 countries). They
applied these data to the UN demographic estimates for the world’s population
to predict the global prevalence of diabetes in adults ≥ 20 years for 1995, 2000,
and 2025. Similar to the study by Danaei et al., countries without prevalence
estimates were extrapolated from neighbouring countries or those with similar
socioeconomic and ethnic characteristics. The prevalence of diabetes worldwide
was estimated to be 4% in 1995 and was projected to increase by 35% to reach
5.4% by 2025, with more than 75% of them living in developing countries. The
number of adults with diabetes was predicted to increase from 135 million in
1995 to 300 million in 2025, with the majority of this increase occurring in
developing countries (King et al., 1998).
2.11.2 Diabetes burden in developing countries
In the past, industrialised countries were the primary focus for non-
communicable diseases (NCDs), and NCDs were known as “diseases of
affluence”(Wagner and Brath, 2012). However, in the recent decades, NCDs
prevalence (including T2DM) have increased globally with higher numbers and
increasing rates in developing countries. It is estimated that NCDs are responsible
for around 50% of the total disease burden in these countries (Boutayeb and
Boutayeb, 2005). The main reason for these elevated levels is the increase in the
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major risk factors (e.g. obesity, physical inactivity, smoking, and changes in diet),
because of rapid urbanisation, lifestyle and nutrition changes. Increasing life
expectancy has also resulted in ageing populations with increased rates of
chronic diseases (Deshpande et al., 2008). It is well documented that T2DM
prevalence is lowest among people who have a more active “primitive” lifestyle
in developing countries, despite similarities in ethnicity and genetic
characteristics (Deepa et al., 2014).
The estimates and future projections of diabetes burden in developing countries
are rising progressively. Over the 30-year period from 1995 to 2025, the increase
in the number of adults with diabetes in developing countries is expected to
increase by 170%, from 84 to 228 million, compared to 42% increase, from 51 to
72 million, in developed countries (King et al., 1998). The biggest increase in
prevalence by 2025 is expected to be in the Pacific and East Asia followed by the
Middle East and North Africa, and the smallest is projected to be in Sub-Saharan
Africa (Narayan KMV, 2006).
The age distribution of people with diabetes is also different in developing
countries. While most diabetes cases in developed countries are older age
groups, many cases in developing countries tend to occur among young and
middle-aged people. There are 320.5 million people of working age (20-64 years)
with diabetes and 94.2 million individuals aged 65-79 with diabetes. This implies
that the health, social, and economic burdens of the disease extend to even
younger ages and for a longer period of an individual’s lifespan.
There are few gender differences in the global number of people with diabetes
between 2015 or 2040. There are about 15.6 million more men than women with
diabetes (215 million men vs 200 million women). This difference is expected to
decrease to about 15.1 million (328 million men vs 313 million women) by 2040.
54
Presently, there are more individuals with diabetes in urban (270 million) than
rural areas (145 million). In low and middle-income countries, the number of
people with diabetes in urban areas is 186 million while 127 million live in rural
areas. By 2040, the worldwide difference is likely to broaden, with 478 million
people living in urban areas and 164 million in rural areas (IDF, 2015).
Health organisations in most developing countries are structured primarily to
confront acute and chronic communicable diseases. These services are usually
not prepared to offer effective prevention and care for NCDs. As a result,
disappointingly, there are now many “poor” developing countries that face a
double burden, since the levels of infectious diseases (e.g. Tuberculosis,
HIV/AIDS, and malaria) continue to be high, in addition to increasing levels of
NCDs (Miranda et al., 2008).
2.11.3 Diabetes burden in the Eastern Mediterranean Region
In the EMR, the problem of T2DM is growing significantly, with a sharp increase in
the disease prevalence in both sexes. Many countries in the region have
experienced rapid and immense socioeconomic development over recent
decades. These socioeconomic changes have been said to be the principal reason
for the epidemiological changes in risk and disease burden in the region. The
WHO has projected that around 47% of the EMR’s disease burden is currently
due to NCDs and this number is expected to increase to 60% by 2020 (Saidi et al.,
2015).
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Figure 1: Map of WHO's Eastern Mediterranean Region (http://www.iapb.org/)
The prevalence of major risk factors for NCDs is projected to be very high in EMR.
According to regional WHO estimates in 2004, 14.5% of adults (≥20 years old)
diabetes and 43% were overweight/obese. As with most developing countries,
many EMR countries have reported a large number of T2DM cases starting in the
second and third decades of age (Musaiger, 2011a).
The IDF’s region of the Middle East and North Africa (MENA), which is similar to
the WHO’s EMR including Algeria and excluding Somalia and Djibouti, has been
recognized as a major hot spot for diabetes , with the highest estimated age-
adjusted prevalence of diabetes (7.4-14.2%) globally in 2015 and will continue to
have the highest predicted prevalence (7.7-14.9%) by 2040 (IDF, 2015).
Most of EMRO countries have national strategies for the prevention and
management of diabetes, and more than half of the countries reported having
diabetes control policies. However, WHO indicated these plans are not being
rationally or widely employed. The countries of the Gulf Cooperation Council
(GCC) have the highest levels of diabetes within the region and are almost always
among the top 10 countries with the highest diabetes prevalence in the world
(Sherif and Sumpio, 2015).
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2.11.4 Prevalence of diabetes in the countries of the GCC
The GCC was established in 1981 between six countries located on the coast of
the Arabian Gulf given the special relations between them, their similar political
systems, and common objectives. The GCC includes Saudi Arabia, Kuwait, Qatar,
Oman, Bahrain and the United Arab Emirates. People of these countries have
many familial inter-relations and share many similarities in environments,
cultural, social and lifestyle (At-Twaijri and Al-Muhaiza, 1996).
Figure 2: Map showing the Gulf Cooperation Council countries
(http://www.erutledge.com/)
The GCC countries are major suppliers of oil. According to the International
Monetary Fund, Qatar was ranked to have the highest gross domestic product
purchasing power parity (GDP-PPP) in the world in 2015.
Accordingly, the GCC countries have witnessed extensive social and financial
developments in the recent decades, with significant changes toward sedentary
lifestyles and ‘Western’ dietary habits and are considered a major focus for
diabetes.
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2.11.5 The state of Kuwait and its Health system
Historical background
The State of Kuwait is located to the Northwest of the Arabian Gulf. To the South
and Southwest it shares the border with the Kingdom of Saudi Arabia and to the
East with the Gulf, to the North and Northwest, it shares the borders with the
Republic of Iraq (Central Statistical Bureau, 2016).
Figure 3: Map of Kuwait (http://www.worldatlas.com)
Due to the strategic location, Kuwait is considered a natural doorway to the
northeast of the Arabian Peninsula which gave the country its known commercial
importance.
In the 17th century, Nomadic tribes from central Arabia (Najd) settled in the Bay
of Kuwait City. Kuwait is a constitutional state under the hereditary rule of the Al
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Sabah family since the middle of the 18th century. The Emir is the leader of the
nation and holds executive authority, appointing the prime minister and the
government.
With a surface area of (17,818)2 kilometres, Kuwait has six governorates: Al-
Asimah, Hawalli, Al-Ahmadi, Al-Farwaniyah, Mubarak Al-Kebir, and Al-Jahrah. The
total population is 3,065,850 (2011). Nationals constitute about 35.6% of the
population, and more than 99% of the population live in urban areas in and
around the capital (Central Statistical Bureau, 2016). The population density in
urbanised areas is several times higher than the reported 172/km2, which is
calculated by dividing the total population by the country’s total surface area.
The public in Kuwait enjoy a high standard of health services; sufficient hospitals,
health centres and clinics staffed by skilled health workers who provide efficient
and safe health care. The burden of disease and health indicators are similar to
those of highly industrialised countries (World Health Organization, 2016).
The Health System in Kuwait
The Ministry of Health in Kuwait is working to provide comprehensive health care
for its citizens, residents and to protect them from physical, psychological
threats, including availability of health services, preventive, curative and other
emergencies. The health services in Kuwait in the past matched the simplicity of
life and the conditions that existed at that time, and expertise and availability of
services were limited. Kuwaitis have thus relied on traditional (alternative)
medicine in the treatment of diseases.
Health care has since evolved. In 1911 an American mission built the first hospital
in the country, which continued to work until 1967. The Ministry of Health has
since become the main provider of health services. Services are provided through
three levels::
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1. Primary care: offered through health centres, which includes General
Medicine - Dentistry - child and maternity care, preventive medicine and
school health, laboratory and radiology.
2. Secondary care: provided through six general public hospitals: Al-Amiri, Al-
Adan, Al-Sabah, Mubarak Al-Kabeer, Al-Farwaniyah and Al - Jahrah.
3. A Tertiary Care: offered through specialised hospitals and medical centres
(Psychiatry - Ibn Sina - communicable diseases - Physical Medicine and
Rehabilitation system).
Burden of Noncommunicable diseases
Food availability is plentiful and affordable to all sections of the population.
Kuwait has a widespread increase in fast food restaurants, leading to the
increased eating of high-fat and high-energy foods, such as fried foods and soft
drinks, mainly among youngsters, with adverse health impact. Overweight and
obesity are highly prevalent risk factors with a considerably higher prevalence
among Kuwaiti nationals. The Nutrition and Catering Administration is under the
Department of Public Health. Much of its work focuses on hospitals. It also works
on healthy diets for the general population; however, the division needs to be
evaluated and strengthened to fulfil more public health aspects, especially given
the high prevalence of obesity, including children and youth.
Kuwait has experienced an increase in CHD, cancer and unintentional injuries
(mainly road traffic accidents). Obesity, dyslipidaemia, physical inactivity and
diabetes have a high prevalence, demanding a modification from therapeutic to
preventive approaches. Regarding DALYs in Kuwait, high body mass index, dietary
risks, and high fasting plasma glucose are the leading risk factors in 2013
(Mokdad, 2016).
A study conducted by the Department of Food and Nutrition in the Ministry of
Health showed that the prevalence of overweight was 38.9% and 28.9% for adult
males and females, respectively and the prevalence of obesity was 39.2% and
53% for adult females and males, respectively (Musaiger, 2011a).
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Diabetes mellitus in Kuwait
Since the discovery of oil, the lifestyle in Kuwait changed dramatically. People
now lack physical activities and have adopted a western lifestyle.  Governmental
jobs do not include physical activities, partially due to the hot weather conditions,
leading to a more sedentary life. The cultural habits in Kuwait involve food in
almost every social event. This gives rise to many health problems; including
metabolic syndrome, with its trilogy; diabetes, hypertension, and dyslipidaemia
leading to CVDs and stroke. According to the recent statistics, T2DM has reached
23.1% of the population (Guariguata et al., 2014).
The growth of T2DM does not only burden health sector, but it also affects the
economy due to its direct and indirect impact on the economy. Direct economic
costs include medical treatment expenditures, acute and chronic complications,
hospitalisations and excess general medical costs, which have placed a
substantial financial burden on the country (Seuring et al., 2015).
Even for a wealthy country like Kuwait, the economic costs of T2DM are hard to
tolerate and should motivate the government to evaluate the extent of the
disease and to seek other methods to prevent the disease and disease-related
conditions. (Alhyas et al., 2012, Channanath et al., 2013, Al-Hussaini and Mustafa,
2016).
Glycaemic control is an important approach for the management of people with
T2DM, and according to the ADA the optimal blood glucose level to prevent
T2DM complication is < 7%. A study in Kuwait reported that the proportion of
individuals with T2DM with poor glycaemic control (HbA1c > 7%) is 79%. A further
study also reported that the proportion of individuals with T2DM having HbA1c >
8% is 66.7% (Al-Rasheedi, 2015).
Delays in treatment intensification can lead to poor control of T2DM, and using
more than one oral antidiabetic agent or adding insulin to the treatment plan if
needed, should not be delayed (Khunti et al., 2013).
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Point of care devices (POC) can help health staff to decide promptly to modify the
strategy and to intensify treatment. At the same time, POC devices are more
convenient to the patients, as they do not need to revisit the clinic to receive the
results. In this study, we will evaluate the accuracy of a POC device against the
reference laboratory machine.
2.12 Management of T2DM
Individuals with high risk of developing T2DM can signiﬁcantly decrease the rate
of diabetes onset by undertaking some interventions.
Lifestyle modification is the cornerstone of diabetes prevention (Tabák et al.,
2012). Some programs have been shown to be effective (51% reduction after four
years) (Salas-Salvadó et al., 2011). Three large studies of lifestyle intervention
have shown a continuous decrease in the incidence of T2DM, with 43% reduction
at seven years in the Finnish Diabetes Prevention Study (Hu, 2011), 51%
reduction over six years in the Da Qing study (Li et al., 2008), and 34% reduction
at ten years (Tuso, 2014).
People with known risks of progressing from prediabetes to T2DM or with an
HbA1c 5.7-6.4%, should be advised of lifestyle changes, recommending a 7%
weight loss and moderate physical activity for at least 150 minutes per week
(Knowler et al., 2002).
The aim of managing patients with diabetes is to stop symptoms and to prevent
the development of complications. Microvascular, macrovascular, metabolic and
neurological risk reduction is accomplished through control of hyperglycaemia,
anti-hypertensive drugs, cholesterol-lowering agents, smoking cessation, and
physical activity (Lorber, 2014).
Ideally, blood glucose in T2DM patients should be maintained at near-normal
levels pre-prandial of < 5 mmol/l (< 100 mg/dl), post-prandial of < 7.8 mmol/l (<
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140 mg/dl) and HbA1c levels < 6.5% (Ceriello and Colagiuri, 2008). However,
emphasis on glucose alone does not provide adequate treatment for patients
with T2DM. Treatment involves multiple goals including hyperglycaemia,
dyslipidaemia, and hypertension (Nyenwe et al., 2011).
T2DM care is best provided by a multidisciplinary team of healthcare
professionals with proficiency in diabetes, working in association with the patient
and the family. The management team should include physicians,
endocrinologists, pharmacists, dieticians, social workers and psychologists
(Bowen and Rothman, 2010).
2.12.1 Dietary control
Nutrition interventions must incorporate a variety of meal planning and nutrition
education that the patients can easily understand and use.
These include reassessing how the goals have been accomplished and
identification of future areas for self-management education. The goal of diet
therapy is to maintain and prolong a healthy, productive and satisfying life.
Goals
 To improve health through optimum nutrition.
 To provide calories for reasonable body weight (BW), normal growth and
development.
 To maintain glycaemic control.
 To achieve optimal blood lipid levels.
 To minimize nutrition related chronic degenerative complications.
Adapting diet therapy to the specific needs of an individual patient is most
essential; however, there are few basic principles that are to be followed.
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Nutrition and Body weight in T2DM
Controlling blood glucose and lipid levels along with weight loss to attain an ideal
weight are the focus of treatment for overweight patients with T2DM. This
identifies the fact that adjustment of fat intake, the spacing between meals,
reducing the size of meals, exercise, and sensible weight loss can be effective in
achieving the targeted blood glucose and lipid levels in patients with T2DM.
The primary goal for patients with T2DM should be to reach and maintain near-
normal blood glucose levels. Making healthy food choices, especially controlling
calorie intake can be advantageous. Current recommendations aim to promote
good glycaemic control and maintain ideal body weight while reducing the risk of
CAD through improved lipid profiles. People with diabetes find it harder to lose
weight compared to those without the disease; it is now clear that they do not
need to reach their ideal body weight to improve their metabolic status; as little
as 5-10% reduction in BW is sufficient to result in clinically relevant benefits
(Wing et al., 2011).
Basic principles for planning a diet for T2DM patients
 Age, sex, activity, height, BW, cultural factors.
 Type of diabetes, mode of treatment, control of diabetes.
 Aggravating factors; infections, gastrointestinal disorders, cardiovascular
disorders, and pregnancy.
Based on these factors, the primary consideration is of calorie requirements, to
achieve one's ideal body weight with a healthy balanced meal.
Definitions frequently used in T2DM
BMI defines obesity. BMI is calculated by the formula:
Weight in kilogram ÷ Height in meter2
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Obese persons are ten times more likely to develop T2DM, and obesity is the
principal risk factor, especially when it is central obesity (higher waist
circumference or higher waist to hip ratio -WHR).
Criteria for obesity
- Normal: 18.5-24.9
- Overweight: 25-29.9
- Obese: More than 30
Most people store their body fat in two distinct ways:
1. Around the middle (apple-shaped)
2. Around the hips (pear-shaped)
Being apple-shaped or so-called truncal obesity (more fat around the waist)
places them in the higher risk category than the pear-shaped (carrying more fat
on hips) (Martín-Timón et al., 2014).
The measures are as follows:
1. Waist-hip ratio (WHR)
- Waist measure midpoint between the last palpable rib and the top of the
iliac crest.
- Hip measure at its maximum.
2. Waist circumference is another quick measure to determine obesity,
especially in the Asian population, due to more marked central obesity.
The cut-off points of WHR:
- Men                   Less than 0.90
- Women             Less than 0.85
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Healthy cut-off points of Waist circumference
- Men 94 cm
- Women 80 cm
2.12.2 Pharmacological control
Insulin secretagogues
The recent management guidelines suggested by various professional bodies
across the world advocate the initiation of treatment of T2DM with medical
nutrition therapy along with metformin. However, when metformin alone is not
sufficient to maintain glycaemic control the addition of an insulin secretagogue (a
substance which promotes secretion) is the next available option (Moses, 2010).
The use of insulin secretagogues may also be considered earlier when the patient
with T2DM has difficulty in tolerating metformin or has a contraindication to
metformin or in those in whom a defective β cell function is thought to be the
predominant pathology (Irons and Minze, 2014).
Role of Insulin secretagogues in the management of T2DM
Defects in both insulin secretion and sensitivity are described in the pathogenesis
of T2DM. Fasting glucose levels are determined by hepatic glucose output, which
is controlled by insulin and glucagon concentrations in the portal circulation
whereas postprandial glucose levels are dependent on the composition of the
diet and insulin-mediated peripheral glucose uptake. While the maintenance of
hepatic glucose output, i.e. fasting glucose requires significantly lower levels of
insulin, enhancement of the peripheral glucose uptake, which is reflected as the
postprandial glucose level requires much higher levels of insulin. It is, therefore,
logical that the sequence of abnormal glucose metabolism starts from IGT,
progresses to minimal fasting hyperglycaemia with significant postprandial
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hyperglycaemia and finally to fasting hyperglycaemia with marked postprandial
hyperglycaemia.
All patients with T2DM with hyperglycaemia have some deficiency in insulin
secretion and the higher the degree of fasting hyperglycaemia; greater is the
insulin deficiency. Therefore, insulin secretagogues which act by improving β cell
function and augment insulin secretion are powerful tools in the management of
T2DM (Maria Rotella et al., 2013).
Sulfonylurea
Sulfonylurea was discovered accidentally while looking for newer sulphonamides.
The first sulfonylurea to be used in clinical practice was carbutamide, which
became available in the 1950s. It was later withdrawn from the market due to
bone marrow toxicity. First-generation sulfonylureas are no longer available.
However, compounds from the subsequent generations are currently widely used
in practice (e.g. glibenclamide, glipizide, and gliclazide) (Kalra et al., 2015).
Mechanism of Action of sulfonylurea
Sulfonylurea stimulates insulin secretion by binding to a specific receptor in the
pancreatic β cell, which causes closure of ATP-sensitive potassium (K+) (KATP)
channels, resulting in membrane depolarization, and the influx of calcium into
the β cell. This increase in intracellular calcium causes contraction of the
intracellular filaments responsible for the release of insulin from β cell secretory
granules (Sola et al., 2015).
Metformin
Metformin has enjoyed widespread popularity since 1957 and has been widely
used all over the world since that time. From 1995 onwards, particularly with the
publication of UKPDS data, there has been a significant increase in the study and
use of metformin. Today, there is universal acceptance that it is the
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pharmacological agent of choice in the initiating treatment of T2DM (Nasri and
Rafieian-Kopaei, 2014).
Mechanism of action of metformin
Metformin is lipophilic and binds to membrane phospholipids in the cell wall and
mitochondria. The cellular targets are the hepatocyte and skeletal muscle cell and
to a lesser extent the adipocyte. The primary enzyme target is adenosine
monophosphate protein kinase or activated protein kinase (AMPK). This enzyme
is a major regulator of intracellular energy production via its effects on glucose
and fat metabolism (Pernicova and Korbonits, 2014).
Usefulness of Metformin in T2DM
All professional bodies presently recommend metformin as the drug of choice for
control of hyperglycaemia once lifestyle measures prove inadequate. A usual
dose is 500 mg once, twice or three times daily. Metformin can be added to all
other oral antidiabetic agents and can be used with insulin. Failure rates with
metformin as monotherapy are relatively high and approach 17% per year, but
when compared to participants with HbA1c < 7 or within three months of
diabetes diagnosis, the failure rate was reduced to 12%. This introducing
metformin early might improve β cell function and delay complication and
prolong the effectiveness of the drug (Brown et al., 2010).
Metformin is beneficial in improving lipid metabolism and reduces the
triglyceride levels parallel to its glucose-lowering effect. Metformin does not
cause weight gain. Some studies have shown it to be weight neutral while others
have found a modest weight loss (Viollet et al., 2012).
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Human Insulin
Human insulin became available for treatment in 1981, initially as semi-synthetic,
and a year later as the first genetically engineered product .
Semi-synthetic human insulin or human insulin, as it was called earlier, was made
by modifying porcine insulin, i.e. enzymatically replacing the B 30 alanine with
threonine, thus convening pork insulin to human insulin (Pickup, 1989).
Human insulin was the first genetically engineered protein used in therapy, and
this method of production is widely used.
Insulin Analogues
Using genetic engineering technique, it became possible to change amino acids at
strategic locations to produce insulin analogues that have different absorption
and pharmacokinetics. Thus, it is possible to have fast and short-acting or long-
acting insulin analogues. The fast-acting analogues are absorbed faster; achieve a
quicker peak and their level declines more rapidly as compared to short-acting
human insulin. Similarly, by changing the amino acid structure or by enhancing
binding to a protein (e.g. albumin); it has been possible to produce long-acting
analogues that have slower and more predictable absorption and can provide
stable insulin level throughout the 24 hours. Several analogues have now been
marketed worldwide (Baeshen et al., 2014).
Types of Insulin
Insulin release occurs both at a continuous basal rate and short-lived large
gushes, secondary to physiologic stimuli related to food intake. Thus, to replace
insulin, there is need of insulin which can rise rapidly in response to a meal as
well as insulin which is released into circulation continuously at a slow rate. When
insulin was discovered, for many years only regular or soluble insulin was
available. Later, prolonged action formulations were developed with protamine
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or zinc or both, as a retarding agent, to delay absorption and extend the duration
of effect.
After the 1996 introduction of human insulin, animal insulin lost its value, and
hence animal insulins have been discontinued (Donner, 2015). The following
types of insulin are now available:
a- Short-acting insulin
b- Analogues (short-acting, long-acting)
c- Intermediate, delayed action due to the addition of neutral protamine
Hagedorn (NPH)
d- Premixed
• short with NPH
• Analogues premix.
Indications for Insulin therapy
The aim of insulin therapy is changing to provide physiological substitution and
painless administration.
Patients with T2DM should try to change their dietary habits and increase their
physical activities- If the glycaemic status is not controlled, the physician will start
oral anti-diabetic drugs ( OAD), the doses should be tailored gradually according
to the blood glucose level. It is preferable to initiate insulin therapy if a patient
with T2DM is not controlled on maximum doses of three oral drugs. It is β cell
failure rather than OAD failure (Nyenwe et al., 2011).
All patients with diabetes have insulin deficiency in a relative or absolute matter.
The following table shows various well-known indications of insulin.
70
Table 7: Indications for Insulin
 Type1 diabetes.
 T2DM not controlled with maximal doses of oral anti-diabetic agents
 Type 2 patients during periods of stress
- Acute infection
- Major surgery
- Acute myocardial infarction, stroke
- Acute fever
- Acute emergencies, e.g. Hyperosmolar non-ketone state, diabetic
ketoacidosis.
 Pregnancy with diabetes
- Renal failure
Incretin-based therapy
Incretins are two intestinal hormones secreted in response to a meal. They were
named glucose-dependent insulinotropic peptide (GIP) and glucagon-like
peptide-1 (GLP-1). Both of these hormones demonstrated insulinotropic
properties.
GLP-1 has a very short half-life of less than 2 minutes, and it is rapidly demolished
by the protease enzyme dipeptidyl peptidase-4 (DPP-4). GIP, in turn, was found
to be very weak (Holst et al., 2009).
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Development of GLP-1 based treatment
To realise the therapeutic potential of GLP-1, either its half-life has to be
prolonged, or the DPP-4 enzyme needs to be blocked. DPP-4 inhibitors can be
classified by their molecular structures into peptidomimetic and non-
peptidomimetic.
 Peptidomimetic DPP-4 inhibitors:
- Vildagliptin
- Saxagliptin
 Non-peptidomimetic DPP-4 inhibitors:
- Alogliptin
- Linagliptin
- Sitagliptin
Gliptins have the capability of reducing HbA1c safely by 0.5 to 2%, with a
prediction that each 1% HbA1c baseline increase provides 0.4 to 0.5% decrease in
HbA1c results (Gupta and Kalra, 2011, Esposito et al., 2015).
Incretin mimetics or analogues
Incretin mimetics or incretin analogues were the first amongst the incretins to be
used in clinical practice. They have strong effect on glycaemic control and cause
significant weight loss without causing hypoglycaemia (Tasyurek et al., 2014).
 Liraglutide
Liraglutide is the first human GLP-1 analogue and was developed by
molecular engineering to increase its half-life up to 13 hours.
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It effectively protects β cells and increases their sensitivity to glucose, which
could explain the prolonged glycaemic control of up to 3 years achieved with
Liraglutide (Mehta et al., 2017).
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a novel therapeutic class
of antidiabetic drugs. SGLT-2 are exclusively present in the epithelial cells of the
proximal renal tubules. SGLT-2 accounts for 90% of the glucose reabsorption in
the kidneys. The selective inhibition of SGLT-2 increases the excretion of glucose
by inhibiting the reabsorption of glucose (Ndefo et al., 2015).
Thiazolidinedione
Thiazolidinediones are a group of antidiabetic agents that stimulate the
peroxisome proliferator-activated receptors. Pioglitazone used as a monotherapy
causes a 0.92% to 1.05% fall in HbA1c levels (Desouza and Shivaswamy, 2010). It
is recommended to be used as a second line agent and in various combinations
with sulfonylureas and metformin (Singh et al., 2014).
Alpha-glucosidase inhibitors
There are three -glucosidase inhibitors, currently available: acarbose, miglitol
and voglibose. This class of oral hypoglycaemic agents competitively inhibit
enzymes in the small intestinal brush responsible for the breakdown of
oligosaccharides and disaccharides into monosaccharides to make them suitable
for absorption (Dabhi et al., 2013).
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Acarbose
Of the three -glucosidase inhibitors, the benefits of acarbose are best
documented. Acarbose increases insulin sensitivity in individuals with T2DM and
IGT (Zhuo et al., 2014).
74
3: Methodology
3.1 Research design (by objectives)
3.1.1 Objective 1: To determine the prevalence of T2DM and IR among a Kuwaiti
adult population attending Nuzha health facility.
This was a cross-sectional survey in Kuwait conducted from October 2015 to
September2016.
Setting: The study was based at Nuzha health care facility (HCF).  Nuzha HCF is a
governmental health centre in an urban area (Kuwait City) providing about
50,000 consultations per year. This primary health care centre provides general
practice (GP) services and selected specialised clinics for a diabetes monitoring
and management, hypertension and obesity.
Figure 4: Nuzha health care centre
Target Population: The target population was adult patients aged 18 years or
more attending Nuzha HCF.
Inclusion/exclusion criteria: All adults attending Nuzha HCF seeking medical
advice for any illness at the general clinics (with minor symptoms only) were
eligible to participate, independently of the reasons why they attended the
clinics.  Eligible patients were enrolled prospectively until the desired sample size
was achieved. We excluded pregnant women, patients with acute infections who
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have a fever, patients on steroids, those unable to consent, patients who are
unable to fast overnight or unwilling to return the next day to the clinic.
We used systemic sampling to choose participants, every 3rd patient starting from
the first patient attending the general clinic; we enrolled three patients daily four
days a week. When a patient refused to participate, we invited patients
consecutively and continuously until a replacement was found.  Then the 3rd
patient interval was resumed.
Patients who agreed to participate and signed a consent form were interviewed
to complete a questionnaire containing demographic background and medical
history.
The participant was fasting for 12 hours, and when it was convenient, a
phlebotomist collected one venous blood sample after the patient has completed
the clinic consultation.  When the participant was not fasting, we gave
instructions to fast for 12 hours and to return the next day in the morning.
The catchment area population of Nuzha health care centre is about 25,000. It
was expected that 20% of the adult population had T2DM. We aimed to establish
the prevalence of DM in the clinic population with an error margin of ±4%, with
95% power and 5% confidence limit. The survey sample size was estimated to be
380 participants.
Laboratory procedures: Patients’ blood was collected to measure Fasting Plasma
Glucose (FPG), Fasting plasma insulin, HbA1c and lipid profile, including high-
density lipoprotein (HDL), low-density lipoprotein (LDL), Triglycerides (TG).  These
tests were free for the participants. Patients were classified as having normal
values, IR or T2DM according to the following parameters.
T2DM was defined as the presence of an abnormal (defined as HbA1c ≥6.5%) and
an abnormal FPG (defined as ≥ 7.0 mmol/l (126 mg/dl).
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Patients with IR but who are not T2DM were defined as patients with FPG < 7.0
mmol (126 mg/dl) but homeostatic model assessment (HOMA2-IR) * ≥ 2.
Patients were defined not to have T2DM or IR if the HbA1c is < 6.5 and FPG is <
7.0 mmol/l (126 mg/dl), and HOMA2-IR < 2.
* HOMA is a model constructed from the combination of several tests is based on
the physiological balance between insulin secretion and glucose concentrations in
blood and are therefore a reflection of the balance between glucose uptake by
tissues and insulin production, the cut-off point for HOMA2-IR is 2 (Berm et al.,
2014).
Laboratory tests
For the FPG test, we collected 2 ml blood in a grey top tube with Potassium
Oxalate/Sodium Fluoride.  Blood samples were centrifuged to separate the serum
within 2 hours, and about 0.5 ml of the plasma were collected in an aliquot for
testing using the Spectrophotometric assay (Beckman UniCel DxC 800).  Specimen
for these assays are stable for up to 3 days if refrigerated.
For the insulin test, we collected 5 ml blood in gold/ yellow top tube.  The
specimen was centrifuged promptly, and about 1ml of serum were tested for
insulin level using immune-assay (Roche, Cobas e 602). Specimens for this assay
are stable for 24 hours if refrigerated and for six months if frozen.
For the HbA1c test collected 1 ml blood in a lavender purple-top tube containing
EDTA.  This tube does not need for centrifugation, and the specimen is stable for
24 hours at room temperature. HbA1c was measured using high-performance
liquid chromatography (HPLC) (Tosoh HLC- G8).
For lipid profile, the phlebotomist drew 5ml blood in a gold-top tube, centrifuge
and about 2ml serum were tested using Spectrophotometric assay (Beckman
UniCel DxC 600 Pro).
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All patients were provided with a feedback of the results.  Patients with normal
results received them via phone call, or they will come personally to collect the
results, as per their stated preference.  Patients with abnormal results were
contacted via email or phone call as per their stated preference and were invited to
attend a clinic appointment to discuss their results with the diabetes clinic staff
(post in Kuwait is unreliable).
3.1.2 Objective 2: To determine the risk factors for (a) T2DM and (b) IR in the same
adult population.
This component was comprised of two case-control studies conducted
simultaneously and was based at the same Nuzha HCF.
Cases of T2DM and IR and controls for both studies were defined using the same
definitions listed above. In the case, control to determine T2DM risk factors,
participants were enrolled both from patients participating in the survey
(objective 1) and from known T2DM patients attending the diabetes clinic at the
same centre. Cases of T2DM among patients involved in the study were identified
by the time results became available and usually within 72 hours after sample
collection.  Patients with T2DM attending the clinic were identified among the
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cases known to the service who are attending spontaneous of routine follow-up
consultations. We contacted the participants identified by the survey by phone
or when they came back to the clinic to inform them about their results and
invite them to participate in the second part of the study.
Patients who agreed to participate and signed a consent form were interviewed
to complete a questionnaire.
The second part included a more detailed questionnaire about their medical
history and lifestyle; we informed them that we would take some measurements:
height, weight, waist and hip circumference and BP.  Patients who agree to
participate were given an appointment. Cases from the survey were enrolled
daily until we reached the desired sample size.
Cases with T2DM were defined as any adult who has a medical history of a
diagnosis of T2DM using the same parameters described above or, at least, two
consecutive FPG with abnormal values.  Some of these cases may have achieved
glucose homeostasis at the time of enrollment but were still considered to have
T2DM.
Controls were adults who did not have T2DM nor IR patients, as defined above.
In the first case-control (risk factors for DM), study cases were adults with DM
and controls were patients with normal glucose and no IR. We estimated that
20% of patients enrolled for this objective would have DM. The survey, therefore,
would identify about (380x 0.2) 76 adults with DM (cases).  We also expected that
10% of the survey participants would have IR (380x 0.1) resulting in 38 cases of IR
and normal glucose. The remaining 266 participants were expected to be healthy
controls (No DM or IR).
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The main risk factors used to establish the sample size were high cholesterol level
(expected to be present in 30% of the adult population), hypertension (30%)
(Boodai et al., 2014). The estimated prevalence of obesity in Kuwait was 40%
(Musaiger, 2011b). If we enrolled participants with a ratio of controls to cases of
1:1; to be 90% confident to have 80% chance to detect odds ratios of ≥ 2.5, the
estimated sample size was 65 DM cases and 65 controls.
In the case-control study to determine the risk factors for IR, all participants were
enrolled from the prevalence survey (objective 1). Cases of IR were defined
according to homeostatic model assessment (HOMA2-IR). * Patient with HOMA2-
IR ≥ 2 but who are not with diabetes (FPG <7 mmol/l) will be defined as cases
with IR.
Controls for this case-control study were the same participants in the survey who
do not have T2DM or IR.
A total of 64 controls were enrolled and32 cases, giving a ratio of 1:2 cases per
control. We chose this ratio because of the expected small number of cases, as
estimated that only about 10% of the survey population would have IR but no
T2DM. According to the available numbers of cases and controls, this ratio would
make it possible to achieve a statistical power > 80% to identify IR risk factors.
For both case-control studies, the interviewer asked the participant to fill a
second questionnaire that includes a more extensive list of potential risk factors
for T2DM and IR (see questionnaires in Appendix 1).  The questionnaire included
all known risk factors for T2DM and IR and included diet, physical activity, BMI,
family history and others. A dedicated nurse measured blood pressure (BP), waist
and hip circumference (cm), weight (kg), height (cm). BMI will be calculated as
weight (kg)/height² (m²).
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Figure 5: Anthropometric and blood pressure measurement room
3.1.3 Objective 3: To describe the prevalence of IR among first-degree relatives of
patients with T2DM.
We conducted a cross-sectional survey of relatives of patients with T2DM. The
study was conducted at the same Nuzha HCF, Kuwait, from October 2015 to
September 2016.
Selection of participant: we asked all known T2DM participants in objective 1 and
all participants of objective 4 to invite one of their first-degree relatives to attend
the clinic to participate in a study identifying the prevalence of IR in this group.
When the patient agrees to invite a relative, we asked them to attend according
to an appointment given and ask them to come fasting for about 12 hours.  We
recruited participants until the sample size was achieved.
There are 2000 diabetic patients being followed at Nuzha HCF. If each diabetic
patient had about ten first degree relatives, the population size for this survey
would be 20,000. The estimated prevalence of IR among the first-degree relatives
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was 50%. To conduct a survey with 90% confidence level and a maximum error of
±5% the required sample size was estimated to be 270.
Eligibility were adults ≥ 18 years old, first-degree relative to a diabetes patient
attending Nuzha HCF.  We excluded pregnant women, relatives with known
diabetes, and patients who have had a fever in the last 14 days, patients on
steroids, those unable to consent, patients who are unable to fast overnight.
We asked the participant to fill the questionnaire then the phlebotomist at Nuzha
HCF collected the venous blood sample.
Laboratory procedures: Relatives blood samples were collected to measure the
same tests, including FPG, Fasting plasma insulin and HbA1c. To test the blood,
we used the same assays mentioned in the methods section for objective one.
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Figure 6: Nuzha laboratory
3.1.4 Objective 4: To establish the proportion of patients with T2DM who achieve
adequate glycaemic control and risk factors for poor glycaemic control.
We conducted a cross-sectional survey study at the diabetes clinics of Nuzha HCF,
Kuwait from October 2015 to September 2016. We used systematic sampling to
enrol patients. Eligibility was adults > 18 years old with a previously known
diagnosis of T2DM who attend a regular appointment at the diabetes clinic. We
excluded pregnant women, patients with acute infections who have a fever,
patients on steroids, those unable to consent.
Cases were classified as having good glucose control if their HbA1c was < 7. Cases
were classified as having poor glucose control if their HbA1c was > 9.
As indicated, the clinic provides medical services for about 2000 diabetic patients.
We estimated that there was a 50% chance of poor glycaemic control. To conduct
a study to demonstrate this proportion with 90% confidence level and 5%
confidence limits, we would require. We will need at least 240 participants.
Every third patient attending the clinic was invited, with three patients enrolled
per day, four days a week. When a patient refused to participate, we invited
patients consecutively until a replacement is found.  Then the 3-patient interval
was resumed.
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Patients who agreed to participate and signed a consent form were interviewed
to complete a questionnaire containing demographic background and medical
history.
We asked the participants to fill a questionnaire with
known risk factors for poor glycaemic control among
T2DM patients, which included diet, physical activity,
BMI, family history, adherence to treatment,
understanding of diabetes and others. A dedicated nurse
measured blood pressure (BP), waist and hip
circumference (cm), weight (kg), height (cm). BMI was
calculated as weight (kg)/height² (m²).
The phlebotomist at Nuzha HCF collected the venous sample; we tested the
blood sample for HbA1c and Lipid profile.
To test the blood, we used the same spectrophotometry assay used in objective
1.
Figure 7: The main researcher filling a questionnaire
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3.1.5 Objective 5: To assess the agreement of a POC device to measure HbA1c
with a reference HbA1c assay kit to monitor DM control among patients with DM
and/or patients with known haemoglobinopathies.
This was a cross-sectional survey in Kuwait and was conducted from October
2015 to September 2016.
Setting: The study was located in two sites according to the type of participants.
At Nuzha HCF diabetes clinic, for patients not known to have abnormal
haemoglobin and at the haematology clinic in Amiri hospital for patients with
known to haemoglobinopathies.
Target Population: Adult patients with T2DM attending diabetes clinic in Nuzha
health care facility and adult patients with abnormal haemoglobin attending
haematology clinic in Amiri hospital.
Eligibility criteria for patients in the Nuzha clinic was: adults > 18 years old with a
known diagnosis of T2DM who attended a regular appointment at the diabetes
clinic. We excluded pregnant women, patients with acute infections and fever,
patients on steroids and those unable to consent.
Eligibility criteria for patients with haemoglobinopathies were adult patients with
abnormal haemoglobin attending the haematology clinic at Al-Amiri Hospital
seeking medical advice. We excluded pregnant women, patients with acute
infections and fever, patients on steroids and those unable to consent. Patients
with haemoglobinopathies were comprised of patients with a known diagnosis of
α thalassemia, thalassemia, and sickle cell anaemia.
85
We asked every second eligible patient attending the haematology clinic to
participate in the study when the second patient refuses to participate we invited
consecutively eligible patients until we enrolled one, then we went back to every
second patient systemic sampling. The plan was to recruit two patients daily.
We asked the participant to sign a consent and to fill a short questionnaire, then
to take a venous blood sample and a blood finger –prick blood sample.
Eligible patients were enrolled prospectively over a period of 12 months or until
the desired sample size in both settings was achieved.
In the literature, the sensitivity of the reference A1c test (Tosoh) is between 70%
and 80%. So, I used the 80% value as the comparative point., and we allowed for
a 5% difference, with type I error (α) = 0.05 and type II error (β) = 0.2, the
required sample size was 200 paired blood tests (200 lab reference HbA1c and
200 POC HbA1c).
Laboratory procedures
A ﬁnger-prick blood sample was collected for in-clinic HbA1c testing with the
rapid one-step automatic test; Boronate affinity technique (Quo-Test) This
machine provides results within about 4 minutes.
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Figure 9: Illustration of collecting blood and running the test
For the reference HbA1c test, we collected 1 ml blood in a purple top tube
containing EDTA as described in previous objectives.
For Hb electrophoresis, we collected 3 ml blood in a purple top tube containing
EDTA; the blood sample was tested in Amiri hospital laboratory using the Bio-Rad
Variant II Haemoglobin Testing System.
Figure 8: A participant giving finger-prick sample for HbA1c
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4: Results
4.1 Objective 1: To determine the prevalence of T2DM and IR among adult
population attending a primary health care facility in Kuwait.
Demographic characteristics of participants.
Four hundred and two subjects, 18 years or older, were interviewed for in Nuzha
health care facility. Of these, 206 (51.2%) were male and 196 (48.8%) female. The
mean (SD) age of the participants was 41.1 (12.92) years with a range from 19 to
91 years. About one-third (n=130, 32%) of participants were < 40 years, 222
(55.2%) between 40 and 60 and 50 (12.5%) > 60 years old, as shown in Table 8.
One hundred and eighty (44.8%) participants were of Indian background, 176
(43.8%) Arabs, 31 (7.7%) from Southeast Asia, 13 (3.2%) Farsi, and two (0.5%)
from other nationalities.
One hundred and sixty-four (40.8%) had higher degree education, 136 (33.8%)
secondary education, 89 (22.1%) primary education and only 13 (3.2%) were
uneducated. Ninety-five participants (23.6%) worked in the government sector,
55 (13.7%) in the private sector, 174 (43.3%) were labourers, 49 (12.2%) were
retired, and 29 (7.2%) were not working at the time of the interview. Most
participants had a partner or were married (330, 82.1%), 49 (11.9%) were single,
16 (4%) widowed, and 7 (1.7%) separated. One hundred and seven (26.6%) had
hypertension, and 295 (73.4%) had normal blood pressure.
Table 8: Demographic characteristics (and blood pressure status) of participants
Demographic characteristics n=402 (%)
Sex Male 206 (51.2)
Female 196 (48.8)
Age, Mean (SD) 41.1 (12.92)
Age group 18-29 48 (11.9)
30-39 82 (20.4)
40-49 116 (28.9)
50-59 106 (26.4)
60-69 34 (8.5)
88
70+ 16 (4)
Ethnicity Arab 176 (43.8)
Indian 180 (44.8)
South East Asia 31 (7.7)
Farsi 13 (3.2)
Other 2 (0.5)
Education No education 13 (3.2)
Primary 89 (22.1)
Secondary 136 (33.8)
Higher education 164 (40.8)
Occupation Government 95 (23.6)
Private 55 (13.7)
Labourer 174 (43.3)
Not working 29 (7.2)
Retired 49 (12.2)
Marital status With partner 330 (82.1)
Single 49 (12.2)
Widowed 16 (4)
Divorced/Separated 7 (1.7)
Smoking No 339 (84.3)
Ex-smoker 30 (7.5)
yes 33 (8.2)
Hypertension Yes 107 (26.6)
No 295 (73.4)
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Biochemical profile of participants.
Blood was obtained from all 402 participants. The mean (SD) FPG was 6.4 (2) with
a range of 3.01 to 19.88 mmol/l. Two hundred ninety-nine (74.4%) had normal
FPG, 38 (9.5%) participants had prediabetes range (FPG 6.1-6.99) and 65 (16.1%)
had FPG ≥7. Insulin measurements were available for 401 participants and their
mean (SD) Insulin was 14.8 (10.7) µU/ml with a range of 0.56 to 107.8 µU/ml (see
below HOMA calculations). The mean (SD) LDL, HDL, and TG of the 402
participants were 3.9 (0.98), 1.24 (0.46) and 1.6 (0.92) mmol/l, respectively, as
shown in Table 9. One hundred and fifteen (28.6%) participants had normal LDL
levels, and 287 (71.4%) were with high levels. One hundred thirty-seven (34.1%)
participants had normal TG levels, and 265 (65.9%) participants had high TG. HDL
level was normal in 174 (43.3%) and low in 228 (56.7%), as shown in Table 9.
Two hundred twenty-five (59.5%) had HbA1c < 6%, 70 (18.5%) had HbA1c
between 6 and 6.49%, and 83 (22%) had HbA1c ≥ 6.5%.
Table 9: Biochemical characteristics of participants
Variables Results available n (%) Mean (SD)
FPG 402 6.4 (2)
≥7 mmol/l 65 (16.1%)
6.1-6.99 38 (9.5%)
<6.1 299 (74.4%)
Insulin [µU/ml] 401 14.78 910.720
Homa2 IR 393 1.95 (1.36)
LDL mmol/l 402 3.9 (0.98)
≥ 2.6 287 (71.4%)
< 2.6 115 (28.6%)
HDL mmol/l 402 1.24 (0.46)
≥ 1.2 174 (43.3%)
< 1.2 228 (56.7%)
TG mmol/l 402 1.6 (0.92)
≥ 1.7 265 (65.9%)
< 1.7 137 (34.1%)
HbA1c [%] 378 6 (1.2)
≥ 6.5 83 (22%)
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6-6.49 70 (18.5%)
< 6 225 (59.5%)
* FPG = fasting plasma glucose, HOMA2 IR = homeostatic model assessment, LDL
= low density lipoprotein, HDL = high density lipoprotein, TG = triglyceride,
HbA1c= haemoglobin A1c.
Participants unaware of having T2DM
To identify the number of participants who did not know they had T2DM, we
excluded participants with known T2DM, which left a total of 327 participants.
HbA1c and FPG results of the 327 patients were cross-tabulated to identify those
with FPG or HbA1c above the T2DM threshold, as shown in Table 10. Fourteen
patients had missing HbA1c results.
HbA1c was < 6.5% in 279 and ≥ 6.5% in 34 participants. FPG was < 7 mmol/l in
294 and ≥ 7 mmol/l in 19 participants. Nine participants had both high HbA1c and
FPG. Both tests, therefore, identified 44 patients unaware of having T2DM.
Table 10: Agreement of FPG and HbA1c among participants not known to have
T2DM
FPG mmol/l
< 7 ≥ 7
HbA1c % < 6.5 269 (96.4%) 10 (3.6%)
≥ 6.5 25 (73.5%) 9 (26.5%)
Prevalence of prediabetes
We excluded 119 participants with diabetes (known and new T2DM), with data
missing from fourteen cases, which left a total of 269 participants. HbA1c and
FPG results of the 269 patients were cross-tabulated to identify those with FPG or
HbA1c within the prediabetes range, as shown in Table 11.
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Table 11: Agreement of FPG and HbA1c in participants with no diabetes
FPG mmol/l
<6.1 6.1-6.99
HbA1c % < 6 199 22
6-6.49 32 16
HbA1c was < 6% in 221 participants and between 6 and 6.49 in 48 participants,
FPG was < 6.1 mmol/l in 231and between 6.1 and 6.49 mmol/l in 38 participants.
Sixteen participants had both HbA1c and FPG within the prediabetes range. Both
tests, therefore, identified 70 (17.4%) participants who had prediabetes. The
agreement of FPG and HbA1c is shown in Table 12.
Prevalence of T2DM and IR among participants
Seventy-five (18.6%) of the 402 participants knew they had T2DM and 44 (10.9%,
95% CI = 7.9% – 14.0%) new cases were identified by the survey, as shown in
Table 12. The overall number of participants with T2DM, therefore, was 119
(29.6%, 95% CI = 25.1% to 34.1%). Table 12 describes the number of cases
diagnosed by history, FPG, and HbA1c.
HOMA2 IR was calculated after exclusion of all known and newly diagnosed
T2DM participants.  Seven participants had insulin levels either < 2.9 or > 57.8,
which are the minimum and maximum range values accepted by the HOMA2-IR
formula and were excluded. Ninety-eight (34.6%) of the remaining 283
participants had HOMA2 IR ≥ 2 and 185 (65.4%) HOMA2-IR < 2. Accordingly, the
prevalence of IR in individuals without T2DM was 34.6% (95% CI = 29.1% –
40.2%).
Table 12: Proportion of participants with T2DM and IR
n = 402
n (%)
known T2DM 75 (18.6)
New FBG≥ 71 19 (6)
New HbA1c ≥ 6.51 34 (11.2)
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Previously unknown T2DM 44 (13.4)
Known and new T2DM 119
(29.6)
Homa2-IR ≥ 22 98 (34.6)
1only includes participants unaware of having T2DM
2only includes participants without T2DM
The age distribution of participants by sex is shown in figure 10, and the
proportion of individuals with normoglycaemia, prediabetes and T2DM by age
and sex are shown in the figures 11 (males) and 12 (females). Most participants
were in their 30s and 50s. The proportion of participants with prediabetes
started to increase in early adulthood (20-30 years) and peaked among
participants in their 40s. The proportion of participants who had T2DM also
started to increase among 20-30-year-old participants and peaked among
participants above 40 years old, with most participants > 50 years having
prediabetes or T2DM. Male participants developed T2DM from an early age, with
about 10% of participants aged 18-29 having T2DM, with an increasing
proportion of participants having overt T2DM and a relative decrease of
prediabetes with age. Most participants > 60 had T2DM and very few
prediabetes.  In contrast, the proportion of women with T2DM was low at
younger ages, with both T2DM and prediabetes increasing steadily with each
decade of life, so that by the > 60 nearly 80% of women had either prediabetes or
T2DM.
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Figure 10: Age distribution by sex
94
Figure 11: Glycaemic status in males, normal, prediabetes, and T2DM (HbA1c)
Figure 12: Glycaemic status in females, normal, prediabetes, and T2DM (HbA1c)
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4.2 Objective 2: Risk factors for T2DM and IR in a clinic study population.
Comparison of participants with and without T2DM or IR
The same individuals participating in objective 1 were further interviewed to
determine the risk factors for T2DM. As stated in objective 1, 185 participants did
not have T2DM or IR (called normoglycaemic patients from now on), 98 had IR
with normal glucose, and 119 had T2DM. Participants with T2DM were older than
patients with IR or who were normoglycaemic. The mean (SD) age of
normoglycaemic, IR andT2DM patients was 42.7 (12.0), 43.2 (11.1) and 51.9
(12.9) years, respectively (Chi-square 34.74, p <0.001). The proportion of
participants who had IR was fairly homogeneous by age, as shown in Table 13. In
contrast, the proportion of participants who had T2DM increased with age. The
proportion of participants who had overt T2DM increased with each decade of
life from a baseline of 8.3% among participants aged 18-29 years old to 30.2% by
the time they were in their 40s and 62% among participants ≥ 60 years old.
Ninety-two (49.7%) of 185 normoglycaemic individuals were male and 93 (50.3%)
female. Forty-eight (49%) of 98 participants with IR were male and 50 (51%)
female, while 66 (55.5%) participants with T2DM were male and 53 (44.5%)
female (Chi-Square 1.218, p= 0.544).
The country of origin of normoglycaemic, IR and T2DM participants is shown in
Table 13. IR was identified more frequently among Indian (56 (31.1%) of 180) and
South East Asian participants (7 (22.5%) of 31) than participants from other
countries. T2DM was identified more often among Indian (55 (30.5%) of 180) and
Arab participants (54 (30.6%) of 176) than participants from other countries.
Indian and Arab participants therefore seemed more likely to have IR and T2DM
than participants from other ethnic backgrounds, although only the higher
proportion of IR was statistically significant (Chi Square= 10.618, p = 0.014).
Education was associated with the presence of IR and T2DM, although this
association was not ordinal. Participants without education were more likely to
have IR than participants with education (Chi Square= 4.027, p = 0.045).
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In contrast participants without education were less likely to have T2DM than
participants with primary or higher degree education (Chi Square= 8.374, p =
0.004).
The type of work was associated with IR and T2DM. Labourers were more likely
to have IR or T2DM than private or government workers. As expected, retired
participants were more likely to have T2DM (Chi Square= 17.814, p= 0.001), but
this is probably due to the association of T2DM with age.
Marital status was associated with T2DM, as widows and widowers were more
likely to have T2DM than single and married individuals (Chi-Square = 24.058, p <
0.001), however, this association is also likely confounded by age (see
multivariate analysis below).
Smoking was associated with T2DM and smokers were more likely to have IR and
T2DM than non-smokers, but this relation was not statistically significant (Chi
Square =3.207, p= 0.524).
The presence of hypertension was associated with both IR and T2DM but was
only significant for T2DM (OR= 3, 95% CI 1.79-5.04, p= < 0.001).
Table 13: Demographic characteristics and blood pressure status of participants
with normoglycaemia, IR and T2DM
Variable Normal
n=185 (%)
IR
n=98 (%)
T2DM
n=119
(%)
Sex Male 92 (49.7) 48 (49) 66 (55.5)
Female 93 (50.3) 50 (51) 53 (44.5)
Age groups 18-29 29 (15.8) 15 (15.3) 4 (3.4)
30-39 47 (25.4) 20 (20.4) 15 (12.6)
40-49 48 (25.9) 33 (33.7) 35 (29.4)
50-59 48 (25.9) 24 (24.5) 34 (28.6)
60-69 10 (5.4) 5 (5.1) 19 (16)
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70+ 3 (1.6) 1 (1) 12 (10)
Age mean
(SD)
42.7 (11.98) 43.2
(11.07)
51.9
(12.86)
Ethnicity Arab 91 (51.7) 31 (17.6) 54 (30.7)
Indian 69 (38.3) 56 (31.1) 55 (30.6)
South East Asia 17 (54.8) 7 (22.6) 7 (22.6)
Farsi 6 (46.2) 4 (30.7) 3 (23.1)
Other 2 (100) 0 (0) 0 (0)
Education No education 4 (30.7) 6 (46.2) 3 (23.1)
Primary 33 (37.1) 23 (25.8) 33 (37.1)
Secondary 59 (43.4) 30 (22.1) 47 (34.5)
Higher education 89 (54.2) 39 (23.8) 36 (22)
Occupation Governmental 57 (60) 20 (21.1) 18 (18.9)
Private 29 (52.7) 14 (25.5) 12 (21.8)
Labourer 66 (37.9) 52 (29.9) 56 (32.2)
Not working 16 (55.2) 4 (13.8) 9 (31)
Retired 17 (34.7) 8 (16.3) 24 (49)
Marital
status
With partner 143 (43.3) 83 (25.2) 104
(31.5)
Single 31 (63.2) 14 (28.6) 4 (8.2)
Widowed 4 (25) 1 (6.2) 11 (68.8)
Separated 7 (100) 0 (0) 0 (0)
Smoking No 158 (46.6) 86 (25.4) 95 (28)
Ex-smoker 14 (46.7) 5 (16.6) 11 (36.7)
Smoker 33 (39.4) 7 (21.2) 13 (39.4)
Hypertension Yes 35 (32.7) 23 (21.5) 49 (45.8)
No 150 (50.9) 75 (25.4) 70 (23.7)
Biochemical characteristics of normoglycaemic, IR and T2DM participants
The biochemical markers of participants with normal glucose metabolism, IR and
T2DM are shown in Table 13.  As expected from the definition of the categories,
the mean (SD) FPG and HbA1c of normoglycaemic participants were within
normal ranges [5.3 mmol/l (0.67) and 5.41% (0.47)] and were lower than in
participants with IR [5.45 (0.67) mmol/l and 5.62% (0.45), p < 0.001 and 0.030] or
T2DM [7.7 (2.9) mmol/l and 7.27% (1.5), p < 0.001 and <0.001].
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A high HDL and TG was significantly related to the presence of IR, but not to
T2DM. Participants with a HDL < 1.2 mmol/l had an increased risk of IR (OR= 2.35,
95% CI 1.4-3.96, p= 0.001) and participants with TG > 1.7 mmol/l, had an
increased risk of IR (OR = 2.14, 95% CI 1.28-3.57).
Table 14: Biochemical characteristics of participants with/without IR and T2DM.
Variables Normal    Mean (SD) IR   Mean (SD) T2DM    Mean (SD)
FPGmmol/l 5.3 (0.67) 5.5 (0.67) 7.7 (2.9)
LDLmmol/l 3.1 (0.87) 3.24 (0.77) 2.96 (0.98)
≥ 2.6    n (%) 131 (45.6) 76 (26.5) 80 (27.9)
< 2.6    n (%) 54 (47) 22 (19.1) 39 (33.9)
HDLmmol/l 1.28 (0.41) 1.17 (0.6 1.24 (0.39)
≥ 1.2    n (%) 92 (51.7) 29 (16.3) 57 (32)
<1.2     n (%) 93 (41.5) 69 (30.8) 62 (27.7)
TGmmol/l 1.4 (0.81) 1.85 (1.03) 1.69 (0.9)
≥ 1.7    n (%) 51 (37.2) 44 (32.1) 42 (30.7)
< 1.7    n (%) 134 (50.6) 54 (20.4) 77 (29)
HbA1c % 5.4 (0.47) 5.6 (0.45) 7.3 (1.5)
Insulin µU/ml 9.25 (3.22) 23.1 (10.1) --
Homa2 IR 1.2 (0.42) 2.97 (0.999) --
The mean (SD) of LDL, HDL, and TG in normoglycaemic participants were similar
to participants with IR and T2DM, except for TG which was higher, and HDL was
lower among patients with IR (p = 0.225, 0.001 and < 0.004, respectively) and
T2DM (p = 0.508, 0.755 and 0.154, respectively), as shown in Figure 13.
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Figure 13: Mean and 95% CI (a) LDL, (b) HDL and (c) triglyceride levels in
participants with normal glucose, IR and T2DM.
Comparing the levels of LDL, HDL, and TG in the normoglycaemic group vs known
and newly diagnosed T2DM shows that the mean of LDL and TG is higher in newly
diagnosed T2DM than in knownT2DM participants, and lower mean of HDL in
newly diagnosed T2DM than in knownT2DM participants (figure 14). These
results might be due to cholesterol-lowering drugs in knownT2DM individuals,
knowing that clinicians tend to control the cholesterol level in T2DM patients.
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Figure 14: Mean and 95% CI of LDL, HDL, and TG in normoglycaemic, newly
diagnosed T2DM, and known T2DM
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Table 15: Descriptive analysis and odds ratios for the study groups.
Normal
n=185
n (%)
IR
n=98
n (%)
T2DM
n=119
n (%)
(normal vs IR)
OR 95%CI
P
value
(normal vs T2DM)
OR 95%CI
P value
Sex Male 92 (44.7) 48 (23.3) 66 (32) 1.03 (0.63-1.68) 0.904 1.26 (0.79-2.00) 0.329
Female 93 (47.4) 50 (25.5) 53 (27.1) Ref Ref
Age groups 18-29 29 (60.4) 15 (31.3) 4 (8.3) Ref Ref
30-39 47 (57.3) 20 (24.4) 15 (18.3) 0.82 (.37-1.85) 0.638 2.31 (0.70-7.65) 0.169
40-49 48 (41.4) 33 (28.4) 35 (30.2) 1.32 (0.62-2.85) 0.466 5.29 (1.70-16.4) 0.004
50-59 48 (45.3) 24 (22.6) 34 (32.1) 0.97 (0.43-2.13) 0.933 5.13 (1.65-16.0) 0.005
60-69 10 (29.4) 5 (14.7) 19 (55.9) 0.97 (0.44-2.13) 0.957 13.8 (3.77-50.3) <0.001
70+ 3 (18.8) 1 (6.3) 12 (75) 0.64 (0.06-6.74) 0.714 29.0 (5.62-149.7) <0.001
Age mean (SD) 42.7 (11.98) 43.2 (11.07) 51.9 (12.86)
Ethnicity Arab 91 (51.7) 31 (17.6) 54 (30.7) Ref 1.44 (0.56-3.70) 0.447
Indian 69 (38.3) 56 (31.1) 55 (30.6) 2.38 (1.39-4.08) 0.002 1.94 (0.75-5.00) 0.172
South East Asia 17 (54.8) 7 (22.6) 7 (22.6) 1.21 (0.46-0.32) 0.702 Ref
Others 8 (53.3) 4(26.7) 3 (20) 1.47 (0.41-5.21) 0.553 0.91 (1.85-4.47) 0.908
Education No education 4 (30.7) 6 (46.2) 3 (23.1) Ref
Primary 33 (37.1) 23 (25.8) 33 (37.1) 0.47 (.12-1.83) 0.274 1.33 (0.28-6.43) 0.720
Secondary 59 (43.4) 30 (22.1) 47 (34.5) 0.34 (0.09-1.29) 0.113 1.06 (0.23-4.98) 0.939
Higher education 89 (54.2) 39 (23.8) 36 (22) 0.29 (.08-1.09) 0.068 0.54 (0.12-2.53) 0.434
Occupation Governmental 57 (60) 20 (21.1) 18 (18.9) 1.40 (0.42-4.70) 0.582 Ref
102
Private 29 (52.7) 14 (25.5) 12 (21.8) 1.93 (0.54-6.86) 0.309 1.31 (0.56-3.09) 0.536
Labourer 66 (37.9) 52 (29.9) 56 (32.2) 3.15 (0.99-10.0) 0.051 2.68 (1.42-5.09) 0.002
Not working 16 (55.2) 4 (13.8) 9 (31) Ref 1.78 (0.67-4.72) 0.245
Retired 17 (34.7) 8 (16.3) 24 (49) 1.88 (0.47-7.49) 0.369 4.47 (1.98-10.1) <0.001
Marital status With partner 143 (43.3) 83 (25.2) 104 (31.5) 1.29 (0.65-2.55) 0.474 5.64 (1.93-16.5) 0.002
Single 31 (63.2) 14 (28.6) 4 (8.2) Ref
Widowed 4 (25) 1 (6.2) 11 (68.8) 0.55 (0.06-5.41) 0.611 21.3 (4.54-100) <0.001
Separated 7 (100) 0 (0) 0 (0) ---- 0.999 -- 0.999
Smoking No 158 (46.6) 86 (25.4) 95 (28) Ref Ref
Ex-smoker 14 (46.7) 5 (16.6) 11 (36.7) 1.87 (0.63-5.54) 0.262 0.49 (0.13-1.77) 0.272
Smoker 33 (39.4) 7 (21.2) 13 (39.4) 2.03 (0.59-6.99) 0.261 1.70 (0.54-5.33) 0.365
Hypertension Yes 35 (32.8) 23 (21.5) 49 (45.8) 1.3 (0.73-2.38) 0.368 3.00 (1.79-5.04) <0.001
No 150 (50.8) 75 (25.4) 70 (23.7) Ref Ref
LDLmmol/l Mean (SD) 3.1 (0 .87) 3.24 (0.77) 2.96 (0.98)
≥2.6 131 (45.6) 76 (26.5) 80 (27.9) 1.42 (0.81-2.52) 0.225 1.18 (0.72-1.94) 0.508
<2.6 54 (47) 22 (19.1) 39 (33.9) Ref Ref
HDLmmol/l Mean (SD) 1.28 (0.41) 1.17 (0.60) 1.24 (0.39)
≥1.2 92 (51.7) 29 (16.3) 57 (32) Ref Ref
<1.2 93 (41.5) 69 (30.8) 62 (27.7) 2.35 (1.40-3.96) 0.001 1.08 (0.68-1.71) 0.755
TGmmol/l Mean (SD) 1.4 (0.81) 1.85 (1.03) 1.69 (0.9)
≥1.7 51 (37.2) 44 (32.1) 42 (30.7) 2.14 (1.28-3.57) 0.004 1.43 (0.87-2.35) 0.154
<1.7 134 (50.6) 54 (20.4) 77 (29) Ref
History of
T2DM in
family
No 67 (44.4) 38 (25.2) 46 (30.4)
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First degree 102 (45.5) 52 (23.2) 70 (31.3) 0.89 (.535-1.51) 0.688 1.00 (0.62-1.62) 0.999
Second degree 14 (63.6) 5 (22.7) 3 (13.6) 0.63 (0.21-1.88) 0.408 0.31 (0.09-1.15) 0.080
Third degree 2 (40) 3 (24.4) 0 (29.6) 2.65 (0.42-16.5) 0.298 -- 0.999
104
Ethnicity, HDL, and TG were selected for the multivariate analysis (Normal vs. IR), of these,
ethnicity and TG became non-significant, while HDL remained significant with an AOR 1.96
(95% CI 1.12-3.42) and a P value of 0.019.
Table 16: Adjusted odds ratios (normal vs IR)
Unadjusted
(normal vs. IR)
OR 95%CI
P value Adjusted
(normal vs. IR)
OR 95%CI
P value
Ethnicity
Arab Ref
Indian 2.38 (1.39-4.08) 0.002
South East Asia 1.21 (.458-.319) 0.702
Others 1.47 (.413-5.21) 0.553
HDL
mmol/l
≥1.2 Ref
<1.2 2.35 (1.40-3.96) 0.001 1.96 (1.12-3.42) 0.019
TG mmol/l
≥1.7 2.14 (1.28-3.57) 0.004
<1.7 Ref
Age group, occupation, marital status, and hypertension were selected for the
multivariate analysis (Normal vs T2DM). Of these, occupation became non-significant,
while the age group 60 to 69 and 70+ remained significant with an AOR of 5.40 (95% CI
1.25-23.3) and 9.59 (95% CI 1.58-58.1) respectively. Similarly, widowers remain
independently related to IR with an AOR of 6.11 (95% CI 1.09-34.40, p=0.040).
Hypertension also remained significant with an AOR of 1.95 (95% CI 1.9-3.49, p= 0.024).
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Table 17: Adjusted odds ratio (normal vs T2DM)
Unadjusted
(normal vs.
T2DM)
OR 95%CI
P
value
Adjusted
(normal vs.
T2DM)
OR 95%CI
P
value
Age group 18-29 Ref
30-39 2.31 (.700-7.65) 0.169
40-49 5.29 (1.70-16.4) 0.004
50-59 5.13 (1.65-16.0) 0.005
60-69 13.8 (3.77-50.3) <0.001 5.40 (1.25-23.3) 0.024
70+ 29.0 (5.62-149.7) <0.001 9.59 (1.58-58.1) 0.014
Occupation Governmental Ref
Private 1.31 (.556-3.09) 0.536
Labourer 2.68 (1.42-5.09) 0.002
Not working 1.78 (.673-4.72) 0.245
Retired 4.47 (1.98-10.1) <0.001
Marital
status
With partner 5..64 (1.93-16.5) 0.002
Single Ref
Widowed 21.3 (4.54-100) <0.001 6.11 (1.09-34.4) 0.040
Separated -- 0.999
hypertension Yes 3.00 (1.79-5.04) <0.001 1.95 (1.9-3.49) 0.024
No Ref
Anthropometric measurements, nutritional habits, and physical activity in a sub-sample of
participants.
Only 173 individuals agreed to participate in the measurement of anthropometric
characteristics.
The sub-sample of 173 participants had measurements for waist and hip circumference,
weight, and height and underwent further interviews to identify risk factors not
documented at the initial survey interview.
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Anthropometric measurements of participants with normoglycaemia, IR and T2DM.
WHR and BMI were available for 58 (%) participants with normal glycaemia, 48 (%) with
IR, and 67 (%) with T2DM, as described in Table 18. Increased waist circumference was
significantly associated with IR and T2DM. Male participants with waist circumferences ≥
94 cm were more likely to have IR (OR = 5.5, 95%CI 1.69-18.1, p= 0.005) than participants
with waist circumference < 94. This risk remained unchanged when using a higher cut-off
≥ 102 (OR = 5.4, 95% CI 1.50-19.70). Waist circumference was also associated with T2DM.
A waist circumference > 94 increased the Odds of having T2DM (OR = 2.18, 95% CI = 0.87-
5.45). Moreover, this risk increased further when using a cut-off ≥ 102 (OR = 4, 95% CI =
1.19-13.40). Among females, a waist circumference > 80 cm was not statistically
associated with IR (OR = 3.8, 95% CI = 0.39-37.10), but the risk increased substantially with
a cut-off ≥ 88 cm (OR = 6.43, 95% CI = 1.21-34.20). T2DM, in turn, had a slightly different
pattern, as the OR for T2DM was not increased with a waist circumference ≥ 80 (OR =
0.85, 95% CI = 0.18-3.92), but rose to 3.04 (95% CI = 0.78-11.90) with a cut-off ≥ 88 cm, as
shown in Table 19. There was no association between a high WHR and IR or T2DM.
BMI was associated with both IR and T2DM. Overweight participants were more likely to
have IR, and this risk increased significantly with BMI ≥ 25 and <30 (OR = 9.73, 95% CI =
2.06-45.9) and BMI ≥ 30 and < 34.9 (OR = 18.33, 95% CI = 3.46-94.96). The odds ratios
increased even more with a BMI ≥ 35 (OR = 88.0, 95% CI 6.99-1108.22). This pattern was
similar for T2DM as the OR increased to 1.95 (95% CI = 0.82-4.63) for overweight
participants and to 2.44 (95% CI = 0.82-7.29) for BMI ≥ 30 and < 35. The odds increase
significantly in participants with BMI ≥ 35 (OR 18.62, 95% CI 2.15-161.24).
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Figure 15: Mean and 95% CI BMI and waist (a. female and b. male) of participants with
normal glucose, IR and T2DM.
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Table 18: Anthropometric measurements of participants
Normal n=58
n (%)
IR n=48
n (%)
T2DM n=67
n (%)
(normal vs IR)
OR 95%CI
P
value
(normal vs T2DM)
OR 95% CI
P value
WHR
Male
< 0.90 5 (62.5) 0 (0) 3 (738.5) Ref Ref
≥ 0.90 28 (28.6) 28 (28.6) 42 (42.8) -- 0.990 2.50 (0.55-11.30) 0.234
Female
< 0.85 5 (50) 1 (10) 4 (40) Ref Ref
≥ 0.85 19 (34.5) 19 (34.5) 17 (31) 5.00 (0.53-46.90) 0.159 1.12 (0.26-4.85) 0.881
Waist (cm)
Male
< 94 18 (46.2) 5 (12.8) 16 (41) Ref Ref
≥ 94 15(22.4) 23(34.3) 29 (43.3) 5.52 (1.69-18.10) 0.005 2.18 (0.87-5.45) 0.097
< 102 29 (39.2) 16 (21.6) 29 (39.2) Ref
≥ 102 4 (12.5) 12 (37.5) 16 (50) 5.44 (1.50-19.70) 0.010 4.00 (1.19-13.4) 0.025
Female
< 80 4 (44.4) 1 (11.1) 4 (44.4) Ref Ref
≥ 80 20 (35.7) 19 (33.9) 17 (30.4) 3.80 (0.39-37.10) 0.251 0.85 (0.18-3.92) 0.835
< 88 10 (35.7) 14 (50) 4 (14.3)
≥ 88 2 (5.4) 18 (48.6) 17 (46) 6.43 (1.21-34.20) 0.029 3.04 (0.78-11.90) 0.109
BMI
< 25 22 (40.5) 2 (5.4) 13 (35.1) Ref Ref
≥ 25 to < 30 26 (32.9) 23 (29.1) 30 (38) 8.25 (2.06-46.00) 0.004 1.95 (0.82-4.63) 0.129
30-34.9 9 (24.3) 15 (40.5) 13 (35.1) 18.33 (3.46-97.08) 0.001 2.44 (0.82-7.29) 0.109
≥ 35 1 (5) 8 (40) 11 (55) 88.0 (6.99-1108.22) 0.001 18.62 (2.15-161.24) 0.008
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Recall diet of participants and its association with IR and T2DM
The analysis of the dietary intake questionnaire for all participants shows that
there is a higher intake of rice and full cream, and lower intake of fruit,
vegetables, and proteins (Tables 19 and 20).
The only statistically significant association found was for the occasional
consumption of sweets (p = 0.046), as most T2DM participants indicated they ate
sweets infrequently (once per month, median rank 8, IQR 4), while normal
participants consumed sweets slightly more often (once per week, with a median
rank of 6 and IQR 3,25).
Table 19: Median and IQR for patients with normal glucose and T2DM
Food habits Normal (n=58)
Median        IQR
T2DM (n=67)
Median IQR Z p
Fruits & veg 4 2 4 3 -0.574 0.566
Fish 5 1 6 2 -1.287 0.198
Eggs 5 2.25 6 3 -1.919 0.055
Pastry 8 3.25 8 3 -0.333 0.739
Wholegrains 3.5 6 6 6 -1.412 0.158
Rice 3 0 3 0 -0.082 0.935
full cream 3 3.25 3 3 -0.360 0.719
fast food 9 1 9 1 -0.044 0.965
Sweets 6 3.25 8 4 -1.995 0.046
Meat 5 2 5 2 -0.616 0.538
sweetened drinks 9 3 8 3 -0.150 0.881
Z = Mann-Whitney Test
The comparison of medians and IQR ranks for patients with normal glucose and
IR is shown in Table 20. A low proportion of participants indicated they consumed
fast foods and they ate more frequently rice, whole grains and full cream milk.
The only significant food associated with IR was the consumption of sweetened
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drinks, with a median of 9 (IQR 3) and 7 (IQR = 4) for participants with normal
glucose and IR, respectively (p= 0.036).
Table 20: Median and IQR rank for participants with normal glucose and IR.
Food habits Normal (n=58)
Median        IQR
IR (n=48)
Median       IQR Z P
Fruits & veg 4 2 4.5 2 -0.646 0.518
Fish 5 1 6 2 -1.880 0.060
Eggs 5 2.25 6 3 -0.593 0.553
Pastry 8 3.25 7 3 -0.296 0.767
Wholegrains 3.5 6 3 6 -0.140 0.888
Rice 3 0 3 0 -0.361 0.718
full cream 3 3.25 3 3 -0.329 0.742
Fast food 9 1 8 1.75 -1.090 0.276
Sweets 6 3.25 5 5 -1.011 0.312
Meat 5 2 5 2 0.000 1.000
Sweetened drinks 9 3 7 4 -2.097 0.036
Z= Mann-Whitney Test
Physical activity was not associated with any of the glycaemic statuses. Forty-four
(75.9%) of 58 normoglycaemic participants indicated they had low physical
activity (<150 minutes/week), and 14 (24.1%) had good activity levels (≥ 150
minutes/ week). Thirty-eight (79.2%) of 48 participants with IR had poor levels of
activity, and 10 (20.8%) indicated they had good activity. Among T2DM
participants, 42 (62.7%) of 67 participants had poor and 25 (37.3%) good physical
activity (Chi-Square = 4.494, p= 0.106).
One hundred seventy-two participants stated why they were inactive the week
before the interview. The most frequent reason for physical inactivity was their
work (Chi-Square= 18.721, p<0.001).
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Prevalence of metabolic syndrome
Twenty-eight men and twenty-nine women had MS. According to the IDF criteria,
MS prevalence was 32.9% (26.4% in males, and 44.6% in females). The MS rate was
higher in females compared to males (Chi-Square = 4.433, p= 0.035).
4.3 Objective 3: Prevalence of IR among first-degree relatives of patients
with T2DM.
This was a cross-sectional survey of relatives of patients with T2DM. All
individuals with known T2DM participating in the study in objectives 1 and 4 were
asked to invite one of their first-degree relatives without T2DM.  If the patient
had agreed to invite a relative, we provided an appointment date for the
interested relative to attend fasting overnight. We recruited 275 first-degree
relatives.
Demographic description
Two hundred and seventy-five first-degree relatives of patients with T2DM
accepted the invitation to be screened and were interviewed. Of these, 149
(54.2%) were male and 126 (45.8%) female. Their mean (SD) age was 46.1 (12.1)
years, as shown in Table 23.
Eighty-three (30.2%) relatives were < 40 years old, 161 (58.6%) between 40 and <
60 and 31 (11.3%) ≥ 60 years old. One hundred and six (38.5%) relatives were
Indians, 134 (48.7%) Arabs, 25 (9.1%) from Southeast Asia, 9 (3.3%) Farsi and one
(0.4%) from another ethnicity. Two (0.7%) had no education, 52 (18.9%) had
primary, 135 (49.1%) secondary and 86 (31.3%) higher education. Eighty
participants (29.1%) worked in the government, 51 (18.5%) in the private sector,
91 (33.1%) were labourers, 43 (12.4%) retired, and 19 (6.9%) were not working at
the time of the interview.
Two hundred and twenty-nine relatives were living with a partner (83.3%), 28
(10.2%) were single, 14 (5.1%) widowed, and 4 (1.5%) had separated.
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Figure 16: Age distribution of participants by gender
Table 21:  Demographic characteristics of first-degree relatives of patients with
T2DM
Demographic variable n=275
n (%)
Age 18-29 31 (11.3)
30-39 52 (18.9)
40-49 78 (28.4)
50-59 83 (30.2)
60-69 22 (8)
70+ 9 (3.3)
Mean (SD) 46.1 (12.1)
Sex Male 149 (54.2)
Female 126 (45.8)
Ethnicity Arab 134 (48.7)
Indian 106 (38.5)
South East Asia 25 (9.1)
Farsi 9 (3.3)
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Other 1 (0.4)
Education No education 2 (0.7)
Primary 52 (18.9)
Secondary 135 (49.1)
Higher education 86 (31.3)
Occupation Governmental 80 (29.1)
Private 51 (18.5)
Labourer 91 (33.1)
Not working 19 (6.9)
Retired 34 (12.4)
Marital status With partner 229 (83.3)
Single 28 (10.2)
Widowed 14 (5.1)
Divorced/Separated 4 (1.5)
Biochemical characteristics Blood tests were available for all participants (Table
22). The mean (SD) FPG was 6.1 (2.1) (mmol/l), mean (SD) Insulin 15.9 (15.7)
mmol/l, mean (SD) Homa2-IR 2.05 (1.54) and the mean (SD) HbA1c 6.11% (1.3).
Table 22: Biochemical characteristics of first-degree relatives of patients with
T2DM
n =275 Mean (SD) Range
FPG (mmol/l) 6.17 (2.1) 3.01-19.9
Insulin 15.9 (15.17) 0.56-160.4
HOMA IR21 2.05 (1.54) 0.41-15.63
HbA1c %2 6.11 (1.3) 4.2-11.9
1 Eight insulin results were out of the HOMA-IR calculator range.
2 Thirteen participants had missing HbA1c results.
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Prevalence of IR
After excluding 80 newly diagnosed T2DM, 131 (67.2%) relatives had a HOMA2-IR
< 2 and 64 (32.8%) and HOMA2-IR ≥ 2. Accordingly, the prevalence of IR with
euglycaemia among relatives was 32.8%. (Table 23), which is similar to the
prevalence of IR among patients without T2DM attending the health centre
(34.5%).
HbA1c was < 5.7% (normal) in 104 (39.7%), between 5.7% and 6.4% in 96 (36.6%)
and ≥ 6.5% (T2DM) in 62 (23.7%) of the relatives. FPG was < 6.1 mmol/l (normal)
in 184 (66.9%), between 6.1 and 6.9 mmol/l (prediabetes) in 40 (14.5%) and ≥ 7
(T2DM) in 51 (18.5%) participants.
Table 23: HOMA-IR, HbA1c and FPG of first-degree relatives of T2DM participants.
n=275
n (%)
HOMA2-IR1
< 2 131 (67.2)
≥ 2 64 (32.8)
HbA1c %2
< 5.7 104 (39.7)
5.7-6.4 96 (36.6)
≥ 6.5 62 (23.7)
FPGmmol/l
< 6.1 184 (66.9)
6.1-6.9 40 (14.5)
≥ 7 51 (18.5)
1Only 195 normoglycaemic participants included
2Results of HbA1c was available in 262 participants.
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Figure 17 describes the distribution of Homa2 IR among the study participants; the
distribution is unimodal, skewed to the right and the mode is between 1 and 2, with
39.3% having Homa2 IR ≥2 (including participants with newly diagnosed T2DM).
Figure 18 describes the distribution of HbA1c among participants; the distribution is
also unimodal and symmetrical, with most of the values falling between 5% and 7%
and 23.7% of participants having HbA1c ≥ 6.5%.
Figure 17: Homa2 IR distribution among first-degree relatives of patients with
T2DM
Figure 18: HbA1c distribution among first-degree relatives of patients with T2DM
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Figure 19: FPG distribution among first-degree relatives of patients with T2DM
Prevalence of T2DM among first-degree relatives
HbA1c was < 6% (normal) in 122 (46.6%) participants; between 6% and 6.4% in 78
(28.4%) and ≥ 6.5% in 62 (23.7%) participants. FPG was < 7 mmol/l in 224 (81.4%)
and ≥ 7 mmol/l in 51 (19.6%) participants.
Although none of the relatives indicated they knew if they had T2DM, 33 (12%)
had both high HbA1c and FPG, 29 (10.5%) had high HbA1c with normal FPG, and
18 (6.5%) had a high FPG with normal HbA1c. This cross tabulation indicates that
both tests would diagnose 80 (29.1%) new T2DM patients among the 275 first
degree relatives (Chi-Square=63.732, p= < 0.001). The agreement of FPG and
HbA1c are shown in Table 24.
Table 24: Agreement of FPG and HbA1c among relatives of patients with T2DM.
FPG Total
< 7 ≥ 7
HbA1c < 6.5 195 (91.5%) 18 (8.5%) 213
≥ 6.5 29 (46.8%) 33 (53.2%) 62
Total 224 51 275
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FPG and HbA1c levels had a positive correlation. Figure 15 presents a scatter plot
of FPG and HBA1C. Using a linear association model, R2 values were 0.57 for the
association between FPG and HBA1C.
Prevalence of prediabetes
We excluded 80 participants with diabetes (known and new T2DM), with data
missing from seven cases, which left a total of 188 participants. Results of HbA1c
and FPG results for the 188 patients were cross-tabulated to identify those with
FPG or HbA1c within the prediabetes range, as shown in Table 27.
This cross tabulation indicates that both tests would diagnose 56 (20.4%) new
T2DM patients among the 275 first degree relatives (Chi-Square=17.576, p= <
0.001). The agreement of FPG and HbA1c are shown in Table 25.
Table 25: Agreement of FPG and HbA1c in participants with no diabetes
FPG mmol/l
<6.1 6.1-6.99
HbA1c % < 6 132 13
6-6.49 28 15
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Figure 20: Correlation between FPG and HbA1c (lines are the 95% CI) among first-
degree relatives of patients with T2DM.
Characteristics of normoglycaemic, IR and T2DM participants
One hundred thirty-one (47.6%) relatives did not have IR, 64 (23.3%) had IR, and
80 (29.1%) had T2DM. The mean (SD) age of relatives with normal glucose, IR,
and T2DM were 46.2 (12.5), 46.3 (11.5), and 51.4 (11.2), respectively (Chi-Square
138.41, p <0.026). IR was associated with female gender, as only 62 (41.6%) of
131 normoglycaemic individuals, 38 (25.5%) of 149 participants with IR, and 49
(32.9%) with T2DM were male (Chi-Square 4.784, p= 0.091).
The country of origin of normoglycaemic and IR relatives is shown in Table 28. IR
was present in 25 (32%) of 106 participants from India, 25 (18.7%) of 134 Arabs, 3
(12%) of 25 South East Asians, 2 (22.2%) of 9 Persian and 1 (100%) from another
ethnicity. While 36 (26.9%) Arab had T2DM, 35 (33%) of Indians, 7 (28%) from
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South-east Asia, and 2 (22.2%) of Farsi had T2DM.  Relatives from India were
more likely to have IR than participants with other backgrounds, (Chi Square=
14.877, p = 0.062).
The type of work was also associated with IR. Relatives who were labourers were
more likely to have IR and T2DM than private sector workers. IR and T2DM were
present in 27 (29.7%) and 34 (37.4%) of 91 manual labourers respectively,
compared to 15 (18.8%) IR and 16 (20%) T2DM of 80 governmental participants,
and 13 (25.5%) IR and 10 (19.6%) T2DM of 51 participants from the private
sector. (Chi square= 20.419, p = 0.009). Marital status was also statistically
associated with IR, 9 (32.1%) of 28 single participants had IR, which was higher
than another marital status, as shown in Table 28. Widowers were more likely to
have T2DM, as 8 (57.1%) of 14 widowers had T2DM, (Chi-Square = 16.604, p =
0.011).
Education was significantly associated with T2DM, and only 16 (18.6%) of 86
participants with higher education had IR and 11 (12.8%) had T2DM, which was
lower than for other education categories, as shown in table 26 (Chi Square=
32.080, p= < 0.001).
Table 26: Demographic characteristics of first-degree relatives with and without
IR
Variable Normal,
n=131
n (%)
IR, n=64
n (%)
T2DM,
n=80
n (%)
Sex Male 62 (41.6) 38 (59.4) 49 (61.3)
Female 69 (58.4) 26 (40.6) 31 (38.8)
Age groups 18-29 21 (16) 8 (12.5) 2 (2.5)
30-39 28 (21.3) 14 (21.9) 10 (12.5)
40-49 39 (29.7) 18 (28.1) 21 (26.3)
50-59 33 (25.2) 20 (31.3) 30 (37.5)
60-69 9 (6.9) 2 (3.1) 11 (13.8)
70+ 1 (0.8) 2 (3.1) 6 (7.5)
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Age mean
(SD)
46.2 (12.5) 46.3
(11.5)
51.4
(11.2)
Ethnicity Arab 73 (55.7) 25 (39.1) 36 (45)
Indian 38 (29) 33 (51.6) 35 (43.8)
South East Asia 15 (11.5) 3 (4.7) 7 (8.8)
Farsi 5 (3.8) 2 (3.1) 2 (2.5)
Other 0 (0) 1 (1.6) 0 (0)
Education No education 1 (0.8) 0 (0) 1 (1.3)
Primary 13 (9.9) 15 (23.4) 24 (30)
Secondary 58 (44.3) 33 (51.6) 44 (55)
Higher
education
59 (45) 16 (25) 11 (13.8)
Occupation Governmental 49 (37.4) 15 (23.4) 16 (20)
labourer 30 (22.9) 27 (42.2) 34 (42.5)
private 28 (21.4) 13 (20.3) 10 (12.5)
Not working 11 (8.4) 2 (3.1) 6 (7.5)
Retired 13 (9.9) 10.9) 14 (17.5)
Marital
status
With partner 106 (80.9) 54 (84.4) 69 (86.3)
Single 17 (13) 9 (14.1) 2 (2.5)
Widowed 3 (2.3) 0 (0) 1 (1.3)
Separated 5 (3.8) 1 (1.6) 8 (10)
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4.4 Objective 4: To establish the proportion of patients with T2DM who
achieve adequate glycaemic control and the risk factors for poor glycaemic
control.
Demographic characteristics of participants
We invited every 3rd T2DM patient attending the T2DM clinic for routine follow-
up and treatment management. Two hundred thirty-six subjects were
interviewed. Of these, 169 (71.6%) were male and 67 (28.4%) female. The mean
(SD) age of the participants was 51.6 (10.4) years with a range from 25 to 86
years, as shown in Table 27. Only 30 (12.7%) participants were < 40 years, 159
(67.4%) between 40 and 60 and 47 (19.9%) > 60 years old. One hundred and fifty-
three (64.8%) participants were of Indian background, 59 (25%) Arabs, 19 (8.1%)
from Southeast Asia, and 5 (2.1%) from other nationalities.
Fifty-three (22.5%) had higher degree education, 78 (33%) secondary education,
80 (33.9%) primary education and 25 (10.6%) were uneducated. Twenty-one
participants (8.9%) worked in the government sector, 27 (11.4%) in the private
sector, 150 (63.6%) were labourers, 29 (12.3%) retired, and 9 (3.8%) were not
working at the time of the interview. Most participants had a partner or were
married (219, 92.8%), 9 (3.8%) were single, 6 (2.5%) widowed, and 2 (0.9%)
separated.
122
Table 27: Demographic characteristics of participants
Demographic characteristics n=236
n (%)
Sex Male 169 (71.6)
Female 67 (28.4)
Age group 18-29 4 (1.7)
30-39 26 (11)
40-49 68 (28.8)
50-59 91 (38.5)
60-69 32 (13.6)
70+ 15 (6.3)
Age, Mean (SD) (years) 51.6 (10.4)
Ethnicity Arab 59 (25.0)
Indian 153 (64.8)
South East Asia 19 (8.1)
Other 5 (2.1)
Education No education 25 (10.6)
Primary 80 (33.9)
Secondary 78 (33.0)
Higher education 53 (22.5)
Occupation Government 21 (8.9)
Private 27 (11.4)
Labourer 150 (63.6)
Not working 9 (3.8)
Retired 29 (12.3)
Marital status With partner 219 (92.8)
Single 9 (3.8)
Widowed 6 (2.5)
Divorced/Separated 2 (0.9)
Hypertension Yes 152 (64.4)
No 84 (35.6)
High cholesterol Yes 162 (68.6)
No 74 (31.4)
Diabetic retinopathy Yes 16 (6.8)
No 220 (93.2)
Diabetic nephropathy Yes 12 (5.1)
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No 224 (94.9)
Cardiovascular disease Yes 17 (7.2)
No 219 (92.8)
Polycystic ovaries Yes 5 (7.5)
No 62 (92.5)
Gestational diabetes Yes 11 (16.4)
No 56 (83.6)
Smoker No 180 (76.3)
Ex-smoker 15 (6.3)
Yes 41 (17.4)
Years with diabetes Mean (SD) 8.9 (7.8)
Number of clinic
visits/year
Mean (SD) 5.7 (1.2)
Biochemical characteristics of study participants
The biochemical markers of participants are shown in Table 28. Seventy-one
(30.1%) of 236 participants had HbA1c ≤ 7% (considered good control), 103
(43.6%) HbA1c between 7% and 9% (called ‘moderate control’), and 62 (26.3%)
had HbA1c >9% and therefore had poor T2DM control. The HbA1c of participants
is shown in figure 21 and Table 34, the mean (SD) HbA1c was 8.1% (1.7) with a
range from 4.3% to 13.8%.
The mean (SD) LDL, HDL and TG were 2.57 (0.81), 1.04 (0.34) and 1.63 (0.83),
respectively. One hundred twelve (47.5%) of 236 participants had high LDL and
48 (20.3%) normal HDL levels, and 188 (79.7%) had low HDL as shown in Table 29.
Eighty-seven (36.9%) of 236 participants had high TG levels.
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Table 28: Biochemical characteristics of participants
Variables n = 236
n (%)
Mean (SD)
LDL mmol/l 2.57 (0.81)
≥ 2.6 112 (47.5)
< 2.6 124 (52.5)
HDL mmol/l 1.04 (0.34)
≥ 1.2 48 (20.3)
< 1.2 188 (79.7)
TG mmol/l 1.63 (0.83)
≥ 1.7 87 (36.9)
< 1.7 149 (63.1)
HbA1c [%] 8.1 (1.7)
≤ 7 71 (30.1)
7-9 103 (43.6)
≥9 62 (26.3)
Figure 21: Dispersion of HbA1c level among participants
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Demographic characteristics of participants by glycaemic status
The results show that only 71 (30.1%) participants had good glycaemic control,
103 (43%) with moderate control, and 62 (26.3%) with poor glycaemic control.
Forty-nine (29%) males had HbA1c ≤ 7%, 74 (43.8%) HbA1c between 7% and 9%
and 46 (27.2%) > 9%. Similarly, 22 (32.8%) females had HbA1c ≤ 7%, 29 (43.3%)
between 7% and 9%, and 16 (23.9) >9%. The proportion of males and females
with poor glycaemic control was similar (Chi-Square= 0.442, P=0.802).
Age was not apparently associated with HbA1c percentage levels, as shown in
figure 17. The mean ages (SD) of patients with good, moderate and poor
glycaemic control were 51.7 (10.2), 51.2 (9.6), and 52.1 (11.7) years, respectively
(Chi-Square= 8.778, P= 0.553).  However, T2DM participants aged 40-60 were
more likely to have good or moderate glycaemic control compared to younger
and older participants as shown in figure 23.
Figure 22: A scattered diagram showing the dispersion of HbA1c according to age
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Figure 23: A stacked histogram showing the prevalence of good, moderate and
poor glycaemic control in different age group
The country of origin was not associated with glycaemic control, as shown in
Table 29. Good glycaemic control was attained by 47 (30.7%) of 153 participants
from India, 15 (25.4%) 59 Arabs, 7 (36.8%) of 19 South East Asians and 2 (40%) of
5 participants from other countries. Conversely, poor control was attained in 41
(26.8%) Indians, 15 (25.4%) Arabs, 4 (21.1%) South East Asians and 2 (40%)
participants from other countries (Chi-Square= 2.695, p= 0.846)
Similarly, glycaemic control was not associated with occupation. Although
patients working in the private sector were less likely to have good glycaemic
control (3 (11.1%) of 27 participants), this association was not statistically
significant. Marital status was also not associated with any of the glycaemic
groups (Chi-Square= 0.118, P=0.943).
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Participants with poor glycaemic control were more likely to have retinopathy
and nephropathy, but this association was not significant at the time of the
interview (P=0.857 and P=0.718, respectively).
A medical history of CVD was associated with poor glycaemic control.  Among the
17 T2DM with a medical history of CVD, 3 (17.6%) had good, 5 (29.4%) moderate
and 9 (52.9%) poor control, while among the 219 participants with no history of
CVD, 68 (31.1%) had good, 98 (44.7%) moderate and 53 (24.2%) poor control
(Chi-Square= 6.752, P= 0.340). There was no significant association between
Polycystic Ovaries syndrome and glycaemic control status (Chi-square= 4.165, P=
0.125). Similarly, a medical history of gestational diabetes and the reported level
of physical activity were not associated with the glycaemic control status
(P=0.672 and P= 0.921, respectively).
Smoking was associated with poor glycaemic control. Seven (17.1%) smokers had
good, 17 (41.5%) moderate, and 17 (41.5%) poor glycaemic control, compared to
62 (34.4%), 79 (43.9%) and 39 (21.7%) of 180 non-smokers having good,
moderate and poor control (Chi-Square= 11.203, P= 0.024). Among the 15 ex-
smokers, 2 (13.3%) had good, 7 (46.7%) moderate and 6 (40%) poor control,
resembling the patter of smokers.
The duration of T2DM was significantly associated with the glycaemic control
status (Chi-Square= 12.067, P= 0.002). Among 90 participants with a history of
T2DM for more than ten years 17 (18.9%) had good control, 40 (44.4%)
moderate, and 33 (36.7%) poor control, while participants with less than 10 years
of T2DM, 54 (37%) participants had good, 63 (43.2%) moderate and 29 (19.9%)
poor glycaemic control.
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Table 29: Demographic characteristics of participants by glycaemic control status
Variable HbA1c
≤ 7%
n (%)
7 <
HbA1c
< 9%
n (%)
HbA1c
≥ 9%
n (%)
P
value
Sex Male 49
(29)
74
(43.8)
46
(27.2)
0.802
Female 22
(32.8)
29
(43.3)
16
(23.9)
Age groups 18-29 1
(25.0)
2
(25.0)
2
(50.0)
30-39 6
(23.1)
10
(38.5)
10
(38.5)
40-49 22
(32.4)
34
(50.0)
12
(17.6)
50-59 26
(28.6)
42
(46.2)
23
(25.3)
60-69 12
(37.5)
11
(34.4)
9
(28.1)
70+ 4
(26.7)
5
(33.3)
6
(40.0)
Age mean (SD) 51.7
(10.2)
51.2
(9.6)
52.1
(11.7)
0.553
Ethnicity Arab 15
(25.4)
29
(49.2)
15
(25.4)
Indian 47
(30.7)
65
(42.5)
41
(26.8)
South East
Asia
7
(36.8)
8
(42.1)
4
(21.1)
Other 2
(40.0)
1
(20.0)
2
(40.0)
Education No education 10
(40.0)
9
(36.0)
6
(24.0)
0.465
Primary 25
(31.3)
31
(38.7)
24
(30.0)
Secondary 19
(24.7)
36
(46.8)
22
(28.6)
Higher
education
17
(32.1)
27
(50.9)
9
(17.0)
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Occupation Governmental 7
(33.3)
8
(38.1)
6
(28.6)
0.943
Private 3
(11.1)
16
(59.3.)
8
(29.6)
Labourer 48
(32)
61
(40.7)
41
(27.3)
Not working 2
(22.2)
4
(44.4)
3
(33.3)
Retired 11
(37.9)
14
(48.3)
4
(13.8)
Marital status With partner 67
(30.6)
95
(43.4)
57
(26.0)
0.204
Single 1
(11.1)
4
(44.4)
4
(44.4)
Widowed 2
(33.3)
4
(66.7)
0 (0.0)
Separated 1
(50.0)
0 (0.0) 1
(50.0)
Hypertension Yes 45
(29.6)
66
(43.4)
41
(27.0)
0.943
No 26
(31.3)
37
(44.6)
21
(24.1)
High
cholesterol
Yes 46
(28.4)
71
(43.8)
45
(27.8)
0.625
No 25
(34.7)
32
(44.4)
15
(20.8)
Diabetic
retinopathy
Yes 4
(25.0)
7
(43.7)
5
(31.3)
0.857
No 67
(30.5)
96
(43.6)
57
(25.9)
Diabetic
nephropathy
Yes 4
(33.3)
6
(50.0)
2
(16.7)
0.718
No 67
(29.9)
97
(43.3)
60
(26.8)
Cardiovascular
disease
Yes 3
(17.6)
5
(29.4)
9
(52.9)
0.340
No 68
(31.1)
98
(44.7)
53
(24.2)
Polycystic
ovaries
Yes 1
(20.0)
4
(80.0)
0 (0.0) 0.125
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No 21
(34.4)
24
(39.3)
16
(26.2)
Gestational
diabetes
Yes 3
(27.3)
6
(54.5)
2
(18.2)
0.672
No 19
(34.5)
22
(40.0)
14
(25.5)
Physical
activity
< 150 min 49
(30.1)
70
(42.9)
44
(27)
0.921
≥ 150 min 22
(30.1)
33
(45.2)
18
(24.7)
Smoker No 62
(34.4)
79
(43.9)
39
(21.7)
0.024
Ex-smoker 2
(13.3)
7
(46.7)
6
(40.0)
Yes 7
(17.1)
17
(41.5)
17
(41.5)
Years with
diabetes
Mean (SD) 6.1
(6.4)
9.4
(7.4)
11.3
(8.9)
0.002
Number of
clinic
visits/year
Mean (SD) 5.7
(0.96)
5.8
(1.1)
5.4
(1.5)
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Biochemical characteristics by glycaemic control status
The biochemical markers of participants with good, moderate, and poor
glycaemic control are shown in Table 30. TG was higher in participants with
HbA1c ≥ 9 % (Chi-Square= 4.923, P= 0.085), with 20 (23%) participants with high
level of TG having good glycaemic control, 38 (43.7%) moderate control, and 29
(33.3%) participants with high TG levels having poor control, compared to 51
(34.2%) participants with normal TG having good control, 65 (43.6%) moderate
control, and 33 (22.1%) having poor control, Figure 24 shows the mean and 95%
CI TG concentrations of participants with good, moderate and poor glycaemic
control.
Plasma LDL and HDL levels were not associated with glycaemic control (P= 0.548
and P= 0.380, respectively).
Figure 24: Mean and 95% CI TG level among the three glycaemic control groups
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Figure 25: Mean and 95% CI of HbA1c in non-smoker, ex-smoker, and smoker
groups
Table 30: Biochemical characteristics of participants by glycaemic control status
Variables HbA1c ≤ 7%
n= 71
7 <
HbA1c
< 9%
n= 103
HbA1c ≥ 9%
n= 62
P
value
LDLmmol/l Mean
(SD)
2.58 (0.85) 2.59
(0.77)
2.51 (0.84)
≥ 2.6    n (%) 32 (28.6) 53 (47.3) 27 (24.1) 0.548
< 2.6    n (%) 39 (31.5) 50 (40.3) 35 (28.2)
HDL mmol/l Mean
(SD)
1.05 (0.29) 1.07
(0.37)
0.97 (0.33)
≥ 1.2    n (%) 17 (35.4) 22 (45.8) 9 (18.8) 0.380
<1.2     n (%) 54 (28.7) 81 (43.1) 53 (28.2)
TGmmol/l Mean
(SD)
1.48 (0.66) 1.64
(0.90)
1.80 (0.84)
≥ 1.7    n (%) 20 (23.0) 38 (43.7) 29 (33.3) 0.085
< 1.7    n (%) 51 (34.2) 65 (43.6) 33 (22.2)
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Anthropometric measurement of study participants by glycaemic control status
There was no association between WHR and T2DM control, and this association
was not significant in males (Chi-Square= 1.475, P=0.478) or females (Chi-Square=
1.863, P=0.394). The waist circumference was not related to HbA1c percentage
levels in males (Table 31). Likewise, in female participants, the association of the
waist circumference and the degree of glycaemic control was not significant (Chi-
Square= 0.718, P= 0.698). Even when the cut-off was raised to 102 cm in males
and 88 in females, no significant relation was detected.
The mean BMI of participants with good, moderate, and poor glycaemic control
were 27.4, 27.3, and 28.1, respectively, as shown in figure 26.  BMI was higher in
participants with poor glycaemic control. However, this association was not
statistically significant (Chi-Square= 10.039, P= 0.437).
Table 31: Anthropometric measurements for participants according to their
glycaemic status
HbA1c
≤ 7%
n= 71
7 < HbA1c <
9%
n= 103
HbA1c
≥ 9%
n= 62
P value
WHR
Male
< 0.90 2 (25.0) 5 (62.5) 1 (12.5)
≥ 0.90 47 (29.2) 69 (42.9) 45 (28) 0.478
Female
< 0.85 3 (60.0) 1 (20.0) 1 (20.0)
≥ 0.85 19 (30.6) 28 (45.2) 15
(24.2)
0.394
Waist (cm)
Male
< 94 19 (30.6) 27 (43.5) 16
(25.8)
≥ 94 30 (28.0) 47 (43.9) 30
(28.0)
0.895
< 102 31 (27) 52 (45.2) 32
(27.8)
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≥ 102 18 (33.3) 22 (40.7) 14
(25.9)
Female
< 80 2 (50.0) 1 (25.0) 1 (25.0)
≥ 80 20 (31.7) 28 (44.4) 15
(23.8)
0.698
< 88 3 (30.0) 4 (40.0) 3 (30.0)
≥ 88 19 (33.3) 25 (43.9) 13
(22.8)
BMI (kg/m2)
< 18.5 1 (100) 0 (0) 0 (0)
18.5-24.9 18 (25.4) 36 (50.7) 17
(23.9)
25-29.9 37 (33.6) 43 (39.1) 30
(27.3)
30-34.9 11 (30.6) 17 (47.2) 8 (22.2)
35-39.9 4 (30.8) 5 (38.5) 4 (30.8)
≥40 0 (0) 2 (40) 3 (60) 0.437
Figure 26: Mean and 95%CI of BMI in the three glycaemic control
groups
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Risk factors for poor glycaemic control – Univariate and multivariate analyses.
The variables associated with poor glycaemic control are shown in table 38.
These include the presence of high Triglyceride (OR 2.24, 95% CI 1.09-4.60);
smoking (OR 3.86, 95% CI 1.47-10.16), and the number of years lived with T2DM
(More than ten years) (OR 3.62, 95% CI 1.73-7.57), as shown in tables 32.
Table 32: Descriptive analysis and odds ratios comparing patients with good and
poor glycaemic control.
HbA1c ≤
7%
n=71 (%)
HbA1c ≥
9%
n=62 (%)
OR 95%CI P
value
Sex
Male 49 (51.6) 46 (48.4) 1.29 (0.60-2.76) 0.510
Female 22 (57.9) 16 (42.1) Ref
Age groups
18-29 1 (33.3) 2 (66.7) Ref
30-39 6 (37.5) 10 (62.5) 0.83 (0.06-
11.27)
0.891
40-49 22 (64.7) 12 (35.3) 0.27 (0.02-3.33) 0.309
50-59 26 (53.1) 23 (46.9) 0.44 (0.04-5.20) 0.517
60-69 12 (57.1) 9 (42.9) 0.38 (0.03-4.81) 0.451
70 + 4 (40.0) 6 (60.0) 0.75 (0.50-
11.31)
0.835
mean (SD)
years
51.7
(10.2)
52.1
(11.7)
Ethnicity
Arab 15 (50.0) 15 (50.0) Ref
Indian 47 (53.4) 41 (46.6) 0.87 (0.38-2.00) 0.747
South East
Asian
7 (63.6) 4 (36.4) 0.57 (0.14-2.37) 0.440
Others 2 (50.0) 2 (50.0) 1.00 (0.12-8.06) 1.000
Education
No education 10 (62.5) 6 (37.5) Ref
Primary 25 (51.0) 24 (49.0) 1.60 (0.50-5.09) 0.426
Secondary 19 (46.3) 22 (53.7) 1.93 (0.59-6.30) 0.276
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Higher
education
17 (65.4) 9 (34.6) 0.88 (0.24-3.22) 0.850
Occupation
Governmental 7 (53.8) 6 (46.2) Ref
Private 3 (27.3) 8 (72.7) 3.11 (0.56-
17.33)
0.195
Labourer 48 (53.9) 41 (46.1) 0.99 (0.31-3.20) 0.995
Not working 2 (40.0) 3 (60.0) 1.75 (0.22-
14.22)
0.601
Retired 11 (73.3) 4 (26.7) 0.42 (0.09-2.06) 0.288
Marital status
With partner 67 (41.4) 95 (58.6) Ref
Single 1 (20.0) 4 (80.0) 4.70 (0.51-
43.27)
0.172
Widowed 2 (33.3) 4 (66.7) ---- 0.999
Separated 1 (100) 0 (0) 1.18 (0.072-
19.22)
0.910
Hypertension
Yes 45 (52.3) 41 (47.7) 1.29 (0.64-2.59) 0.482
No 26 (55.3) 21 (44.7) Ref
Smoker
No 62 (61.4) 39 (38.6) Ref
Ex-smoker 2 (25) 6 (75) 4.77 (0.92-
24.83)
0.063
Yes 7 (29.2) 17 (70.8) 3.86 (1.47-
10.16)
0.007
LDLmmol/l
Mean (SD) 2.58
(0.85)
2.51
(0.84)
≥2.6 32 (54.2) 27 (45.8) 0.94 (0.47-1.87)
<2.6 39 (52.7) 35 (47.3) Ref 0.860
HDLmmol/l
Mean (SD) 1.05
(0.29)
0.97
(0.33)
≥1.2 17 (65.4) 9 (34.6) 0.54 (0.22-1.32) 0.175
<1.2 54 (50.5) 53 (49.5) Ref
TGmmol/l
Mean (SD) 1.48
(0.66)
1.80
(0.84)
≥1.7 20 (40.8) 29 (59.2) 2.24 (1.09-4.60) 0.028
<1.7 51 (60.7) 33 (39.3) Ref
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Physical activity
< 150 min 49 (52.7) 44 (47.3) Ref
≥ 150 min 22 (55) 18 (45) 0.91 (0.43-1.92) 0.806
Years with diabetes
< 10 54 (65.1) 29 (34.9) Ref
≥ 10 17 (34) 33 (66) 3.62 (1.73-7.57) 0.001
Multiple regression (Table 33) showed that smoking (AOR 4.13, 95% CI 1.47-
11.59), a high TG concentration (AOR 2.22, 1.01-4.91), and living with T2DM for
more than ten years (AOR 4.03, 95% CI 1.81-9.00) were independent risk factors
for poor glycaemic control.
Table 33: Adjusted odds ratios (good vs poor glycaemic control)
Adjusted OR (95%CI) P value
Smoker
No Ref
Ex-smoker 2.8 (0.49-16.42) 0.244
Yes 4.13 (1.47-11.59) 0.007
TG mmol/l
< 1.7 Ref
≥ 1.7 2.22 (1.01-4.91) 0.048
Years with diabetes
< 10 Ref
≥ 10 4.03 (1.81-9.00) 0.001
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Table 34: Anthropometric characteristics and odds ratios for participants with
good and poor glycaemic control
HbA1c ≤ 7%
n= 71
HbA1c ≥ 9%
n= 62
OR 95%CI P value
WHR
Male
< 0.90 2 (66.7) 1 (33.3) Ref
≥ 0.90 47 (51.1) 45 (48.9) 1.92 (0.17-21.86) 0.601
Female
< 0.85 3 (75) 1 (25) Ref
≥ 0.85 19 (55.9) 15 (44.1) 2.37 (0.22-25.14) 0.474
Waist (cm)
Male
< 94 19 (54.3) 16 (45.7) Ref
≥ 94 30 (50) 30 (50) 1.19 (0.52-2.74) 0.687
< 102 31 (49.2) 32 (50.8) Ref
≥ 102 18 (56.3) 14 (43.8) 0.75 (0.32-1.77) 0.517
Female
< 80 2 (66.7) 1 (33.3) Ref
≥ 80 20 (57.1) 15 (42.9) 1.50 (0.12-18.13) 0.750
< 88 3 (50) 3 (50) Ref
≥ 88 19 (59.4) 13 (40.6) 0.68 (0.12-3.93) 0.671
BMI (kg/m2)
< 25 19 (52.8) 17 (47.2) Ref
≥ 25 to < 30 37 (55.2) 30 (44.8) 0.91 (0.40-2.04) 0.812
30-34.9 11 (58) 8 (42) 0.813 (0.27-2.50) 0.717
≥ 35 4 (36) 7 (64) 1.96 (0.49-7.87) 0.345
The logistic regression analysis of anthropometric variables shows no significant
relation to the glycaemic control status of the study participants (Table 34).
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Nutritional behaviour of participants by glycaemic control status
The food habits of the participants were analysed using Mann-Whitney’s test using the same method described in objective 2 results.  Food
habits did not have significant associations with the glycaemic control status (Table 35).
Table 35: Median and IQR for participants with good and poor glycaemic control
Food habits HbA1c ≤ 7%
(n=71)
Median     IQR
HbA1c ≥ 9%
(n=62)
Median            IQR
Mann Whitney’s
Z p
Fruits & veg 5 3 5 3 -0.995 0.320
Fish 6 2 6 2 -0.138 0.890
Eggs 6 1 5.5 2.25 -0.508 0.611
Pastry 8 3 8 3 -1.258 0.208
Wholegrains 8 6 8 6 0.552 0.581
Rice 3 0 3 0 -0.575 0.565
full cream 3 6 3 4 -0.749 0.454
fast food 9 1 8 1 -1.119 0.263
Sweets 6 4 7 4 -1.502 .133
Meat 5 2 5 1 -0.759 0.448
sweetened drinks 9 2 9 3 -0.367 0.714
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4.5 Objective 5: Accuracy of a point-of-care device to measure HbA1c for
the monitoring of HbA1c among patients with T2DM and patients with
known haemoglobinopathies.
This was a cross-sectional study.  The participants were the same individuals
participating in objective 4 with a known diagnosis of T2DM.  The HbA1c
measurements of both a POC device (Quo-test, EKF DIAGNOSTICS) and the
Laboratory HbA1c (Tosoh HLC G8, TOSOH BIOSCIENCE) of 217 participants were
available. Tosoh HLC G8 was used as the reference standard to assess the
performance of Quo-test POC.
A further smaller group of participants (n=41) were recruited from the
haematology clinic of Amiri Hospital.  A reference centre for patients with known
haemoglobinopathies.  Most of the participants in this group were known to have
sickle cell anaemia. The comparison of the two tests used the same approach as
for the larger group.
Demographic characteristic of participants
One hundred sixty-two (73.3%) participants were male and 59 (26.7%) female.
Their mean age was 52, with only 3 (1.4%) being younger than 30 years old and
47 (21.4%) were > 60 years, as shown in Table 36.
Table 36: Demographic characteristics of participants with T2DM and no
haemoglobinopathies
n = 221
n (%)
Gender
Male 162 (73.3)
Female 59 (26.7)
Age group
18-29 3 (1.4)
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30-39 22 (10.0)
40-49 65 (29.4)
50-59 84 (38.0)
60-69 32 (14.5)
70+ 15 (6.9)
Mean (SD) years 52 (10.3)
In another group of participants with known abnormal haemoglobin, 19 (46.3%)
participants were male and 22 (53.7%) female. Their mean age was 35.7, with 34
(82.6%) being younger than 50 years old and 7 (17.4%) were > 50 years, as shown
in Table 37.
Table 37: Demographic characteristics of participants with abnormal haemoglobin
n = 41
n (%)
Gender
Male 19 (46.3)
Female 22 (53.7)
Age group
18-29 16 (39.0)
30-39 12 (29.3)
40-49 6 (14.6)
50-59 3 (7.3)
60-69 4 (9.8)
70+ 0 (0.0)
Mean (SD) years 35.7 (13.7)
The accuracy of the Quo-test in the diagnosis of the HbA1c status in individuals
with T2DM.
The data in Figure 27 shows a strong positive correlation between the results of the
POC device and the reference test results, the r squared = 0.935
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Figure 27: Quo-test POC/Tosoh Laboratory HbA1c results
The Bland-Altman plot (Figure 28) showed that the linear regression of the
difference and mean difference is - 0.063. This difference was not statistically
significant (p= 0.354). This means that the difference between the two diagnostic
measures is not significant and accordingly we cannot reject the null hypothesis.
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Figure 28: Bland-Altman plot
Table 38 describes the agreement between Quo-test and the Tosoh laboratory
results when using a cut-off of 9%. Fifty-nine (%) had an HbA1c above 9% and 158
and HbA1c <9% when assessed by the reference laboratory test.  Among the 59
participants with high HbA1c, 53 (89.8%) were classified as high by the Quo-test
POC and 6 (10.2%) as having HbA1c < 9%.  Among the 158 participants with HbA1c
below 9%, 5 (3.2%) were classified as having an HbA1c ≥ 9% and 153 (96.8%) < 9%
by the Quo-test POC device. Kappa test 0.871, P< 0.001 and prevalence and bias
adjusted Kappa (PABAK) = 0.899, corresponding to strong agreement.
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Table 38: Agreement between Quo-test POC HbA1c and Tosoh Laboratory HbA1c
(reference) when using an HbA1c cut-off of 9%.
Lab
HbA1c
Total
< 9% ≥ 9%
POC HbA1c
≥ 9% 5 (3.2%) 53
(89.8%)
58
< 9% 153
(96.8%)
6 (10.2%) 159
Total 158 59 217
Kappa = 0.871, p <
0.001
PABAK* = 0.899
*Po= (b+c)/total number = (53+153)/217, Prevalence and bias adjusted Kappa
(PABAK) = 2 Po– 1 = 0.899.
Table 39 shows the agreement of the Quo-test POC and the Tosoh laboratory
HbA1c results when the cut-off used is 7%.  Fifty-eight (%) participants had an
HbA1c <7 and 159 had values ≥ 7%.  Among the 159 participants with HbA1c ≥ 7%,
151 (95%) had an HbA1c ≥ 7% by the Quo-test POC and 8 (5%) HbA1c < 7%.  Among
the 58 participants with HbA1c <7, 4 (6.9%) had a Quo-test POC HbA1c ≥ 7% and 54
(93.1%) < 7%. Kappa test 0.862, P< 0.001 and the prevalence and bias adjusted
Kappa (PABAK) = 0.889.
Table 39: The agreement of POC HbA1c and Lab HbA1c (Kappa) when HbA1c cut-
off point is 7%
Lab HbA1c Total
< 7% ≥ 7%
POC HbA1c
≥ 7% 4 (6.9%) 151 (95%) 155
< 7% 54 (93.1%) 8 (5%) 62
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Total 58 159 217
Kappa = 0.862, p < 0.001
PABAK = 0.889
The Quo-test POC and the Tosoh reference test were only able to measure HbA1c
levels in only 21 out of 41 participants with abnormal haemoglobin. Both tests
failed to detect HbA1c levels in patients with HbF > 30%, which is likely due to the
HPLC and boronate HbA1c results not being able to provide results when HbF is >
10-15%.
Figure 29 shows the agreement of the two tests in the 16 participants with
results available.  There is a clear difference with the results obtained for
participants with normal haemoglobin, and individuals with abnormal
haemoglobin. There are noticeable differences between the two test results if
compared to different levels of HbF (figure 30).
Figure 29: POC/LAB agreement plot in people with abnormal haemoglobin
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Figure 30: HbA1c difference (Lab-POC) plot according to HbF level
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5: Discussion
Objectives 1 and 2
Diabetes mellitus is perhaps the most important non-communicable disease
epidemic to hit the globe in the present century, with major public health
implications and potential to increase the demand for health services. Kuwait and
other countries in the Middle East face an especially grave problem, because the
prevalence of T2DM is one of the highest in the world, despite these countries
having significant differences in their economic status (Alsairafi et al., 2016).
Approximately, 9.1% of adults in the EMRO region have T2DM, and 7.8% pre-
diabetes (PDM) in 2015 (IDF, 2015) and Kuwait has one of the world’s highest
prevalence (Abuyassin and Laher, 2016) with an estimated T2DM prevalence
among adults of 17.9% (Alarouj et al., 2013).
Prevalence of T2DM
The proportion of patients with T2DM in this study population was 29.6%.  This
percentage is much higher than the prevalence reported in national surveys, and
it is likely reflecting the study setting, and the population included. Participants
approaching a health care facility are usually less healthy than the general
population and elderly, which it is likely to increase the prevalence of T2DM. For
logistical reasons, it was not feasible to conduct a population survey for this
study, as samples needed to be centrifuged and frozen within 2 hours of blood
collection, and the time and resources available were limited. Despite this
selection bias, our results are similar to those observed among patients attending
primary care clinics in Saudi Arabia (Alqurashi et al., 2011).  This cross-sectional
study in Saudi Arabia reported a prevalence of T2DM of 30% among adults
attending outpatient ambulatory clinics. In our study, 44 (10.9%) of 402
participants were new cases of T2DM who were unaware of their condition.  This
result is comparable to those reported by a cross-sectional study in a primary
health care centre of the UAE (Saadi et al., 2010), where 14.6% of participants
had been unaware of having T2DM. These results show the importance of
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screening campaigns, and especially those targeting high-risk groups and
individuals attending general ambulatory health services.
Our findings, therefore, identify T2DM as one of the leading causes of morbidity
among adult populations attending health services in Kuwait.  Although this high
prevalence is often missed by routine health services, these metabolic changes
are likely to result in a higher prevalence of the complications of T2DM and
increased utilisation of services in the future.
Risk factors for T2DM
The so-called ‘classical’ risk factors continue to be the main factors associated
with T2DM. The prevalence of obesity and hypertension and the processes of
urbanisation and immigration have increased significantly during the past five
decades in Kuwait.  Furthermore, a sedentary lifestyle and weight gain are linked
to the increasing prevalence of T2DM worldwide.  All of these factors are likely to
be significant contributors to the growing prevalence of T2DM in Kuwait (Serour
et al., 2007, Al-Rasheedi, 2015).
Studies have shown that T2DM can be prevented by lifestyle changes that include
a reduced caloric intake and increased physical activity and increased physical
activity (Psaltopoulou et al., 2010). Programmes addressing sedentary and poor
feeding lifestyles have been effective in reducing the progression of T2DM in
individuals at high risk (Saaristo et al., 2010, Rautio et al., 2012), although the
main limitation of these interventions is the lack of long-term adherence of
participants (García-Pérez et al., 2013). The increasing prevalence of T2DM in
Kuwait along with the higher complication and mortality rate of these patients
requires an urgent assessment of how to address the risk factors that predispose
individuals in Kuwait to T2DM to developed tailored interventions that are
suitable for Kuwait’s cultural background and climate. There is also an urgent
need for healthcare providers to identify and treat modifiable risk factors, health
organisations should develop and maintain programmes that focus on T2DM
prevention.
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T2DM is a multisystem disease. Hence, a good strategy requires the attention of
other comorbidities (Munshi et al., 2016).  This thesis highlights that obesity,
hypertension, dyslipidaemia, and other factors are commonly associated with
T2DM. In our study, the characteristics related to T2DM were hyperlipidaemia
(high triglyceride) and hyper-lipoproteinemia (high LDL levels). These results
resemble the results observed elsewhere in the world. For example, in an Indian
study, the lipid profile of 150 patients with T2DM showed that hyperlipidaemia is
significantly associated with an elevation in postprandial blood sugar (Dixit et al.,
2014). Hyperlipidaemia is more frequent in patients with T2DM and is a primary
contributor to the high-risk to cardiovascular disease. Epidemiologic studies have
demonstrated that high concentrations of LDL and triglyceride, and low levels of
HDL are major risk factors for CVD in patients with T2DM and are frequent
comorbidities of T2DM (Leon and Maddox, 2015). Hypercholesterolemia is a well-
recognised risk factor for atherosclerotic diseases, especially among individuals
with T2DM (Stamler et al., 1993).
T2DM was once considered a disease of elderly populations.  However the age at
diagnosis of T2DM is decreasing, and it is now increasingly diagnosed in young
adults to the extent that early onset may soon become the predominant form of
the disease (Yu et al., 2016).
Our study showed that among the clinic population studies, there is an increase
in the prevalence of T2DM with age, and all participants > 80 years old had
T2DM.  However, the burden of T2DM was also high among young adults, as a
significant proportion of individuals in their 20s and 30s already had T2DM. Our
study that T2DM in the age group of 18 to 29 was already detectable and this
prevalence increased steadily after that.  At the age of 60-69, the study
population was 5.4 more likely to have T2DM, and this odd rose to 9.5 by 70
years of age.
In Kuwait, T2DM seems to start early, and public health programmes should
promote effective lifestyle modifications including weight loss, implementation of
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a healthy diet like the Mediterranean diet, together with an increase in the
physical activity from an early age (Asif, 2014).
Impaired insulin production and its physiological effectiveness in elderly
individuals versus young adults have also been reported (Du et al., 2014). Possible
explanations for the reduced insulin effectiveness with ageing include hormonal
changes, decreased physical activities, increased abdominal fat mass and
mitochondrial dysfunction (Kalyani and Egan, 2013). Moreover, ageing is
associated with chronic inflammatory cascades leading to endoplasmic reticulum
stress leading to islet cell dysfunction contributing to decreasing insulin
production and abnormal glucose metabolism (Park et al., 2014).
After adjusting for age, and ethnicity, our study showed that widowers were 6.1
times more likely to have T2DM than single individuals. Although age confounded
this, the loss of a spouse has been associated with depressive symptoms, less
physical activities, lower interest in health, increased risk of solitude and isolation
from the community (Stroebe et al., 2007). Some studies have reported a higher
prevalence of T2DM among widowed individuals compared to married individuals
of comparable age (Cornelis et al., 2014). In 379 non-institutionalized men and
women aged >70 years, T2DM was less prevalent among married participants
compared to those widowed (Hiltunen, 2005).  These finding can be linked to the
fact that marriage provides a more stable environment, reduces loneliness and
stress, and is linked to better health habits (Espinosa and Evans, 2008).
Our study shows that hypertension is also significantly associated with T2DM
(OR= 1.95). T2DM and hypertension are two of the leading risk factors for
atherosclerosis and its complications, including strokes and heart attacks. The
Hong Kong Cardiovascular Risk Factor Prevalence Study showed that only 56% of
people with hypertension are normoglycemic and only 42% of individuals with
T2DM have normal blood pressure (Cheung, 2010). In the US, 30% of patients
with T2DM have hypertension, and this prevalence is increased to between 50%
and 80% of patients with T2DM (Landsberg and Molitch, 2004). A prospective US
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cohort reported that T2DM was almost two times as likely to develop in subjects
with hypertension as in subjects with normal blood pressure (Sampanis and
Zamboulis, 2008). The link between these conditions is believed to be Insulin
resistance. In the insulin-resistant state, there is inhibition of several insulin
signalling pathways, thus contributing to vasoconstriction. Insulin inhibits the
release of glucose from the liver, which in turn inhibits the release of the free
fatty acids (FFAs) from adipose tissue. FFAs are believed to induce IR and increase
the level of oxidative stress resulting in endothelial dysfunction and arterial
intima and leading to hypertension (Cheung and Li, 2012). Intervention for the
early detection of T2DM, therefore, should also screen for high blood pressure,
and in turn, interventions for the detection of hypertension should check all
patients with hypertension for T2DM.
Several indexes such as Waist Circumference, BMI, and WHR, are used to
determine general and central obesity in clinical practice. Whereas BMI is the
most commonly used parameter for evaluation of obesity, it is not the best
measure to identify the body composition as well as regional body fat distribution
because it is a marker of general obesity rather than central obesity (Rahman and
Berenson, 2010).
The diagnosis of central (abdominal) obesity which correlates with the visceral
accumulation of adipose tissue including fatty liver, and the development of
subsequent metabolic abnormalities and cardiovascular morbidity is more
important than BMI, especially for T2DM (Elbassuoni, 2013). Visceral fats are
linked with lipolytic activity and reduce insulin activity through increasing fatty
acids. Moreover, visceral fat accumulates macrophages that release
inflammatory cytokines, which can impair insulin sensitivity, moreover, visceral
fat is known to secretes adipokines that impair insulin sensitivity (Hardy et al.,
2012).
Our study showed that males with a waist circumference ≥ 94 cm are 5.5 times
more likely to have IR than participants with waist circumference < 94 cm and
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males with waist circumference ≥ 102 cm are 5.4 times more likely to have IR
than those with waist circumference < 102 cm. While females with waist
circumference ≥ 88 cm were 6.4 times more likely to have IR than females with
waist circumference < 88 cm.
Obesity is linked to many medical conditions, the most devastating of which may
be T2DM. However, many obese individuals, despite being insulin resistant, do
not develop T2DM. In these cases, it is likely that the pancreatic β cells of the islet
of Langerhans are able to compensate the IR by releasing higher amounts of
insulin to maintain normal glucose tolerance. As explained before, increased
levels FFAs is the main factor causing IR, and eventually T2DM.
Physical activity improves glycaemic control and reduces the risk of CVD and
mortality in patients with T2DM. Walking was the most common form of daily
physical activity, with numerous studies demonstrating its beneficial effects on
reducing the risk of T2DM. Furthermore, it improves glycaemic control, insulin
sensitivity, and the incidence of obesity. Walking for at least 30 min per day five
days a week was reduces the risk of T2DM by approximately 58% (Colberg et al.,
2010, Hamasaki, 2016). Only 28.3% of T2DM had good physical activity (> 150
min/week), this is considered very low compared to 61.5% of European adults
achieving the WHO physical activity recommendation (Marques et al., 2015).
Although ensuring that patients with T2DM participate in daily physical activity
may be difficult, well-designed longitudinal studies that focus on daily physical
activity in Kuwait should be conducted in the future.
Prevalence of IR
IR is very often a precursor of T2DM (Wilcox, 2005) and the most powerful
predictor of the future development of T2DM.  In addition to a high prevalence of
T2DM, our study also found a high prevalence of IR.
IR prevalence is widely variable across geographical settings.  European countries
seem to have a lower prevalence of IR and, for example, it is estimated that 17%
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of the Danish population had IR (Friedrich et al., 2012). In contrast, it has been
reported that 39.1% of Americans of Hispanic descent have this condition (Qu et
al., 2011). In the Middle East, an Iranian population study reported that the
prevalence of IR was also high with 51% of participants having IR (Bermudez et
al., 2016).
The proportion of participants with IR in our study population was 34.6%, and
therefore the prevalence of IR was relatively high. This high prevalence is not
unexpected, given the increasing prevalence of obesity and the increased
consumption of fast foods and inactive living styles of the modern Kuwait
population (Karageorgi et al., 2013).
IR was more prevalent early in life in males than females in our study. This can be
explained by the results of an American study (Karakelides et al., 2010) which
reported that insulin sensitivity was higher in young women. Males usually have
more hepatic and visceral fat, whereas females have more subcutaneous or
peripheral fat. These differences, as well as differences in sex hormones, may
contribute to a higher IR in males than females (Geer and Shen, 2009).
IR is a contributor to the development of impaired glucose tolerance and T2DM.
Several studies have suggested that IR exists before hyperglycaemia in nearly all
T2DM patients and that hyperinsulinemia occurs before the presence of
pathological abnormalities of IGT (Imamura et al., 2013, DeFronzo and Tripathy,
2009). Hyperinsulinemia and IR are harmful even in euglycemic subjects. For
example, a fasting plasma insulin level of 39 µU/mL or greater is associated with a
31% increased risk of cardiovascular events in individuals without T2DM (Rubins
et al., 2002).  Similarly, in the Paris Prospective Study, people with no T2DM who
had hyperinsulinemia were much more likely to experience atherosclerosis
(Fontbonne and Eschwège, 1991). Similar to the association between
hypertension and T2DM, IR is also observed in as many as 50% of individuals with
high blood pressure. The oxidative stress-associated inflammation and
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endothelial dysfunction of IR are both linked to an elevation of blood pressure
and vascular dysfunction (Zhou et al., 2014).
These side effects might also be mediated by hypertriglyceridemia (Murguía-
Romero et al., 2013) and because Insulin inhibits the hormone-sensitive lipase in
the adipose tissue resulting in unrestrained lipolysis leading to an increased flux
of fatty acids to the liver, which results in higher hepatic triglyceride production
(Vergès, 2015).
Our study showed that the prevalence of PDM in the study population was
17.4%, a high percentage for most settings but comparable to the prevalence
observed in neighbouring countries (Klautzer et al., 2014).  A similar result was
reported in a cross-sectional study in a primary health clinic in Saudi Arabia
where the prevalence in adults was 17.6% (Turki et al., 2016). As for T2DM, the
prevalence of PDM varies geographically. The WHO North America and Caribbean
Region has a high prevalence of impaired glucose tolerance (15.0%), while the
WHO European Region has a lower prevalence of 4.8%. The estimated global
prevalence of PDM is 6.7% (IDF, 2015).
Prevalence of metabolic syndrome
The global prevalence of MS differs depending on sociodemographic factors, as
well as the diagnostic criteria used. European MS prevalence has been estimated
as 41% in men and 38% in women using IDF diagnostic criteria (McCracken et al.,
2018). Our study showed a prevalence of 26.4% in males, and 44.6% in females.
A previous study in Kuwait showed a prevalence of 41.7% in males and 40.1% in
males according to IDF criteria (Al Zenki et al., 2012).
IR and PDM risk factors
Insulin sensitivity is also determined by a critical factor, which is body fat
distribution and is therefore associated with body mass (Patel and Abate, 2013,
Kranendonk et al., 2015). Insulin sensitivity differs substantially even in
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individuals with normal weight because of their differences in body fat
distribution. Individuals whose fat distribution is more central have more IR than
individuals whose fat distribution is peripheral (Al-Goblan et al., 2014, Hayashi et
al., 2008).
Our results showed that 32.9% of the participants were obese. This figure is very
high and is greater than in other cities.  For example, 29.5% of clinic attendees in
north-east European cities, 21.9% in northern Mediterranean cities, and 20.1% in
north-west European cities were obese (Han et al., 2017).
Our study also found that IR was significantly associated with the presence of low
HDL concentrations (OR= 1.96, 95% CI 1.12-3.42). Low levels of HDL have been
associated with impaired insulin action. In population-based studies, measures of
insulin action correlate negatively with HDL (D’Agostino et al., 2004). The
presence of IR results in enhanced cholesterol esters transfers from HDL to
triglyceride-rich lipoproteins and in reciprocal triglyceride transfer, producing
triglyceride-enriched HDL. The delayed clearance of triglyceride-rich lipoproteins
leads to reduced HDL concentrations (Vergès, 2015). It appears that hepatic IR
reduces HDL by either decreasing HDL production or promoting a shift of HDL to
non-HDL lipoproteins (Perry et al., 2014).
Moreover, our study showed that overweight participants were 8.3 times more
likely to have IR. Participants with obesity class I were 18.3 times more likely to
have IR, and participants with obesity class II were 88 times more liable to have IR
than individuals with normal weight.
Unexpectedly, while IR was significantly associated with BMI, T2DM was not.
These results echo the results of a recent cohort study in Japan, involving 3,083
adult participants over four years, which reported that a high BMI was associated
with IR and that most participants with high BMI who developed T2DM had IR,
but that participants with normal BMI who develop T2DM mainly through β cell
dysfunction (Tatsumi et al., 2015). However, this is unlikely to be the main reason
for the lack of association between BMI and IR.  A major limitation of our study is
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its cross-sectional design.  It is likely that we missed this early stage as a high
proportion of participants already had T2DM, and most of these individuals had
experienced a phase of IR in the years before the study.  A further explanation of
the lack of association of BMI and T2DM was the poor glucose control in many
cases. Individuals with poor glycaemic control often lose body mass and may
become cachectic due to their metabolic derangement.  Our study, therefore,
needs to be followed by prospective cohort studies to test whether this lack of
association is true, or an artefact of the study design used here.
Although the diet assessment in this study had many limitations, participants
consuming sugar-sweetened drinks were more likely to have IR. Data from the
Study on Nutrition and Cardiovascular Risk in Spain involving 7842 participants
revealed that drinking sugar-sweetened beverages is positively related to IR.
However, although the consumption of sweeteners has been shown to modify
glucose metabolism, individuals with IR may have modified their behaviours
because of their obesity and the causal association between these two factors is
debatable.
Although this study component has identified some significant results, there are
significant limitations to our data that require discussion to contextualise the
findings.
Firstly, the study to identify risk factors used a case-control design. Case-control
studies are analytical, descriptive studies, which are efficient to identify the
characteristics of the participants with a higher or lower frequency among cases
than controls.  Although these studies are efficient to identify multiple risk
factors, and to examine their likely statistical interactions, they are unable to
establish causality.  The risk factors identified in this thesis, therefore, may be
markers of the disease, which may not be necessarily in the causal pathway (or
the “cause”) of IR or T2DM.  Our findings therefore merely indicate that their
presence was statistically more (or less) frequent among the cases than the
controls.
157
A further limitation of the study design was the systematic sampling.  This
method selects individuals by identifying every (Xth) number of patients attending
a clinic or study setting.  Although this sampling method has the advantage of
being easy to implement than a random selection, it is also more prone to
selection bias.  For example, in a busy clinic, it is likely that waiting patients are
not in a queue, that healthier individuals may be sent to the back of the queue,
prioritising some population groups (e.g. elderly or very young patients and those
who are frail or may have contagious illnesses). The enumerator may also
subjectively recruit patients whom he/she knows are more likely to accept to
participate.  These potential biases, therefore, may have resulted in selection bias
and increased or decreased the prevalence of the diseases we were investigating.
The study was also based in a health centre, and cases and controls were selected
among patients attending the clinic.  Controls are defined as individuals without
the outcome of interest (in this case DM or IR), and these are usually selected
among individuals from the same reference population. It is often a difficult
decision whether to select cases from the same clinical setting as the cases or in
another setting (e.g. in the community).  In our study, we decided we would
define cases at the time of the statistical analysis (by conducting several tests and
identifying those who fulfilled the case definition). Controls, therefore, were
patients attending the clinic and therefore had multiple reasons for attending the
clinic (follow up appointments, chronic conditions). These types of controls have
been shown to have poorer health than the general population (e.g. more likely
to be smokers and to have poorer lifestyles) which would mask differences
between cases and a healthy (general population) and thus result in
ascertainment bias.
We recruited 402 participants from whom we obtained most information.
However, only 173 participants agreed to be measured to obtain their
anthropometric measures. This was expected given the cultural context and the
norm in this population. However, the lack of anthropometric data for more than
half of the population, and in particular for women reduces the power of the
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study to examine the association of IR, PDM and T2DM with overweight and
obesity.
The smaller sample size would increase in an increased risk of type I and II errors,
which means the incorrect rejection of a true null hypothesis (a "false positive"
finding), or incorrectly retaining a false null hypothesis (a "false negative"
finding), respectively.  Therefore, some of the associations reported as statistical
significant may be spurious, and some other potential associations may have
been missed due to the small sample size of the sub-set. Furthermore, the
likelihood of participation is also likely to be associated with the awareness and
perception of the diseases, potential fear of stigmatisation, resulting in further
selection bias.
Another limitation was the limited information obtained by the physical activity
and dietary questionnaire.  The questions only included self-reported data and
were conducted in the outpatient clinics.  It is thus likely the data contains
substantial recall bias, as there might be significant recalling difficulties
remembering a 7-day diet, participants may try to exaggerate their physical
activities exclude harmful nutritional habits and minimise portions to please or
impress the interviewer.
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Objective 3
Prevalence of IR in first-degree relatives of T2DM patients
As indicated in previous sections, in IR, skeletal muscles and liver tissues do not
respond properly to insulin and consequently cannot easily absorb glucose from
the bloodstream. Thus, the body needs higher levels of insulin to help glucose
enter the cells. The β cells in the islets of Langerhans try to keep up with this
increased demand for insulin by producing more. As long as the β cells can
produce enough insulin to overcome the insulin resistance, blood glucose levels
stay in the normal range.  Over time, IR can lead to PDM and T2DM due to
exhaustion of the β cells and their inability to keep pace with the body's
increased need for insulin (Cerf, 2013).
Several studies outside Kuwait have reported that first-degree relatives of
individuals with T2DM are more likely to have impaired mitochondrial function,
with mitochondrial adenosine triphosphate (ATP) synthesis being reduced by
approximately 30%. These reductions in mitochondrial function are associated
with severe muscle IR (Petersen and Shulman, 2006). Our findings demonstrate
that in this population with a high level of T2DM, the prevalence of IR in first-
degree relatives of T2DM was also very high, reaching 32.8%. A similar high
prevalence was observed in India, a country that also has a high prevalence of
T2DM, were 37.8% of first-degree relatives of individuals with T2DM had IR
(Kumar et al., 2005). Although this is alarmingly high, both IR and T2DM need to
be considered together as Our study showed that the prevalence of PDM in first-
degree relatives of individuals with T2DM was 20.4%, a recent Chinese study
recruiting 1544 first-degree relatives of T2DM showed 27.4% had PDM (Zheng et
al., 2016).
Our study also indicates that 29.1% of participants had an undiagnosed problem
of T2DM. Our study also shows that the prevalence of PDM in first-degree
relatives was 20.4%. Although IR and pre-T2DM overlap considerably, this means
that 61.9% of first degree relatives had either IR/PDM or T2DM.  Although some
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of these relatives may have been aware of their diagnosis and were in denial,
they were not receiving medications and were likely poorly controlled.
A recent Chinese study recruiting 1544 first-degree relatives of T2DM showed
that 27.4% had PDM (Zheng et al., 2016). Furthermore, a further Chinese study,
recruiting 2306 adults reported a prevalence of T2DM of 26.6% in first degree
relatives (Hong Ma et al., 2011), and a further Chinese study showed a
prevalence of undiagnosed T2DM of 30% (Zheng et al., 2016) and therefore our
findings are unusual but similar to studies reported in other locations with high
prevalence of T2DM.
Risk factors for IR and T2DM in first-degree relatives of T2DM
The vast majority of participants labelled as labourers (or manual workers) were
professional drivers or housemaids.  Our study showed that individuals in this
category had a higher prevalence of IR (OR=3.6).  Studies in other countries have
reported that both professions are linked with a high risk of T2DM. A cross-
sectional study in Iran recruiting 1903 professional drivers showed that 43% of
them had preT2DM and 9.1 % had T2DM (Izadi et al., 2013). A cross-sectional
study in the UAE of 599 migrant women reported that 18.6% of housemaids had
PDM (Shah et al., 2017) and thus our findings are in agreement with these
studies.
Our findings show that T2DM increased significantly with age among first-degree
relatives is not surprising. Participants aged 60-69 had an AOR of 8.4 for having
T2DM; this ratio rose to 13.5 in participants > 70 years old. These results are
consistent with the literature worldwide.  In the Middle East, an Iranian study
reported a significant relationship between age and T2DM in individuals first
degree related to T2DM patients (Adibi et al., 2007).
In conclusion, this study highlights the increasing prevalence of IR and T2DM in
first degree relatives of patients with a history of T2DM, and it is imperative to
screen for T2DM and IR all first-degree relatives of patients with T2DM.
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Moreover,  there is a high risk of T2Dm and IR among labourers (especially drivers
and housemaids), specific interventions could be targeted to these high-risk
groups to intervene and modify their lifestyles and risk profile.
This study component also has several limitations that are similar to those
discussed in chapters 1 and 2. In addition, although the euglycemic clamp
method is considered the gold standard method for assessing IR; however,
because this is an invasive and labour-intensive method, and we used the
HOMA2-IR as a simple, minimally invasive method that has been demonstrated
as a useful tool for epidemiological studies. However, there is no data on the
performance of the HOMA-IR in Kuwait. Furthermore, although we tried to
select a representative sample of first degree relatives, it is possible that
individuals who felt unwell or whose relatives had more severe T2DM were more
likely to participate, resulting in selection bias. Furthermore,  we had to ask
individuals with T2DM attending the clinic to ask their relatives to come and
participate in the study. This may have led to the selection of a member of the
family suspected to have T2DM to take part in the study.
On the other side, our study has a strong point. Studies using insulin levels and
Homa2-IR calculations are costly and uncommon in the literature outside
industrialised settings.  Our study is the first in Kuwait to identify the prevalence
IR using Homa2-IR in a general clinic population.
162
Objective 4
T2DM is a complex disease with many complications and comorbidities. T2DM is
a metabolic disease that concerns not just the control or treatment of high blood
sugar levels but also lifestyle changes and lifelong care regarding self-
management and medical care. The aim of proper T2DM management is
managing hyperglycaemia, prevention and treatment of acute and chronic micro
and macrovascular complications and addressing comorbid diseases such as
hypertension and dyslipidemias. Ideally, glucose homeostasis should frequently
be monitored, but this is often difficult in settings where the population is less
aware of the importance of glucose control and not used for intensive
monitoring. A patient's glycaemic control over the preceding 8 to 12 weeks can
also be measured by the regular measurement of HbA1c in patients with normal
haemoglobin levels.  The frequency of this monitoring depends on the clinician’s
decision, and local treatment guidelines and a HbA1c target level of < 7.0 % is
desirable (Araki et al., 2017).
The care of an individual with T2DM requires many aspects of the disease to be
managed by a team of professionals so that a decrease in morbidity and mortality
may be achieved. T2DM care has moved from hyperglycaemia and dyslipidemias-
focused management to a wider plan. All people with T2DM should, if possible,
undergo a comprehensive T2DM evaluation at initial presentation.
The lipids measured should include LDL, HDL, and triglyceride.
In individuals with T2DM, levels of HDL, LDL and triglyceride should be measured
at the time of initial diagnosis, and screening is recommended annually. Testing
may be done every two years if patients have low risk values (LDL < 2.6 mmol/l,
HDL > 1.2 mg/dl and triglyceride < 1.7 mg/dl) (Rana et al., 2015).
Prevalence of good glycaemic control
The prevalence of good glycaemic control (defined as an HbA1c <7.0) in our study
population was 30.1%.  Although this may seem remarkably low, this result is
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similar to studies in other settings. An Iranian study of 500 patients with T2DM
revealed that only 29.4% had good glycaemic control (Yousefzadeh et al., 2015).
However, these results are much lower than those found in the developed world.
A study in Germany investigating changes in T2DM care indicators over the
period 2008-2011 reported that 65.4% achieved good glycaemic control (Du et
al., 2015).
Our findings, therefore, indicate that the degree of glucose control among
patients with T2DM in a clinic population in Kuwait was poor and clinical services
need to implement interventions to improve its management.
A major limitation of this finding is that the questionnaire did not include some
key variables that could explain in more detail the reasons for poor control
among the patients. This was due to ‘poor control’ being defined retrospectively,
and we did not follow these patients with further interviews to gain more detail
insights of the reasons for the poor control.  The findings of this chapter,
therefore, need to be interpreted with caution and should be complemented by
further qualitative studies to develop case studies, in-depth interviews of
individuals with poor control and clinical staff etc.
Participants were also selected at the time they decided to attend the clinic and
thus it is likely some of them had come to the service because they perceived
their T2DM was poorly controlled.  If this were the case and patients with poor
control attended the clinic less frequently, our findings would overrepresent the
proportion of all T2DM registered in the clinic with poor control.
Risk factors for poor glycaemic control
Our study demonstrated that triglyceride is related to poor glycaemic control
(OR=2.2). The mean triglyceride (SD) in participants with HbA1c ≤ 7.0 was 1.48
(0.66) mmol/l while the mean triglyceride (SD) in participants with HbA1c ≥ 7.0
was 1.80 (0.84) mmol/l.  Among participants with HbA1c ≤ 7.0, 28.2% had
triglyceride ≥ 1.7 mmol/l compared to 46.8% of participants with HbA1c ≥ 7.0.
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These findings coincide with the results of an Ethiopian cohort study of 165
individuals with T2DM which reported a significant relationship between high
triglyceride and poor glycaemic control (Mullugeta et al., 2012).
Smoking was significantly related to poor glycaemic control (OR=4.1), cigarette
smoking is known to be associated with increased prevalence of T2DM (Chang,
2012). Men smoking ≥ two packs per day at baseline had 45% increase in T2DM
prevalence than non-smokers individuals, and a 74 % increase in women
compared to women who never smoked (Bolego et al., 2002). The effect of
stopping smoking is dependent on age, the amount of tobacco use and weight
changes after quitting smoking (Stein et al., 2014).
Our study showed that participants with T2DM for more than ten years were four
times more likely to have poor glycaemic control than participants with and
illness < ten years’ duration. Similar results were reported in Sudan, where a
significantly high proportion of poor glycaemic control was observed in patients
with T2DM for more than two decades (OR=4) (Kamuhabwa and Charles, 2014).
Furthermore, a Jordanian study showed that patients who had the disease for
more than seven years were two times more likely to have poor glycaemic
control (Khattab et al., 2010).
In conclusion, a high proportion of patients with T2DM attending Nuzha clinic had
poor glycaemic control.  Patients may benefit from better education and
awareness of the disease and its complications and more frequent annual lipid
profile testing, annual retinography, annual T2DM education sessions, referral to
a dietitian, and physical education.
There are limitations to this study of risk factors associated with the cross-
sectional model, which may interfere with causal evaluations; however, there
was sufficient information to observe associations and ORs for the data.
Self-reported data usually are difficult to be independently verified. We had to
take what participants say. Self-reported data can contain several potential
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sources of bias. As explained in previous sections for patients attending the
clinics, our questionnaire included questions about the nutritional habits and
physical activities and those limitations also apply here.
166
Objective 5
The ADA considers glycaemic control as one of the important strategies for the
management of T2DM, and HbA1c is the best measure of glycaemic levels over
the previous 12 weeks. Lowering HbA1c to ≤ 7.0% has been shown to reduce
macro and microvascular complications of T2DM if implemented soon after the
diagnosis. The ADA recommends a goal of HbA1c < 7.0% for people with T2DM
(ADA, 2016).
Despite the guidelines being available and the robustness of evidence about
microvascular and macrovascular complications due to hyperglycaemia, the
clinical goals for T2DM control are not usually achieved. In almost all T2DM
clinics, only a fraction of individuals with T2DM achieve the therapeutic targets.
Typically, individuals with T2DM are monitored for HbA1c every three to six
months (CADTH, 2014). This generally requires a visit to the laboratory, involving
a nurse or phlebotomist for venepuncture, with a follow-up appointment two
weeks later in the clinic to discuss the results with the treating physician once
they are available from the laboratory.
As this is time-consuming, the need for employing HbA1c POC tests for T2DM
monitoring is increasing.  POC tests for HbA1c are more practical for the patients,
the HbA1c level can be checked immediately, and the relevant prescription
changes and modifications in management can be made in one visit.
Furthermore, enabling immediate treatment decisions may result in better
diabetic control, improved outcomes, fewer patient visits to the clinic, and
reduction of costs.
Several studies have shown that immediate feedback of results to patients, has a
significant association with reductions in HbA1c levels (Plüddemann et al., 2011).
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Performance of the Quo-Test against the gold standard test
We, therefore, evaluated the Quo-test POC device against the local HbA1c
reference standard, a Tosoh G8 assay.  The device was tested using two cutoffs
(7.0% and 9.0%) as these are commonly used to determine glycaemic control
status.
When the HbA1c cut-off is was 9%, the agreement was excellent, with a Kappa
agreement test of 0.871 and adjusted Kappa (PABAK) = 0.899. Similar results
were observed when using the HbA1c cut-off of 7.0%, as the agreement was
excellent, the Kappa test was 0.862, and the adjusted Kappa (PABAK) was 0.889.
To our knowledge, no one has conducted a similar study in Kuwait.
The linear correlation showed a very high positive association between the
results of the POC device and the reference test results, with an r2 = 0.935. A
systematic review of five observational studies of devices approved by the ADA
including the Bayer's A1cNow+, Bio-Rad's In2it, and Siemens’ DCA Vantage
showed a positive correlation between POC HbA1c testing and the laboratory
reference HbA1c ( r2 = 0.967) (Health Quality, 2014).
The Bland- Altman plot showed no significant differences between the results of
the Quo-test and the reference test in our study, with a mean difference between
the quo-test and the Tosoh G8 of 6%, another similar study showed a difference
of 10% between the Bio-Rad In2it and Cobas, and 5% between DCA 2000 and the
Variant II (Yeo et al., 2009).
The coefficient of variation in our study was 2.1%. Although the NGSP has not set
forth goals for precision and accuracy, it recommends a CV <3% (preferably <2%).
Comparatively, the ADA recommends a CV <4%, and ideally <3% (Whitley et al.,
2015). In conclusion, the POC device performed well within a clinic environment,
and the results are available immediately.  The results have the potential to
improve patients’ management, and further prospective studies are needed to
assess this potential.
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6: Recommendations
As a researcher, I wish to maximise the impact of my study convincing the
policymakers that a new policy or a different approach is valuable and should be
introduced in the national strategy combating the epidemic of T2DM.
According to the results of the study, the burden of T2DM in Kuwait is huge, and
keeping this in mind; we need a specific strategy to prevent the disease and delay
its complications.
Patients attending ambulatory services in Kuwait have a high prevalence of T2DM
and its precursor stages of pre-diabetes and insulin resistance.  The magnitude of
these conditions has enormous public health implications and will increase health
service utilization and decrease the quality of life of the country’s population.  It
is therefore recommended that Kuwait declares T2DM prevention and control a
top priority for national health programming and intervention research.
Initiatives should encourage the population to adopt healthier lifestyles, including
promoting awareness and encouraging physical activities and weight control.  Key
at-risk populations need to be prioritised.  These include first degree relatives of
T2DM, people > 40 years old, individuals with BMI > 25 and people with
hypertension, and hyperlipidaemia. Such initiatives on preventing T2DM should
be monitored and evaluated continuously.
The country should consider conducting community-based surveys at the
household level, detecting undiagnosed T2DM. Research is also needed to,
investigate risk factors for hyperglycaemia and high prevalence of obesity as well
as the acceptability and barriers to adopting healthier lifestyles, approaches to
encourage physical inactivity within Kuwait adverse weather environment. Such
data could help to justify the need for the development of specific interventions,
as well as national programs and guidelines to achieve significant reductions in
T2DM levels in the population of Kuwait.
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In individuals with T2DM, an educational program that emphasises changes
towards a healthier lifestyle and proper diet regime, especially in patients with
longer duration of T2DM may improve the glycaemic control. The use of an NGSP
certified HbA1c POC device is more convenient for patients and healthcare
providers, and provide opportunities for prompt therapy modification, and may
increase the chances to improve glycaemic control.
Interventions at a macro level that go beyond personal decisions are also needed.
It is likely interventions will require multi-disciplinary approaches to ensure
interventions are appealing, acceptable and efficacious.  Areas such as legislation
and urban planning will likely have a longer-term effect than the promotion of
individual diets and lifestyles alone.  The country, therefore, should consider the
development of legislation to reduce the location, advertising and opening hours
of fast food providers; request them to reduce the size and calorie content of
their foods and to increase the availability of healthier options.  The Government
should consider increasing the price of caloric foods and drinks, as successfully
introduced in other countries.  In addition, urban planning could promote the
increase of sports facilities, consider unusual approaches such as developing
cycling and jogging routes that are shaded and educators and employers should
create opportunities for physical activity in schools and at work.  If the
government fails to take notice of the epidemic, the sad alternative will be to
increase the number of health facilities that deal with the chronic complications
of T2DM, such as amputations, blindness and early death.
Future research questions
This thesis has highlighted that DM and IR are very frequent among adults
attending a major primary health care clinic in Kuwait and the characteristic
associated with these conditions.  We propose the following research questions
for future studies in the country:
a. Conduct a systematic review of interventions that are effective for the
control of IR, MS and DM in cultural and economic contexts similar to Kuwait.
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b. Explore the acceptability in Kuwait of interventions known to be effective for
the prevention of IR and DM in other contexts and the adaptations that are
necessary to increase their adoption.
c. Conduct further studies tounderstand bettr the poor glycaemic control
attained by a large proportion of patients attending the diabetic clinic and test
whether quality improvement interventions lead to better control.
d. Consider the possibility of implementing large-scale population
interventions to explore the efficacy of different approaches to the control of IR,
DM and to reduce the risk of IR progressing to a full DM.
e. Explore whether the provision of POC rapid diagnostics for HbA1c leads to
better clinical management.
f. Consider whether a repeat and representative national survey is needed to
assess the full extent of the problem in Kuwait.
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Appendices
Prevalence of Type 2 DM and IR questionnaire (objective 1)
Patient number Date date
Name of health care facility file number
Name Address
Mobile phone
Demographic characteristics
Age Years [not known = 99] Sex (Male=1, Female=2)
Marital status [Single=1, with partner/married=2, divorced/separated=3, widowed=4]
Education (no education=1, primary=2, secondary=3, higher education=4)
Occupation (governmental=1, private=2, employed for wages=3, out of work=4, retired=5, a homemaker=6)
Medical history
Do you have diabetes? (Yes=1, No=2, don’t know=3)
Do you have Hypertension? (Yes=1, No=2, don’t know=3)
Laboratory data (if not available=999)
HbA1c level
FPG level
Insulin level
LDL level
HDL level
Triglyceride level
AIP
Area
dd mm yy
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DM and IR risk factors questionnaire (for objective 2)
Patient number Date date
Name of health care facility file number
Name Address
Mobile phone
Patient group (DM=1, IR=2, No DM and No IR=3)
Demographic characteristics
Age (Years) Sex (Male=1, Female=2)
Marital status (Single=1, with partner/married=2, divorced/separated=3, widowed=4)
Education (No education=0, primary=1, secondary=2, higher education=3, prefer not to answer=4)
Occupation (governmental=1, private=2, labourer=3, not employed=4, other=5)
Family history of T2DM (first degree=1, second degree=2, third degree=3, no history of T2DM=4)
Ethnicity (Arab=1, South Asian=2, Indian=3, Persian=4, others=5)
Anthropometric
Height (cm) Body Mass Index (BMI = kg/m²)
Weight (kg) Waist/Hip Ratio (WHR)
Waist (cm) Systolic blood pressure (mmHg)
Hip (cm) Diastolic blood pressure (mmHg)
---------------------------------------------------------------------------------------------------------------------------
----------
Life style
Smoking (Yes=1, No=2, ex-smoker=3, prefer not to answer=4)
If smoker, how many cigarettes per day? (Don’t know=99)
dd mm yy
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Diet habits
Type of food
Per day Per week Per month
Never
1
time
2
times
3 or
more
1
time
2
times
3 or
more
1 to
3
times
Less
than
once
Vegetables/ fruits
Fish
Meat/Poultry
Eggs
Pastry
Whole grain seeds
Rice
Full cream  dairy products
Fast food
Canned/Bottled drinks
containing sugar
Do you consume olive oil?
Physical activity
Think about all the vigorous activities that you did in the last 7 days. Vigorous physical
activities refer to activities that take hard physical effort and make you breathe much harder
than normal.  Think only about those physical activities that you did for at least 10 minutes at
a time.
3. During the last 7 days, on how many days did you do vigorous physical activities
like heavy lifting, digging, aerobics, or fast bicycling?
_____ days per week
No vigorous physical activities Skip to question 3
4. How much time did you usually spend doing vigorous physical activities on one of
those days?
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_____ hours per day
_____ minutes per day Don’t know/Not sure
Think about all the moderate activities that you did in the last 7 days. Moderate activities
refer to activities that take moderate physical effort and make you breathe somewhat harder
than normal.  Think only about those physical activities that you did for at least 10 minutes at
a time.
5. During the last 7 days, on how many days did you do moderate physical activities
like carrying light loads, bicycling at a regular pace, or doubles tennis?  Do not
include walking.
_____ days per week
No moderate physical activities
6. How much time did you usually spend doing moderate physical activities on one of
those days?
_____ hours per day
_____ minutes per day
Don’t know/Not sure
---------------------------------------------------------------------------------------------------------------------------
----------
Medical history
(Yes=1, No=2,
don’t know=3)
Have you ever been diagnosed with high blood glucose?
Hypertensive?
On any kind of antihypertensive medication?
On any kind of Lipid lowering therapy?
Have you ever been diagnosed with ischemic heart disease?
History of polycystic ovaries (for females)?
History of gestational diabetes (for females)?
Do you have any other chronic disease? (Yes=1, No=2, don’t know=3) if yes please specify)
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IR in first degree relative’s questionnaire (objective 3)
Patient number Ddate date
Name of health care facility file number
Name Address
Mobile phone
Patient is relative to group (DM=1, IR=2, No DM and No IR=3)
Demographic characteristics
Age Years (not known=99) Sex (Male=1, Female=2)
Marital status (Single=1, with partner/married=2, divorced/separated=3, widowed=4)
Education (No education=0, primary=1, secondary=2, higher education=3, prefer not to answer=4)
Occupation (governmental=1, private=2, labourer=3, not employed=4, other=5)
Ethnicity (Arab=1, South Asian=2, Indian=3, Persian=4, others=5)
Laboratory results
FPG level
Insulin level
HbA1c level
Area
dd mm yy
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Diabetic clinic questionnaire (for objective 4)
Patient number Date date
Name of health care facility file number
Name Address
Mobile phone
Demographic characteristics
Age Years Sex (Male=1, Female=2)
Marital status (Single=1, with partner/married=2, divorced/separated=3, widowed=4)
Education (No education=0, primary=1, secondary=2, higher education=3, prefer not to answer=4)
Occupation (governmental=1, private=2, labourer=3, not employed=4, other=5)
Family history of T2DM (first degree=1, second degree=2, third degree=3, no history of T2DM=4)
Ethnicity (Arab=1, South Asian=2, Indian=3, Persian=4, others=5)
Anthropometric
Height (cm) Body Mass Index (BMI = kg/m²)
Weight (kg) Hip (cm)
Waist (cm) Systolic blood pressure (mmHg)
Waist/Hip Ratio (WHR) Diastolic blood pressure (mmHg)
---------------------------------------------------------------------------------------------------------------------------
----------
Life style
Smoking (Yes=1, No=2, ex-smoker=3, prefer not to answer=4)
If smoker, how many cigarettes per day? (Don’t know)
Area
dd mm yy
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Diet habits
Type of food
Per day Per week Per month
Never
1
time
2
times
3 or
more
1
time
2
times
3 or
more
1 to
3
times
Less
than
once
Vegetables/ fruits
Fish
Meat/Poultry
Eggs
Pastry
Whole grain seeds
Rice
Full cream dairy products
Fast food
Canned/Bottled drinks
containing sugar
Physical activity
Think about all the vigorous activities that you did in the last 7 days. Vigorous physical
activities refer to activities that take hard physical effort and make you breathe much harder
than normal.  Think only about those physical activities that you did for at least 10 minutes at
a time.
7. During the last 7 days, on how many days did you do vigorous physical activities
like heavy lifting, digging, aerobics, or fast bicycling?
_____ days per week
No vigorous physical activities Skip to question 3
8. How much time did you usually spend doing vigorous physical activities on one of
those days?
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_____ hours per day Don’t know/Not sure
_____ minutes per day
Think about all the moderate activities that you did in the last 7 days. Moderate activities
refer to activities that take moderate physical effort and make you breathe somewhat harder
than normal.  Think only about those physical activities that you did for at least 10 minutes at
a time.
9. During the last 7 days, on how many days did you do moderate physical activities
like carrying light loads, bicycling at a regular pace, or doubles tennis?  Do not
include walking.
_____ days per week No moderate physical activities
10. How much time did you usually spend doing moderate physical activities on one of
those days?
_____ hours per day Don’t know/Not sure
_____ minutes per day
Medical history
Diabetic for how long? (By Years, less than 12 months=0, if don’t know=999)
If diabetic for more than a year, how many visits to the diabetic clinic in the last 12 months?
(If not applicable=999)
Hypertensive (Yes=1, No =2, don’t know=3)
On any kind of antihypertensive medication? (Yes=1, No =2, don’t know=3)
On any kind of Lipid lowering therapy? (Yes=1, No =2, don’t know= 3)
Have you ever been diagnosed with diabetic eye disease? (Yes= 1, No=2, don’t know=3)
Have you ever been diagnosed with diabetic kidney disease? (yes=1, no =2, Don’t know=3)
Have you ever been diagnosed with ischemic heart disease (Yes=1, No=2, don’t know=3)?
History of polycystic ovaries (for females)? (Yes=1, No=2, don’t know=3)
Laboratory data
HbA1c by laboratory (if not available=999)
The records of the last 5 lipid profile test
Test (if not available=999) DATE M/Y DATE M/Y DATE M/Y DATE
M/Y
DATE M/Y
HDL
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LDL
Triglyceride
AIP
Accuracy of POC test questionnaire (objective 5)
Patient number Date date
Name of health care facility file number
Name Address
Mobile phone
Demographic characteristics
Age Years [not known = 99] Sex (Male=1, Female=2)
Marital status [Single=1, with partner/married=2, divorced/separated=3, widowed=4]
Education (no education=0, primary=1, secondary=2, higher education=3, prefer not to answer=4)
Occupation (governmental=1, private=2, labourer=3, not employed=4, other=5)
Medical history
Do you have diabetes? (Yes=1, No=2, don’t know=3)
Do you have abnormal haemoglobin? (Yes=1, No =2, don’t know=3)
ONLY IF THE ANSWER IS YES, PLEASE ANAWER THE NEXT QUESTION
Type of abnormal Haemolgobin
(α thalassemias= 1,betathalassemias= 2, sickle cell=3, other=4, not available=999)
Laboratory data
HbA1c level reference lab (if not available=999)
HbA1c level POC device
Area
dd mm yy
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Consent Form (English)
Study Title: Prevalence and risk factors of diabetes and insulin resistance in
patients attending a health care Centre in Kuwait, and the accuracy of a point
of care device to measure glycated haemoglobin to monitor patients with
diabetes.
Principal Investigator: Dr. Ahmad Almotawa Study Site: Nuzha HCF- Kuwait
* All data gathered on this form and any information you provide us for the study
will be confidential and will not be communicated to anyone outside the study
team.
Signing this declaration does not affect your right to decline to take part in any future
study.
Please
initial
box
1. I confirm I have read and understood the information sheet dated 14-9-
2015, Version 1.1 for the above study.  I have had the opportunity to
consider the information, ask questions and have had these answered
satisfactorily.
2. I understand that participation in this study is voluntary and I am free to
withdraw   consent at any time, without giving a reason, without any
penalties.
3. I understand that data collected during the study, may be looked at by
individuals from LSTM and from regulatory authorities.  I give permission
for these individuals to have access to my records.
4. I hereby declare that I have not been subjected to any form of coercion in
giving this consent.
5. I agree to the data about me collected in this study being stored for
further use in the future.
6. I agree that my blood sample will be transported to Amiri hospital to be
analyzed.
7. I agree to gift this blood sample for future research purpose
8. I agree to take part in this study.
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erutangiS etaD tnapicitrap fo emaN
erutangiS etaD gnikat nosrep fo emaN
tnesnoC
)cibarA( mrof tnesnoC
ﯾﻛون ﻻوأﻧﺎ أدرك أﻧﮫ ﻗداﻻﺧﺗﺑﺎر اﻟﺗﺷﺧﯾﺻﻲ اﻟﺟدﯾد ﻟﻣرض اﻟﺳﻛرﺑﺣثاﻟدﻋوة ﻟﻠﻣﺷﺎرﻛﺔ ﻓﻲﻟﻲﻟﻘد وﺟﮭت
دﻓﻊ اي ﻣﺑﻠﻎ ﻧﺗﯾﺟﺔ اﻟﻣﺷﺎرﻛﺔ.ھﻧﺎك أي ﻓﺎﺋدة ﺑﺎﻟﻧﺳﺑﺔ ﻟﻲ ﺷﺧﺻﯾﺎ ﻣن ھذا اﻻﺧﺗﺑﺎر، وأﻧﻧﻲ ﻟن ﯾﺗم 
.اﻟﻣوﺿوعﻗراءﺗﮭﺎ ﻟﻲ. وﻗد أﺗﯾﺣت ﻟﻲ اﻟﻔرﺻﺔ ﻟطرح اﻷﺳﺋﻠﺔ ﺣول ھذاتﻟﻘد ﻗرأت اﻟﻣﻌﻠوﻣﺎت اﻟﺳﺎﺑﻘﺔ، أو ﺗﻣ
ﻧﺳﺣﺎب ﻣن اﻟﺑﺣث ﻓﻲ أي وﻗت ﻣن م أن ﻟدي اﻟﺣﻖ ﻓﻲ اﻻأﻋﻠﻟﻣﺷﺎرﻛﺔ  ﻓﻲ ھذا اﻟﺑﺣث وﻋﻠﻰ اأواﻓﻖ طوﻋﺎ 
.اﻟﻣﻘدﻣﺔ ﻟﻲدون أن ﺗؤﺛر ﻋﻠﻰ اﻟرﻋﺎﯾﺔ اﻟطﺑﯾﺔ
__________________اﻟﻣﺷﺎرك      اﺳم 
___________________ﻣﺷﺎرك اﻟﺗوﻗﯾﻊ 
____________________ﺔﯾوم / ﺷﮭر / ﺳﻧﺗﺎرﯾﺦ 
ﻛﻧت ﻻ ﺗﻌرف اﻟﻘراءهإذا 
اﻟﻔرﺻﺔ ﻟطرح اﻷﺳﺋﻠﺔ. وأؤﻛد أن ﻣﺷﺎركﻋﻠﻰ اﻟﻣﺷﺎرﻛﯾن اﻟﻣﺣﺗﻣﻠﯾن، وﻛﺎن ﻟﻠﻟﻘد ﺷﮭدت ﻗراءة ﻧﻣوذج اﻟﻣواﻓﻘﺔ 
ﻗد أﻋطﻰ ﻣواﻓﻘﺗﮫ ﺑﺣرﯾﺔ.ﻣﺷﺎركاﻟ
_____________________ ﻟﺷﺎھداﺳم ا
ﺑﺻﻣﺔ اﻟﻣﺷﺎرك                                                  
______________________ﺗوﻗﯾﻊ اﻟﺷﺎھد 
__________________ﺳﻧﺔ/ﯾوم / ﺷﮭر ﺗﺎرﯾﺦ
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( اﻟﻲ اﻟﻣﺷﺎركاﻟﻣواﻓﻘﺔ اﻟﻣﺳﺑﻘﺔ)ﺗم ﺗﻘدﯾم ﻧﺳﺧﺔ ﻣن ھذا اﻟﻧﻣوذج 
_____________________ﺗوﻗﯾﻊ ﻣﺳﺎﻋد اﻟﺑﺣث  
_________________ﺗوﻗﯾﻊ اﻟﺑﺎﺣث   _____________________اﻟﺑﺎﺣث أﺳم
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Background and rationale
The first clear description of diabetes was made by Aretaeus of Cappadocia, a
famous Greek physician of the 2nd AD century. He described the disease as a
chronic disease of thirst, excessive drinking, excessive urination and short life
span (Laios et al., 2012).
Although neglected for many years, today, DM is a seriously growing worldwide
disease which has reached epidemic proportions. There are more than 387
million people living with DM around the world, with 43% of them being
undiagnosed. It is estimated that one person dies every seven minutes due to DM
and that governments will need to spend 1/9th of their health care expenditure
on  DM (IDF, 2014).
Diabetes Mellitus (DM) is a syndrome encompassing a group of metabolic
disorders characterised by insufficient insulin secretion, resistance to the action
of insulin or both (American Diabetes, 2009).
Global disease burden is continually shifting away from communicable to non-
communicable diseases and from years of life lost (YLLs) to years lived with
disability (YLDs).
The global burden of disease study proposed disability-adjusted life years (DALYs)
as the sum of YLLs and YLDs, to measure disease burden. Global DALYs calculated
from 187 countries for 291 causes in both male and female from 1990 to 2010,
DALYs remained stable but significant shift has occurred in DALYs due to DM,
increasing by 69%, with an obvious increase in DALYs of chronic kidney disease
due to DM by 77%.(Murray et al., 2012).
Prevalence of diabetes is increasing globally; it is well recognised as major health
problem. In the year 2003, it was estimated that there were 194 million with
prevalence of 5.1%.(Federation, 2003)
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Today, according to the International Diabetes Federation (IDF) world atlas there
are more than 387 million people with diabetes in the world, with prevalence of
8.3%.(IDF, 2014)
The several studies revealed that there is an enormous economic burden of
diabetes, affecting patients in Low and middle-income countries (LMICs) mostly
in a direct way (Seuring et al., 2015, Tharkar et al., 2010).
Global burden
Patients with DM are categorised into four broad types:   Type 1 (T1DM), Type 2
(T2DM), gestational DM (GDM) and DM due to other causes. T2DM is the most
common presentation, with GDM being frequent but short lived, followed by
T1DM (William T. Cefalu, 2015).
Insulin action
Insulin (from the Latin, insula meaning island) is a hormone produced by beta
cells of the islets of Langerhans in the pancreas (Sonksen and Sonksen, 2000).
Insulin is released mainly when the level of glucose increases in the blood stream
(Buchwald et al., 2015), Activation of insulin receptors leads mechanisms that
directly affect glucose uptake by protein molecules in the cell membrane that
transport glucose into the cell, leading to lowering blood glucose level (Najjar,
2001).
Pathogenesis of Type 2DM
Type 2 DM is characterized by hyperglycemia resulting from a defect in the
pancreas insulin secretory function and/or Insulin resistance (IR) (Gareth
Williams, 2002).
Pre-diabetes and insulin resistance
Prediabetes is the medical stage in which not all of the symptoms existing to
diagnose a person as diabetic, but impaired fasting glucose (IFG), which refers to
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a condition in which the fasting plasma glucose (FPG)  is elevated above the
normal levels but is not high enough to be classified as DM (Nichols et al., 2007).
IFG is strongly associated with Insulin resistance and dysglycemia, predisposing to
life threatening cardiovascular diseases among other serious diseases (Barr et al.,
2007).
IR is a condition in which the insulin target cells fail to respond to the normal
actions of insulin. The pancreas produces insulin, but the cells in the body tissues
become resistant to insulin and are unable to use it as efficiently, leading to high
blood glucose level. Subsequently, Beta cells increase their production of insulin
trying to reach proper glycemic control, causing a high blood insulin level (Chiu et
al., 2007). Dietary fat has been strongly recognised as a stimulant of insulin
resistance, and it is known that IR coexists with obesity (Eckel et al., 2011, Kahn
et al., 2006).
Anthropometric characteristics
The recent socio-economic transition in the Middle East resulted in a parallel
increase in the prevalence of overweight and obesity(Saadi et al., 2010). Among
Arab and Mediterranean, diabetes occurs at lower level of BMI than the Western
populations, and a small increase in weight can produce a state of glucose
intolerance (Jaber et al., 2003, Nakagami et al., 2003). An excess of body fat,
especially around the abdomen, increases the probability of developing a range
of diseases. It includes diabetes, insulin resistance, hypertension, dyslipidemia,
ischemic heart diseases and some forms of cancer (King et al., Rodriguez, 2006).
Obesity is a major risk factor for diabetes. In white population, obesity is defined
as a BMI of more than 30 kg/m2 and overweight as a BMI of equal to or more
than 25 kg/m2. WHO consider these numbers are valid for Arab population too.
Several studies in Asian populations showed that there is a phenotype
characterised by normal BMI but just like obese people are having insulin
resistance, diabetes and Ischemic heart disease. This phenotype is called
metabolically obese-normal weight, despite having normal BMI; those individuals
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have less muscle mass and greater abdominal obesity (Ruderman et al., 1998,
Ramachandran et al., 2010).
Racial/ Ethnic predisposition
There is strong evidence that there is a higher prevalence of T2DM among
migrant populations in Europe, with an increase in the morbidity and mortality
related to the disease compared to the native European populations(Wandell et
al., 2010). London school of hygiene and tropical medicine is taking part in an
interdisciplinary study on obesity and diabetes among African migrants; the study
is funded by the European Union. The study aims to understand the reasons of
the high prevalence of T2DM among the migrant populations. Prevalence of
obesity and diabetes is greater in migrants from south Asia, Africa and the
Caribbean region(Oldroyd et al., 2005).
A population-based study in Israel showed that Arabs in Israel are at 70% higher
risk for adult onset T2DM and a significantly younger age of presentation with the
disease than the Jewish group (Kalter-Leibovici et al., 2012). Another study was
done in Los Angeles showed that Hispanic and African children are more insulin
resistance than the white children(Goran et al., 2002). Similarly, a study recruiting
626 Arab American in Michigan revealed that the combined rate of glucose
intolerance 32.3% for women and 49.8 for men (p= 0.0001) (Jaber et al., 2003).
Recruiting 34,456 adult immigrants, the data of the national health interview
survey from 1997 to 2005 analysed by Reena Oza-frank and Narayan K.M, The
data showed that men and woman from Mexico, Central America and the
Caribbean were more likely to be diabetic than European migrants (OR = 2 for
both groups)(Oza-Frank and Narayan, 2010).
Obesity
A study in the UK followed 7176 male participants showed that diabetes
increases significantly with obesity and overweight(Goya Wannamethee et al.,
2005) (overweight is defined as  25 < BMI < 30, while obesity is BMI ≥ 30).
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Complications of diabetes mellitus
In Kuwait, the prevalence of T2DM and GDM is unusually high, with an estimated
crude prevalence of 17.9% of 20-79 years old adults having T2DM. As Kuwait has
a relatively young population, the age-adjusted prevalence is even higher with
23.1% being affected (IDF/Kuwait, 2014).
The rapidly growing prevalence of T2DM in the developing countries is linked to
the effect of urbanisation and lifestyle changes (Al-Moosa et al., 2006, Shetty and
Schmidhuber, 2006).
Although T2DM is a preventable disease, it requires regular screening, early
detection, lifestyle changes and proper treatment to reduce its incidence and
associated morbidity and mortality (Care, 2004, Eriksson and Lindgarde, 1991,
Tuomilehto et al., 2001). T2DM is associated with many factors; some of which
are modifiable and others that are not. The fixed factors include, among others,
age, sex and genetic susceptibility; while the modifiable include socioeconomic
status, lifestyle and environmental factors, obesity (Eckel et al., 2011), a high
body mass index (BMI) (Hamer et al., 2014), inflammatory markers (Chagas et al.,
2012), poor dietary habits and inactivity (Fletcher et al., 2002).
With the purpose of developing a programme to control the progression of DM in
Kuwait, it is important to do a situation analysis of the disease in the country and
to describe the leading risk factors associated with T2DM in the community.
Although it is recognised that T2DM is a major health problem in Kuwait, Kuwait
does not have a DM surveillance system. Chronic hyperglycaemia is the
distinctive sign of T2DM. Until recently, its diagnosis was established with the
detection of elevated glucose levels in the blood (Berg, 2013).
In the late 20th century the aim was to identify patients at risk of developing signs
and symptoms of acute hyperglycaemia. In 1997 however, the American Diabetes
Association recommended that the diagnostic levels of plasma glucose should be
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based on the risk of developing a chronic complication and accordingly the
diagnostic of preference became the measurement of fasting plasma glucose
(FPG), which was set to ≥ 7 mmol/L and oral glucose tolerance test threshold ≥
11.1 mmol/L.  Despite these changes, single measurements of FGP was still a
poor marker of the long term glycaemic control, and it was recommended that
other markers should be used to reflect the long term euglycemic state of the
individual.  Haemoglobin A1c (HbA1c) is a haemoglobin variant created when the
glucose molecule binds to the chain of haemoglobin A (Weykamp et al., 2009).
The proportion of haemoglobin that is glycated accurately reflects the average
plasma glucose concentration in the proceeding 2-3 months in most patients
(Nathan et al., 2008). HbA1c, therefore, became the recommended test for the
diagnosis of T2DM, with a threshold of 6.5% (ADA, 2015), and an accepted
marker to monitor the degree of glucose control attained.
Until recently, HbA1c measurements required referral of the patient or transport
of the sample to a reference laboratory.  Point of care (POC) tests for HbA1c are
nowadays available and obtaining immediate HbA1c results has the potential to
improve glycaemic control by providing rapid information to the managing
clinician and is more convenient to the patient (Miller et al., 2003).  Some, but
not all of these POC tests do not seem to have the same accuracy than tests
conducted at reference centres; especially in the presence of anaemia,
haemoglobinopathies, chronic renal failure and other conditions and the
consideration of adopting POC HbA1c diagnostics should be proceeded by an
evaluation of their performance.  There is however limited evidence of the
performance of the POC HbA1c devices in Kuwait suggesting that further
research on the effectiveness of POC against laboratory HbA1c is needed.
Aim of the study
In this project, we propose to assess the burden and risk factors for diabetes,
factors associated with poor glucose control and assessing diagnostic methods
for initial diagnosis and monitoring of diabetes that are suitable for the point of
care of patients.
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Objectives of the study
The study will have the following objectives:
I. To determine the prevalence of Type 2 DM and IR among adult population
attending a primary health care facility in Kuwait.
II. To determine the risk factors for Type 2 DM and IR in this adult population.
III. To describe the prevalence of IR among first degree relatives of patients
with Type 2 DM.
IV. To establish the proportion of patients with type 2 DM who achieve
adequate glycaemic control and the risk factors for poor glycaemic control.
V. To assess the accuracy of a POC device to measure A1c for the diagnosis of
Type 2 DM among patients with DM and patients with known
haemoglobinopathies.
Capacity building and training
 Dedicated staff will be trained on the operation and troubleshooting of
POC/HbA1c.
 Sites visits may identify additional capacity building required to conduct the
study to international standards.
Evaluation site
The Liverpool School of Tropical Medicine:
LSTM has about 350 academic staff and extensive expertise in developing and
evaluating disease control programmes, with a first-class track record for
researching health problems in resource developing countries.  Over the last
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decade, LSTM has led many related projects on tropical diseases, developing and
mainstreaming frameworks for diagnosis, improving screening strategies and
treatment and designing and testing interventions to promote gender equity.
The LSTM team has conducted multi-centre projects on barriers to access
diagnosis and treatment uptake.  These strengthened the international evidence
underlining accelerated diagnostic schemes and packages that bridge the gap
between the service and the patient, increase case detection and treatment
uptake.  The School has extensive experience in managing large projects with
substantial staff and funding.
Al Amiri hospital
The Amiri Hospital is a general hospital located in Kuwait City, and it serves an
estimated 400,000 patients per year. The hospital was built in 1949 to be the first
government owned hospital. The capacity of this hospital is about 400 beds. The
hospital earned accreditation for complying with international health care quality
standards including achieving the highest level of performance possible,
improving patient outcomes, and creating an environment for continuous
improvement.
The laboratory is equipped with the latest technology for accurate testing.
Nuzha HCF
Nuzha HCF is a governmental health centre in an urban area (Kuwait City)
providing about 50,000 consultations per year. This primary health care centre
provided general practice (GP) services and selected specialised clinics for
diabetes monitoring and management, hypertension and obesity.
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Study plan
This will be a prospective collaboration of two health institutions: Nuzha health
centre and Al-Amiri hospital in Kuwait with technical support from the Liverpool
School of Tropical Medicine (LSTM).
The study will be coordinated by Dr Ahmad Almotawa and supported by his PhD
supervisors who will maintain close electronic and Skype communication.
Protocol change decisions will be made in consultation with Prof Cuevas at LSTM.
The study will be independent of POC device Agent Company to ensure its
objectivity.
Study design
There will be cross-sectional studies and case-control studies.
Methodology
Objective 1: To determine the prevalence of Type 2 DM and IR among a Kuwaiti
adult population attending Nuzha health facility.
This will be a cross sectional survey in Kuwait and will be conducted from
September 2015 to September2016.
Setting: The study will be based at Nuzha health care facility (HCF).  Nuzha HCF is
a governmental health centre in an urban area (Kuwait City) providing about
50,000 consultations per year. This primary health care centre provides general
practice (GP) services and selected specialised clinics for diabetic monitoring and
management, hypertension and obesity.
Target population: The target population will be adult patients aged 18 years or
more attending Nuzha HCF.
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Inclusion/exclusion criteria: All adults attending Nuzha HCF seeking medical
advice for any illness at the general clinics will be eligible to participate,
independently of the reasons why they attend the clinics.  Eligible patients will be
enrolled prospectively over a period of 12 months or until the desired sample size
is achieved. We will exclude pregnant women, patients with acute infections who
have fever, patients on steroids, those unable to consent, patients who fail to fast
overnight or unwilling to return the next day to the clinic.
We will use systemic sampling to choose participants, every 5th patient starting
from the first patient attending the general clinic, we are planning to enrol 3
patients daily 5 days a week. If a patient refuses to participate, we will invite
patients consecutively, continuously until a replacement is found.  Then the 5th
patient interval will resume.
Patients who agree to participate will be interviewed to complete a questionnaire
containing demographic background and medical history.
If the participant has been fasting for 12 hours and if it is convenient, a
phlebotomist will collect one venous blood sample after the patient has
completed the clinic consultation.  If the participant is not fasting, we will give
instructions to fast for 12 hours and to return the next day in the morning.
Laboratory procedures: Patients’ blood will be collected to measure Fasting
Plasma Glucose (FPG), Fasting plasma insulin, A1c and lipid profile, including high-
density lipoprotein (HDL), low-density lipoprotein (LDL), Triglycerides (TG).  These
tests will be free for the participants. See laboratory tests below.
Patients will be classified as having normal values, IR or DM according to the
following parameters.
 DM will be defined as the presence of an abnormal (defined as A1C ≥6.5%)
and an abnormal FPG (defined as ≥126 mg/dl (7.0 mmol/L)).
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 Patients with IR but who are not DM will be defined as patients with FPG <
125 mg/dl (6.9 mmol/L) but homeostatic model assessment 2 (HOMA)2 -IR >
2.
 Patients will be defined not to have DM or IR if the A1c is < 5.7, and FPG is <
110 mg/dl (6.1 mmol/L), and HOMA2 ≤ 2.
* HOMA 2 is a model constructed from the combination of several tests is based
on the physiological balance between insulin secretion and glucose
concentrations in blood and are therefore a reflection of the balance between
glucose uptake by tissues and insulin production.
All patients will be provided feedback of the results.  Patients with normal results
will receive them via email or phone call, as per their stated preference.  Patients
with abnormal results will be contacted via email or phone call as per their stated
preference and will be invited to attend a clinic appointment to discuss their
results with the DM clinic staff (post in Kuwait it unreliable).
Objective 2: To determine the risk factors for (a) Type 2 DM and (b) IR in the same
adult population.
This component will be two case control studies conducted simultaneously and
will be based at the same Nuzha HCF.
Cases of DM and IR and controls for both studies will be defined using the same
definitions listed above.
(a) In the case control to determine Type 2 DM risk factors, participants will be
enrolled both from patients participating in the survey (objective 1) and
from known DM patients attending the diabetes clinic at the same centre.
Cases of DM among patients participating in the survey will be identified at
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the time results become available and usually within 72 hours after sample
collection.  Patients with DM attending the clinic will be identified among
the cases known to the service who are attending spontaneous of routine
follow up consultations.  We will contact the participants identified by the
survey by phone or email to inform them about their results and invite them
to participate in the second part of the study which will include more
detailed questionnaire about their medical history and life style, we will also
inform them that we will take some measurements: height, weight, waist
and hip circumference and BP.  Patients who agree to participate will be
given an appointment. Cases from the survey will be enrolled daily until
reaching the desired sample size.
Patients enrolled in the DM clinic will also be enrolled consecutively, restricting
the number to two patients per day, to obtain a mixture of participants from the
clinic who were aware, and the survey (who were unaware) of having DM. Cases
of DM will be defined as stated above for patients attending the survey.  Cases
with DM will be defined as any adult who has a medical history of a diagnosis of
DM using the same parameters described above or at least two consecutive FPG
with abnormal values.  Some of these cases may have achieved glucose
homoeostasis at the time of enrolment, but will still be considered to have DM.
Controls will be adults who do not have DM nor IR patients, as defined above.
A total of N=64 controls will be enrolled for N=64 cases, giving a ratio of 1:1 cases
per control, we choose that ratio because we can attain cases from the diabetic
clinic to participate in this case control study.
(b) In the case control study to determine the risk factors for IR, all participants
will be enrolled from the prevalence survey (objective 1).  Cases of IR will be
defined according to homeostatic model assessment (HOMA) 2.
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Patient with HOMA2 > 2 but who are not diabetic (FPG <7 mmol/L) will be
defined as cases with IR.
Controls for this case control study will be the same participants in the survey
who do not have DM or IR.
A total of N=64controls will be enrolled for N=32cases, giving a ratio of 1:2 cases
per control, we choose that ratio because it is we are expecting small number of
cases, as we are estimating that only about 10% of our survey population would
have IR but no DM, and according to the available numbers of cases and controls,
this ratio would make it possible to achieve a statistical power > 80% to identify
IR risk factors.
For both case control studies, the interviewer will ask the participant to fill a
second questionnaire that includes a more extensive list of potential risk factors
for DM and IR (see questionnaires in appendix 1).  The questionnaire will include
all known risk factors for TYPE 2 DM and IR and will include diet, physical activity,
BMI, family history and others. A dedicated nurse will measure blood pressure
(BP), waist and hip circumference (cm), weight (kg), height (cm). BMI will be
calculated as weight (kg)/height² (m²).
Laboratory tests
 For the FPG test, we will collect 2 ml blood in a grey-top tube with Potassium
Oxalate/Sodium Fluoride.  Blood samples will be centrifuged to separate the
serum within 2 hours, and about 0.5 ml of the plasma will be collected in an
aliquot for testing using the Spectrophotometric assay (Beckman UniCel DxC
800).  Specimen for these assays are stable for up to 3 days if refrigerated.
 For the insulin test, we will collect 5 ml blood in a gold/yellow-top tube.  The
specimen will be centrifuged promptly, and about 1ml of serum will be
tested for insulin level using immune-assay (Beckman UniCel Dxi 600).
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Specimens for this assay are stable for 24 hours if refrigerated and for 6
months if frozen.
 For the A1c test we will collect 1 ml blood in a lavender (purple)-top tube
containing EDTA.  This tube does not need for centrifugation, and the
specimen is stable for 24 hours at room temperature.  A1c will be measured
using high-performance liquid chromatography (Tosoh’s HLC- G7).
 For lipid profile, the phlebotomist will draw 5ml blood in a gold-top tube,
centrifuge and about 2ml serum will be tested using Spectrophotometric
assay (Beckman UniCel DxC 600 Pro).
Objective 3: To describe the prevalence of IR among first degree relatives of
patients with Type 2 DM.
We will conduct a cross sectional survey of relatives of patients with Type 2 DM
study will be conducted at the same Nuzha HCF, Kuwait, from September 2015 to
September 2016.
Selection of participants will be identified from patients following up at Nuzha
diabetic clinic
We will ask all diabetic patients to invite at least one adult direct relative (first-
degree consanguineous relative), including siblings, parents or son/daughters to
participate in the study. If the patient agrees to invite a relative, we will ask them
to attend according to an appointment given IR and to come fasting for about 12
hours.  We will recruit participants until the sample size is achieved.
Eligibility will be adults >18 years old, first degree relative to a diabetic patient
attending Nuzha HCF.  We will exclude pregnant women, relatives with known
diabetes, and patients who have had fever in the last 14 days, patients on
steroids, those unable to consent, patients who are unable to fast overnight.
We will ask the participant to fill the questionnaire then the phlebotomist at
Nuzha HCF will collect the venous blood sample.
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Laboratory procedures: Relatives blood samples will be collected to measure the
same tests, including Fasting Plasma Glucose (FPG), Fasting plasma insulin and
A1c.
 For the FPG test, we will collect 2 ml blood in a grey-top tube with Potassium
Oxalate/Sodium Fluoride.  Blood samples will be centrifuged to separate the
serum within 2 hours, and about 0.5 ml of the plasma will be collected in an
aliquot for testing using the Spectrophotometric assay (Beckman UniCel DxC
800).  Specimen for these assays are stable for up to 3 days if refrigerated.
 For the insulin test, we will collect 5 ml blood in a gold/yellow-top tube.  The
specimen will be centrifuged promptly, and about 1ml of serum will be
tested for insulin level using immune-assay (Beckman UniCel Dxi 600).
Specimens for this assay are stable for 24 hours if refrigerated and for 6
months if frozen.
For the A1c test, we will collect 1 ml blood in a lavender (purple)-top tube
containing EDTA.  This tube does not need for centrifugation, and the specimen is
stable for 24 hours at room temperature.  A1c will be measured using high-
performance liquid chromatography (Tosoh’s HLC- G7).
Objective 4: To establish the proportion of patients with type 2 DM who achieve
adequate glycaemic control and risk factors for poor glycaemic control.
We will conduct a cross sectional survey study at the diabetic clinics of Nuzha
HCF, Kuwait from September 2015 to September 2016. We will use systematic
sampling to enrol patients. Eligibility will be adults > 18 years old with a
previously known diagnosis of Type 2 DM who attend a regular appointment at
the diabetic clinic. We will exclude pregnant women, patients with acute
infections who have fever, patients on steroids, those unable to consent and
those unable to fast overnight.
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We will use systematic sampling to choose participants.  Every 3rd patient
attending the clinic will be inviting, with 3 patients enrolled per day, 5 days a
week. If a patient refuses to participate, we will invite patients consecutively until
a replacement is found.  Then the 3-patient interval will resume.
Patients who agree to participate will be interviewed to complete a questionnaire
containing demographic background and medical history.
We will ask the participants to fill a questionnaire with known risk factors for
poor glycaemic control among DM patients, which will include diet, physical
activity, BMI, family history, adherence to treatment, understanding of DM and
others. A dedicated nurse will measure blood pressure (BP), waist and hip
circumference (cm), weight (kg), height (cm). BMI will be calculated as weight
(kg)/height² (m²).
The phlebotomist at Nuzha HCF will collect the venous sample; We will test the
blood sample for A1c and Lipid profile.
Laboratory procedures:
 For the A1c test, we will collect 1 ml blood in a lavender (purple)-top tube
containing EDTA.  This tube does not need for centrifugation, and the
specimen is stable for 24 hours at room temperature. A1c will be measured
using high-performance liquid chromatography (Tosoh’s HLC- G8).
 For lipid profile, the phlebotomist will draw 5ml blood in a gold-top tube,
centrifuge and about 2ml serum will be tested using Spectrophotometric
assay (Beckman UniCel DxC 600 Pro).
Cases will be classified as having good glucose controls if A1c < 7, Controls with
classified as having poor glucose control if A1c > 9.
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Objective 5: To assess the accuracy of a POC device to measure A1c for the
diagnosis of Type 2 DM among patients with DM and patients with known
haemoglobinopathies.
This will be a cross sectional survey in Kuwait and will be conducted from
September 2015 to September2016.
Setting: The study will be based at Nuzha HCF diabetic clinic and the haematology
clinic (for haemoglobinopathies). This clinic is based at Al-Amiri hospital; it is a
specialized clinic for patients with abnormal haemoglobin.
Target population: The target population will be the same patients participating
in objective 4 study for DM. Eligibility criteria for patients with
haemoglobinopathies will be adult patients with abnormal haemoglobin
attending the haematology clinic at Al-Amiri hospital seeking medical advice.
Patients with haemoglobinopathies will comprise patients with a known diagnosis
of α thalassemia, beta-thalassemia and sickle cell anaemia.
We will ask every 2nd eligible patient attending the haematology clinic to
participate in the study; we will invite consecutively eligible patients until we
enrol one, then we will go back to every 2nd patient systemic sampling. We are
planning to recruit 2 patients daily.
We will ask the participant to fill a short questionnaire then to take a venous
blood sample and a blood finger –prick blood sample.
Eligible patients will be enrolled prospectively over a period of 12 months or until
the desired sample size in both settings is achieved.
Laboratory procedures
 A ﬁnger-prick blood sample will be collected for in-clinic HbA1c testing with
the rapid one-step automatic test, Boronate affinity technique (Quo-Test)
This machine provides results with in about 4 minutes.
234
 For the reference A1c test we will collect 1 ml blood in a lavender (purple)-
top tube containing EDTA as described in previous objectives.
Physicians will be blinded to POC HbA1c results and will rely on the reference
HbA1c results for clinical decision making.
---------------------------------------------------------------------------------
* Wallace, T. M., J. C. Levy and D. R. Matthews (2004). "Use and Abuse of HOMA
Modelling." Diabetes Care 27(6): 1487-1495.
*Gayoso-Diz, P., A. Otero-Gonzalez, M. Rodriguez-Alvarez, F. Gude, C. Cadarso-
Suarez, F. Garcia and A. De Francisco (2011). "IR index (HOMA-IR) levels in a
general adult population: curves percentile by gender and age. The EPIRCE
study." Diabetes Res Clin Pract 94: 146 - 155.
* Qu, H.-Q., Q. Li, A. R. Rentfro, S. P. Fisher-Hoch and J. B. McCormick (2011).
"The Definition of Insulin Resistance Using HOMA-IR for Americans of Mexican
Descent Using Machine Learning." PLoS ONE 6(6): e21041.
Sample size calculation
Objective 1: To establish prevalence of TYPE 2 DM and IR in a Kuwait
The population in Nuzha health care centre catchment area is about 25,000; it is
expected that 20% of the adult population has TYPE 2 DM. We aim to establish
the prevalence of DM with an error margin of +/-4%, with 95% power and 5%
confidence limit, the survey sample size will be 380 participants.
Objective 2: To determine the risk factors for (a) Type 2 DM and (b) IR in the
same adult population.
We will conduct 2 case control studies simultaneously; the participant will be the
same participants from the first objective. We will classify the patients into
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patients with diabetes, patients with insulin resistance IR and normal patients
(NO DM and NO IR)
In the first cc study cases are adults with DM and controls are patients with
normal glucose and no IR. We estimate that 20% of patients enrolled for
objective 1 will have DM.  The survey, therefore, will identify about (380x 0.2) =
76 adults with DM (cases).  We also expect that 10% of participants in the survey
will have with IR (380x 0.1) resulting in 38 cases of IR and normal glucose.  The
remaining 266 participants are expected to be normal controls (No DM or IR).
The main risk factors used to establish the sample size are high cholesterol level
(expected to be present in 30% of the adult population), hypertension (30%) and
obesity (40%).  If we enrol participants with a ratio of controls to cases of 1:1; to
be 90% confident to have 80% chance to detect odds ratios of 2.5 or more, the
estimated sample size will be 65 DM cases and 65controls.
For the second case control study, again the participants are from the first
objective, and cases are IR patients, control are normal patients. We are looking
for risk factors with the same prevalence as stated above. With a ratio of controls
to cases of 2:1, to be 90% confident to have 80% chance to detect an odds ratio
of 3 or more, the calculated sample size is 35 cases and 65 controls.
Objective 3: To describe the prevalence of IR among first degree relatives of
patients with Type 2 DM.
There are 2000 patients following up at Nuzha HCF, assuming that each diabetic
patient has about 10 first degree relatives, the population size for this survey
would be2000. The estimated prevalence of IR among the first-degree relatives is
50%. To conduct a survey with 90% confidence level and a maximum error of 5%
the required sample size will be 270.
Objective 4: To establish the proportion of patients with type 2 DM who achieve
adequate glycaemic control and the risk factors for poor glycaemic control.
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We will conduct a descriptive survey in the diabetic clinic. The clinic provides
medical services for about 2000 diabetic patients. We estimate that there is 50%
chance of poor glycaemic control. To conduct a study with 90% confidence level
and 5% confidence limits. We will need at least 240 participants.
Objective 5: To assess the accuracy of a POC device to measure A1c for the
diagnosis of Type 2 DM among patients with DM and patients with known
haemoglobinopathies.
In the literature, the sensitivity of reference A1c test (Tosoh) is between 70% and
80%.
So, I used the 80% as the comparative point, and I allowed for 10% difference,
with α = 0.05 andbeta= 0.2 the required sample size will be 200 tests in each
group, (total of 400).
Study outcome
For objective 1:
The outcome is the prevalence of participants with DM, IR according to the
following parameter
 DM will be defined as the presence of an abnormal (defined as A1C ≥6.5%)
and an abnormal FPG (defined as ≥126 mg/dl (7.0 mmol/L)).
 Patients with IR but who are not DM will be defined as patients with FPG <
125 mg/dl (6.9 mmol/L) but homeostatic model assessment (HOMA)2-IR > 2.
For objective 2:
The outcome measure is to describe the association of Type 2 DM and IR with the
following assumed risk factors: age, sex, obesity, BMI, cholesterol, triglyceride
and BP.
For objective 3:
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The outcome measure is the prevalence of IR among first degree relatives of
people with Type 2 DM.
For objective 4:
The outcome measure will be the percentage of the diabetic patient attending
Nuzha HCF with good glycaemic control and to describe the risk factors
associated with the poor glycaemic control.
Good glycaemic control is when A1c < 7, and poor glycaemic control is when A1c
> 9.
Patients with A1c between 7 and 9 will be considered as fairly controlled.
For objective 5:
The outcome measures are to describe the accuracy of POC device in measuring
A1c, describing the precision of the POC device, comparing the means (95% CI)
and difference (95% CI) against the reference laboratory results.
Study management
Study team
The study activities will be initiated by the Liverpool School of Tropical Medicine
(Prof Luis Cuevas, Ahmad Almotawa and Russell Dacombe), Nuzha health centre,
Al-Amiri Hospital in Kuwait.
The research will be conducted within the context of routine clinical and
laboratory practise at the study sites and procedures required will be performed
by those providing patients’ services.
Responsibilities of study team members
Responsibility of LSTM team
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 Development of the initial protocol;
 Initial site assessment visit;
 Coordination of ethical approval applications;
 Facilitate study initiation;
 Study monitoring;
 Development of standardised study forms and record keeping procedures;
 Development of standardised databases;
Responsibility of Nuzha health care centre
 Feedback of the initial protocol in collaboration with LSTM;
 Support data analysis and reporting;
 Provision of the study support staff in Kuwait.
 Facilitate the enrolment of patients at its hospital facilities.
 Record results in laboratory record book.
 Conduct two HbA1c tests, one in the Centre using POC device and the other
one in the reference lab as the usual routine.
 Conduct I.V glucose and insulin level per participant.
 Conduct the study survey.
Responsibility of Al-Amiri hospital
 Feedback of the initial protocol in collaboration with LSTM;
 Support data analysis and reporting;
 Provision of the study support staff in Kuwait.
 Facilitate the enrolment of patients at its hospital facilities.
 Record results in laboratory record book.
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 Conduct two HbA1c tests, one in the Centre using POC device and the other
one in the reference lab as the usual routine.
 Conduct I.V glucose and insulin level per participant.
 Conduct the study survey.
Trouble shooting
Clinical and laboratory staff should approach the study coordinators, and in turn,
the latter should approach the LSTM.  External technical assistance can be
arranged if needed.
Study site preparation
Nuzha health care centre and LSTM investigators should review the master
protocol with the study team. Any changes to the master protocol would need to
be approved by Prof Cuevas at LSTM.
Ethical considerations
Institutional review board (ethics committee) approvals to the protocol will be
requested from the ethical committees in LSTM and Nuzha health care Centre.
Once the study is approved, the letter of approval with the names and affiliation
of all the members of the ethics committees will be stored at LSTM for
documentation. The consent form and patient information sheets must be
available in English and Arabic. LSTM will prepare Material Transfer Agreements,
as needed.
Benefits for Participants
All participants will have an HbA1c and I.V glucose level, and therefore patients
will obtain an optimal glycaemic diagnosis. Within the context of a research
study, patients are also likely to benefit from good medical services. No
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reimbursement of patient’s costs will be offered as costs for patients will be
equal or less than those incurred by attending the routine diagnostic services.
Potential harms to the Participants
Within the context of the national public health services and following National
Guidelines of counselling and testing.  Participants will be informed they do not
need to answer questions they find unpleasant or disturbing.
Training for study staff
Site assessment visits and study initiation visits will be critical to ensure that
training needs are identified and addressed and do not delay the study or
compromise quality.  Training in standardised procedures integral to the study
will be provided as necessary and may include the use of the POC device,
obtaining samples of good quality and interviewing techniques. POC device will
be installed and calibrated according to the manufacturer.  Staff will be trained
on-site on the use of the POC.
Piloting the study protocol
The study protocol will be implemented at the study sites for 3-5 days as a pilot
phase; we will try to query 20 patients before collection of data to be included in
the analysis.  This period will familiarise staff with the procedures and identify
potential for errors.
Biosafety guidelines for clinic and laboratory staff
Laboratory workers are responsible for their own safety and that of their co-
workers. Transmission of the blood borne disease can only happen if the staff did
not follow the local and international infection control recommendations.
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Statistical analysis
For objective 1:
Patients will be classified as having normal values, IR or DM according to the
following parameters.
 DM will be defined as the presence of an abnormal (defined as HbA1C
≥6.5%) and an abnormal FPG (defined as ≥126 mg/dl (7.0 mmol/L)).
 Patients with IR but who are not DM will be defined as patients with FPG <
125 mg/dl (6.9 mmol/L) but homeostatic model assessment 2 (HOMA 2)-IR >
2.
 Patients will be defined not to have DM or IR if the HbA1c is < 5.7 and FPG is
< 110 mg/dl (6.1 mmol/L), and HOMA 2 ≤ 2.
Although euglycaemic clamp is the gold standard to quantify IR, we will use
HOMA- IR calculation as an IR indicator, because it is much less sophisticated and
practically more convenient.
The formula for calculation will be: HOMA 2 = (Insulin x glucose mmol/L) ÷ 22.5
The cut-off point for IR will be 2.
For objective 2
The outcome measure is to describe the association of Type 2 DM and IR with the
following assumed risk factors: age, sex, obesity, BMI, cholesterol level,
triglyceride level and BP.
Categorization of risk factors
Blood pressure (BP) will be measured for each individual in mmHg; readings will
be separated into four categories:
Diastolic Systolic
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Category 1 < 90 < 140
Category 2 < 90 ≥ 140
Category 3 ≥ 90 < 140
Category 4 ≥ 90 ≥ 140
Hypertension in this study will be defined as the presence of any of the following
conditions:
If SBP ≥ 140 mmHg, or if DBP is ≥ 90, or if the patient is on antihypertensive drug.
Cholesterol levels (mmol/L) will be divided into categories (<4.3; 4.3–5; 5.1–5.8;
and >5.8); cholesterol= 5 mmol/L will be considered to be high. Patient on anti-
hyper cholesteric drug will be defined as high also.
Triglyceride level Normal triglycerides = < 2.0 mmol/l, Borderline High
triglycerides = 2- 4 mmol/l, High triglycerides = > 4 mmol/l.
Measures of obesity will include waist circumference, body mass index [BMI;
weight in kilogrammes divided by the square of the height in meters (kg/m)2],
and waist-to-hip ratio. Following WHO guidelines, waist circumference will be
considered to be abnormal if ≥ 102 cm for men and ≥ 88 cm for women; and
waist-to-hip ratio (WHR) will be considered abnormal if >0.95 cm for men and
>0.85 cm for females.
Participants will be classified as overweight if BMI = 25 and <30 and obese if BMI
≥30.
The demographic variables include age, grouped into 10-year age bands between
20 and 80 years (18 and 19 will be included in the first band); sex; and marital
status.
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History of DM in the family, smoking, dietary habits and physical activity will also
be included.
Strategy of analysis
Then multiple Logistic regression analyses will be conducted to analyse the
significant factors associated with the dependent variable (Type 2 DM and IR).
Independent variables were selected on the basis of the literature of diabetes risk
factors.
We will conduct Univariate, and a multivariate, results will be presented as crude
and adjusted odds ratios with associated 95% Confidence intervals.
For objective 3
The outcome measure is the prevalence of IR among first degree relatives of
people with Type 2 DM.
We will use the same IR definition and cut-off point mentioned above in objective
1.
For objective 4
The outcome measure will be the percentage of the diabetic patient attending
Nuzha HCF with good glycaemic control and to describe the risk factors
associated with poor glycaemic control.
Good glycaemic control is when HbA1c < 7, and poor glycaemic control is when
HbA1c > 9
We will use the same risk factors categorization and strategy of analysis used in
objective 2
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Strategy of analysis
Then multiple Logistic regression analyses will be conducted to analyse the
significant factors associated with the dependent variable (good and poor
glycaemic control).
We will conduct Univariate, and a multivariate, results will be presented as crude
and adjusted odds ratios with associated 95% Confidence intervals.
For objective 5
The outcome measures are to describe the accuracy of POC device in measuring
HbA1c, describing the precision of the POC device, comparing the means (95% CI)
and difference (95% CI) against the reference laboratory results.
Strategy of analysis
HbA1c POC results will be compared to reference laboratory results.  Pearson
correlations will be calculated to compare the performance of the POC method to
standard laboratory analysis; accuracy will be measured by the area under the
ROC curve.
To test the null hypothesis of non-equivalence (a difference of more than 0.5 in
HbA1c) between the methods, we will use the paired t test to determine whether
the HbA1c value from the POC test is equivalent to the value from the laboratory
test.
Matched data will be used to compare the sensitivity, specificity and the
agreement between the Quo-test to the reference results.
